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Abstract 
 
Rho GTPases are molecular switches that regulate many aspects of cell physiology. A number 
of Rho GTPases are essential for the formation of new vessels from pre-existing ones, a 
process known as angiogenesis. RhoJ/TCL belongs to the Cdc42 subfamily of Rho GTPases. 
Previous bioinformatic and primary cell line analyses identified RhoJ as being highly 
expressed in endothelial cells. The aim of this project was to investigate the expression 
pattern and endothelial function of RhoJ, particularly in the processes necessary for 
angiogenesis. Silencing RhoJ with siRNA impaired tube formation and migration. On the 
cellular level, RhoJ knockdown increased focal adhesions, actin stress fibres and collagen gel 
contraction, suggesting increased actomyosin contractility. Pharmacological inhibition of 
ROCK and myosin II, two regulators of actomyosin contractility, restored motility and tube 
formation after RhoJ knockdown. RhoJ localised to blood vessels of developing mice and in 
various human normal and pathological tissues. In zebrafish embryos RhoJ was not expressed 
in endothelial cells, instead RhoJ was expressed in the musculature where it was involved in 
regulating somite formation. This study is the first to describe a role for RhoJ as a negative 
regulator of focal adhesion numbers and actomyosin contractility and to demonstrate a critical 
role of this Rho GTPase in endothelial cell migration and tube formation, thus identifying a 
potential new player in angiogenesis.  
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C h a p t e r  o n e  
1 | Introduction 
 
 2 
1.1 The endothelium 
1.1.1 Overview 
The endothelium is a single layer of simple squamous endothelial cells (ECs) that line the 
interior surface of all blood and lymphatic vessels. Depending on their location, vascular ECs 
have unique structural and functional properties. The vascular endothelium acts as a physical 
barrier that separates the blood from underlying tissue but also plays an important part in 
many physiological functions. ECs control transcellular and paracellular transport of proteins, 
solutes, gases and cells across the blood vessel wall (1, 2). ECs also regulate blood 
coagulation and haemostasis, vasomotor tone and inflammatory responses (3). In addition, the 
de novo or angiogenic development of blood vessels, is orchestrated by ECs (4). Thus, the 
endothelium is a heterogeneous and dynamic organ that has vital secretory, metabolic and 
immunological functions (5, 6).  
 
1.1.2 Morphology of the vascular endothelium 
The endothelium of the entire adult vascular system weighs approximately 1 kg and contains 
around 1-6 x 1013 ECs, which are each between 10-15 µm in diameter and 2-5 µm thick (5). 
ECs overlap along their perimeter and are attached to one another at these sites through cell-
cell contacts known as adherens junctions and tight junctions (7). These junctions also 
mediate contact inhibition signalling to prevent EC growth and motility (7, 8). 
 
In all blood vessels, the endothelial layer is surrounded by a basement membrane; these two 
together are known as the tunica intima. In arteries and veins, but not capillaries, the tunica 
intima is surrounded by a single or multiple layers of vascular smooth muscle cells (tunica 
media) and an additional layer of collagenous connective tissue, synthesised by fibroblasts 
(tunica adventitia) (9). Capillaries only consist of the tunica intima layer and are partially 
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covered by pericytes (10). Vascular smooth muscle cells and pericytes, also known as mural 
cells, provide structural support to blood vessels but evidence also shows that endothelial-
mural cell signalling is vital for the switch between endothelial quiescence and activity (11-
13).  
 
ECs have been shown to display great morphological heterogeneity across the vascular 
system (14). Phenotypic differences in the appearance of capillary endothelium among and 
within tissue vascular beds have been reported. For example, capillaries in the brain and retina 
are lined continuously with endothelium to maintain the blood brain barrier and low 
permeability (5). In contrast, the capillary endothelium in the sinusoids of the liver, lymph 
nodes, bone marrow and spleen is discontinuous, enabling cells to pass through the gaps 
between ECs (5, 15, 16). Moreover, intestinal villi, endocrine glands and kidney glomeruli 
have fenestrated capillary ECs to facilitate selective permeability needed for efficient 
absorption, secretion and filtration (17, 18). The shape of ECs also varies across the vascular 
tree. In response to high shear stress and hydrostatic pressure, arterial ECs align in the 
direction of flow and are long and narrow whereas venous and capillary ECs are cuboidal, 
plump and show a cobblestone morphology (17, 19). Furthermore, the expression and 
organisation of tight junctions across the vascular system also differs. For example, arterial 
vessels and brain capillaries are rich in tight junctions to maintain vessel integrity but 
postcapillary venules display disorganised and loose cell-cell junctions to facilitate the 
inflammation-induced movement of leukocytes into tissues (19, 20).  
 
ECs from different sites of the vascular tree also show diverse gene expression profiles (21). 
There is endothelial gene expression heterogeneity between macro and microvessels, arteries 
and veins and different organs. Morphological and genotypic differences in the endothelium 
across the vascular tree reflect specialised functions of ECs depending on their location. An 
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example of molecular endothelial heterogeneity is the exclusive expression of lung specific 
EC adhesion molecule (LuECAM-1), a homing receptor involved in cell trafficking, by 
pulmonary microvessels and some splenic venules (22). In addition, brain endothelium is 
found to express a large number of unique cell surface transporters, several of which have 
been shown to be important for blood brain barrier function (23).  
 
1.1.3 Endothelial cell functions 
The endothelium was initially thought of as an inert physical barrier that simply separated the 
blood from surrounding tissue. However, over the last three decades much work has shown 
that ECs are highly metabolically active with many regulatory functions.  
 
ECs play an important role in the control of vasomotor tone and blood pressure by secreting 
vasodilators (nitric oxide, prostacyclin) or vasoconstrictors (platelet-activating factor, 
endothelin) in response to mechanical stimuli (5). Since ECs have direct contact with the 
blood, the endothelium is also vital to coagulation and haemostasis. In the physiological 
setting, the luminal side of the endothelium acts as an antithrombotic surface, preventing clot 
formation. However, in response to vascular damage, the endothelial layer transforms into a 
procoagulant surface and thus triggers clotting and then fibrinolysis (5). Moreover, ECs act as 
‘gate-keepers’ to regulate vessel permeability and the transport of molecules and cells through 
the vascular wall. Transport through the endothelium is achieved in two ways; using 
specialised vesicle transport systems (transcellular) or through EC retraction and disruption of 
cell-cell junctions (paracellular) (7). In addition, ECs play an important role during 
inflammation whereby they express adhesion molecules (selectins and ICAM-1) on their 
surface to allow leukocytes to roll along and tether to vessel walls and transmigrate into 
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tissues (24). And finally, in response to positive growth factors, ECs undergo a cascade of 
signalling events that are vital to the development of new blood vessels (25). 
 
1.2 Development of the vasculature 
1.2.1 Overview 
Angiogenesis is the formation of new vessels from pre-existing vasculature and is essential 
for fetal development. Angiogenesis rarely occurs in normal adults and is only 
physiologically observed during wound healing and in the female reproductive organs (4, 26). 
Angiogenic vascular development requires a fine balance between stimulatory and inhibitory 
signals. A tilt in this equilibrium can give rise to excessive or insufficient angiogenesis, which 
can substantially contribute to a number of pathologies such as diabetic retinopathy, heart 
ischaemia, rheumatoid arthritis and cancer metastasis (4). Anti-VEGF therapy is currently 
being used to treat angiogenesis dependent diseases, but the complex reactions to these drugs 
highlights the importance for further development of future therapeutic strategies. 
 
1.2.2 Vasculogenesis  
Vasculogenesis is the de novo formation of primary blood vessels during early 
embryogenesis. This process involves the differentiation of mesodermal germ cells into 
angioblasts. Following that, these stem cells further differentiate into ECs (27). ECs then 
aggregate and assemble to form blood islands, which subsequently fuse together to form the 
primitive vascular plexus (4, 26). This primary structure is then further expanded and 
developed through angiogenesis, which is the process of microvessel formation from pre-
existing vessels (4).  
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1.2.3 Angiogenesis  
The cellular mechanism of sprouting angiogenesis is a multistep process (summarised in 
figure 1.1). The process is initiated by angiogenic growth factors activating ECs (tip cells) on 
parental blood vessels to secrete proteolytic enzymes, such as matrix metalloproteinases 
(MMP) and plasminogen activators (PAs), to breakdown the surrounding basement 
membrane (28, 29). Once ECs lose their contact with surrounding mural cells, tip cells begin 
to invade and migrate into the degraded matrix area and are followed by proliferating ECs 
(30). ECs then differentiate and assemble to form capillary-like sprouts, which extend and 
elongate further into the interstitial space. Following that, lumen formation occurs and to 
stabilise the newly formed vessels, new basement membranes are synthesised and pericytes 
are recruited to the abluminal surface. New angiogenic sprouts fuse with one another or 
existing vessels to form loops and blood flow is established. (31, 32).  
 
1.2.3.1 Pro-angiogenic factors 
Numerous factors that promote the events underlying blood vessel growth have been 
identified, however, here only the major molecules involved in stimulating angiogenesis will 
be briefly discussed.  
 
Soluble growth factors are secreted from surrounding macrophages, astrocytes, fibroblasts, 
mural cells or ECs and are sometimes sequestered in the extracellular matrix (ECM)  and 
basement membrane. Upon degradation of the matrix, they are released to activate ECs (33). 
One of the most well-characterised soluble factor that potently stimulates vasculogenesis and 
angiogenesis is vascular endothelial growth factor-A (VEGF-A) (34). VEGF-A binds to 
transmembrane tyrosine kinase receptors (VEGFR-1, VEGFR-2) and non-tyrosine kinase 
neuropilin co-receptors on ECs and stimulates all the major steps in the angiogenesis cascade 
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Figure 1.1 The cellular mechanism of sprouting angiogenesis. (1) Endothelial cells 
on existing vessels are activated in response to growth factor stimulation. (2) Activated 
endothelial tip cells secrete proteolytic enzymes to breakdown the basement membrane. 
(3) Endothelial cells lose contact with surrounding mural cells and migrate into the 
degraded matrix area. Behind the leading tip cell, endothelial cells are stimulated to 
proliferate. (4) Endothelial cells differentiate into a lumen-containing tubule. (5) The 
new microvessel is stabilised by the recruitment of a new basement membrane and 
pericyte cells.  
1 | Introduction 
 
 8 
such as EC migration, proliferation, survival, and tube formation/sprouting in response to 
hypoxia (35-37). Much evidence has shown that activation of angiogenesis is mediated 
mainly downstream of VEGF-A/VEGFR-2 signalling (38-40). Loss of VEFG-A results in 
embryonic lethality (41, 42) thus it is vital for normal angiogenesis in the developing embryo. 
Another member of the VEGF family, placenta-derived growth factor (PlGF) stimulates 
vessel formation by binding to VEGFR-1 and VEGFR-2. 
 
Fibroblast growth factor-2 (FGF-2) also plays a pivotal role in activating angiogenesis and 
was one of the first pro-angiogenic growth factors to be identified. FGF-2 signals through 
FGF transmembrane tyrosine kinase receptors on ECs and stimulates their migration, 
invasion, proliferation and differentiation, and also has been shown to induce the release of 
proteases such as collagenase, MMPs and PAs (43-45).  
 
The binding of angiopoietin (Ang) ligands to the endothelial Tie-2 tyrosine kinase receptor 
also modulates angiogenesis. Ang1 and Ang2 both bind with similar affinity to Tie-2 receptor 
but have opposing effects. Ang2 is a naturally occurring antagonist of Ang1. In response to 
hypoxia, Ang2 blocks Ang1 induced Tie-2 phosphorylation, by competitively binding to Tie-
2 (46, 47). In the presence of VEGF, the binding of Ang2 to Tie-2 enables ECs to dissociate 
from one another to allow cells to migrate and undertake mitosis (30, 32, 48). In addition, 
Ang1/Tie-2 signalling stimulates the interactions between ECs and pericytes, to stabilise 
newly formed capillaries (27, 40).  
 
The binding of Ang1 to Tie-2 on ECs leads to the endothelial secretion of platelet-derived 
growth factor-BB homodimer (PDGF-BB). The tyrosine kinase receptor for PDGF-BB 
ligand, PDGFRβ, is found on the surface of pericytes and vascular smooth muscle cells (48, 
49). Thus the release of PDGF-BB generates a gradient to stimulate the movement of 
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pericytes to the region of new vessel formation for stabilisation (10, 44). PDGF-BB has also 
been found to stimulate EC tube formation and sprouting (32).  
 
In addition to soluble factors, many integrins (cell surface heterodimeric matrix adhesion 
molecules) such as vitronectin receptors (αvβ3 and αvβ5) have been shown to stimulate 
angiogenesis by mediating EC migration and tube formation (32, 47, 50, 51). Chemokines 
derived from immune cells are also important in modulating angiogenesis. For example, in 
pathological angiogenesis the binding of interleukin-8 (IL-8) to its receptors on ECs leads to 
increased EC proliferation and also increases the activity of MMPs (32, 46). 
 
1.2.3.2 Endogenous inhibitors of angiogenesis  
Fragments of the degraded basement membrane and ECM can act as endogenous inhibitors of 
angiogenesis (52). For example, arresten is derived from type IV collagen and inhibits MMP 
activation, VEGF-dependent EC migration and FGF-2-dependent EC proliferation (53, 54). 
Similarly, other fragments of type IV collagen such as canstatin and tumstatin have also been 
shown to inhibit EC proliferation, migration and tube formation by stimulating apoptosis and 
binding to integrins necessary for angiogenesis (52, 54-56). A fragment of collagen XVIII, 
known as endostatin has also been found to directly inhibit EC proliferation and migration by 
inducing EC apoptosis and G1 arrest. Endostatin also indirectly suppresses MMP activity and 
blocks the binding of VEGF-A to VEGFR-2 (52, 57). Thrombospondins (TSPs) are 
glycoproteins stored in the ECM and are potent inhibitors of angiogenesis. TSP-1 induces the 
recruitment of mural cells to the site of angiogenesis, thus blocking EC migration and TSP-2 
mainly inhibits EC migration by increasing EC apoptosis (52, 58).  
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Cytokines and growth factors derived from cells and blood plasma have also been recognized 
for their anti-angiogenic effects. The type 1 interferon, IFN-α is an anti-angiogenic cytokine 
released from leukocytes, fibroblasts and macrophages and was one of the first molecules 
found to have inhibitory activity on ECs. The effects of IFN-α include inhibition of FGF-2 
production, downregulation of IL-8, VEGF-A gene expression and direct impairment of EC 
proliferation and migration (52, 59). Surrounding leukocytes and mast cells can also release 
IL molecules to suppress angiogenic growth, for example, IL-4, IL-12 and IL-18 all show 
anti-angiogenic activity. IL-4 acts to block FGF-2-induced angiogenesis whereas IL-12 and 
IL-18 induce the expression of other inhibitory cytokines (52, 59).  
 
Moreover, fragments of blood coagulation factors also inhibit angiogenesis. For example, 
angiostatin, a fragment of plasminogen, inhibits the growth of ECs by binding directly to ATP 
synthase on their surface, and triggering apoptosis (52, 60). In addition, cleavage of 
antithrombin III and prothrombin also produces anti-angiogenic molecules, which act to 
inhibit EC proliferation. Furthermore, platelet factor-4 is a protein released by platelet α-
granules during blood clotting and directly binds to FGF-2 thus inhibiting its role in 
stimulating EC growth (52, 60). Also, fragments of the central E-domain of fibrinogen 
(alphastatin, β43-63) have been shown to have anti-angiogenic activity by blocking EC 
migration and differentiation (61-64). Tissue inhibitors of matrix metalloproteinases (TIMPs) 
inhibit the breakdown of the basement membrane by binding to the active sites of MMP 
enzymes. TIMPs are also known to inhibit EC growth, differentiation and induce apoptosis, 
independent of MMP inhibition (60). There are many other matrix, cell and blood derived 
endogenous inhibitors of angiogenesis but since this is not an exhaustive review, they have 
not all been discussed here. The various positive and negative regulators of angiogenesis that 
have been mentioned are summarised in table 1.1. 
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Stage of angiogenesis Stimulators Inhibitors 
   
Matrix degradation 
 
MMPs, PAs, 
Collagenase,  
FGF-2 (FGFR), IL-8 
TIMPs, Arresten, Endostatin 
 
   
Migration VEGF-A (VEGFR-2), 
FGF-2 (FGFR),  
Ang2 (Tie-2), Integrins 
Arresten/Canstatin/Tumstatin, 
Endostatin, TSP-1/TSP-2, 
IFN-α, Fibrinogen-E, Ang1 
(Tie-2) 
   
Proliferation VEGF-A (VEGFR-2), 
FGF-2 (FGFR),  
Ang2 (Tie-2), IL-8 
 
Arresten/Canstatin/Tumstatin, 
Endostatin, IFN-α, IL-4, 
Angiostatin, Platelet factor-4, 
Antithrombin III/Prothrombin 
fragments,  
Ang1 (Tie-2) 
   
Tube formation & 
sprouting 
VEGF-A (VEGFR-2), 
FGF-2 (FGFR),  
PDGF-BB (PDGFRβ),  
Ang2 (Tie-2), Integrins 
PlGF (VEGFR-1/2)  
Canstatin/Tumstatin, TSP-2, 
IL-4, Fibrinogen-E, Ang1 
(Tie-2) 
 
   
Vessel stabilisation PDGF-BB (PDGFRβ), 
Ang1 (Tie-2) 
Ang2 (Tie-2) 
 
   
 
Table 1.1 Summary of the stimulatory and inhibitory factors of the angiogenesis 
cascade. Brackets indicate receptors. 
 
 
1.2.3.3 Physiological and pathological angiogenesis  
In physiological conditions, angiogenesis occurs in the embryo where it establishes the 
primary vasculature, but in adults, capillary growth is an infrequent event and the ECs of most 
tissues are quiescent with a low mitotic rate (65). However, angiogenic growth and regression 
is known to occur in regular cycles in female reproductive organs such as the ovaries and the 
endometrium (65, 66). The development and growth of the follicles and corpus luteum of the 
ovary leading up to ovulation requires an adequate blood supply, which is delivered through 
angiogenesis (66). During each menstrual cycle, the regeneration of the uterine endometrial 
tissue (in preparation for implantation) is also supported by angiogenesis (67). Moreover, 
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angiogenesis is also vital for wound healing and tissue repair. In response to inflammation 
and growth factors, released by immune cells, ECs are activated to undertake angiogenesis to 
re-establish the supply of oxygen and nutrients to wounded tissues by replacing damaged 
capillaries (68).  
 
In normal conditions, angiogenesis is a tightly controlled and highly ordered process, which is 
only switched ‘on’ for brief periods then completely inhibited under the balanced regulation 
of angiogenic activators and inhibitors (69). When the balance between stimulatory and 
inhibitory signals is lost, aberrant angiogenesis occurs and this leads to numerous pathologies. 
 
Folkman and colleagues (1971) were the first to show that tumour growth and survival 
beyond a few millimetres is dependent on a rich blood supply (70-72). In tumour 
angiogenesis, growth factors (such as VEGF-A) are produced at high levels from tumour cells 
and tumour stromal cells and are released in response to hypoxia to induce ECs to invade, 
migrate and proliferate into the developing tumour to form new vessels (27, 70, 71, 73, 74). 
Correlations have been found between the level of VEGF-A expression (and other pro-
angiogenic factors), disease progression and survival of several cancers (75). It is thought that 
the pro-angiogenic factors involved in activating angiogenesis are similar for both 
physiological and pathological angiogenesis. However, in contrast to physiological 
angiogenesis, the blood vessels formed from tumour angiogenesis are disorganised and 
tortuous. They frequently display fenestrated endothelium, have physical contact with tumour 
cells and do not generate well-ordered, hierarchically branched vascular networks. Also they 
fail to undergo full maturation (pericytes are often absent) and so are highly leaky and 
unstable (51, 76-79).  
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Destabilisation of atherosclerotic lesions is also an angiogenesis-dependent process. Similar 
to the tumour microenvironment, atherosclerotic plaques become hypoxic as they increase in 
size. Thus the angiogenic development of new vessels leads to the progression of 
atherosclerotic plaques and their subsequent rupture, which can lead to thrombosis (80). 
Retinal neovascularisation in ocular disease, which is the main cause of blindness in diabetes 
mellitus sufferers is another example of uncontrolled VEGF-induced angiogenesis (81, 82). 
Furthermore, angiogenesis is also an inducer of the pathogenesis of certain inflammatory 
diseases such as psoriasis and rheumatoid arthritis (83, 84). Moreover, pathologies of the 
female reproductive system have been found that are associated with disturbances of the 
angiogenic process such as dysfunctional uterine bleeding, endometriosis, failed implantation 
and polycystic ovary syndrome (67, 85). Conversely, insufficient or inadequate angiogenesis, 
where poor capillary growth leads to poor perfusion of tissues and in some cases tissue death, 
underlies several pathologies such as coronary and brain ischaemia, non-healing fractures, 
delayed wound healing and chronic ulcers (86). 
 
1.2.3.4 Anti-angiogenic agents in cancer therapy 
Given that VEGF has a central role in promoting tumour growth and metastasis, the VEGF 
signalling pathway became an attractive target for anti-cancer therapeutic intervention. Two 
strategies have been employed to inhibit the VEGF signalling pathway, one of which includes 
the use of monoclonal antibodies. Bevacizumab (avastin) is a humanised anti-VEGF-A 
monoclonal antibody. By binding to circulating VEGF-A, it limits the binding of the soluble 
factor to cell surface receptors and reduces angiogenesis. It was the first commercially 
available angiogenesis inhibitor and is currently used to treat colorectal, lung, breast and renal 
cancers in combination with standard chemotherapy (77, 87). The other approach used to 
inhibit the VEGF signalling pathway is to target VEGFRs. Tyrosine kinase inhibitors, 
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sorafenib (nexavar) and sunitinib (stutent) are also currently being used clinically to treat 
cancers. These work by inhibiting VEGFR phosphorylation and the subsequent activation of 
the angiogenesis cascade (88). 
 
The use of anti-angiogenic drugs in cancer therapy has been effective in improving overall 
survival of cancer patients however in many cases there is a lack of response or disease 
reoccurrence (25, 77, 79). This occurs due to tumours acquiring resistance against the anti-
VEGF treatment (89). It is has been hypothesised that resistance to VEGF pathway inhibition 
may be mediated through tumour cells increasing the expression levels of VEGF/VEGFRs or 
by tumour cells upregulating alternative pro-angiogenic pathways leading to more aggressive 
and wide-spread disease (79). It has been proposed that a combination of different pro-
angiogenic pathways need to be inhibited in order for anti-angiogenic drugs in tumours to be 
effective. Therefore, to maximise efficiency of angiogenesis inhibition, other anti-angiogenic 
agents are currently being tested in preclinical and clinical trials to use alongside anti-VEGF 
drugs. These include cilengitide (αvβ3/αvβ5 inhibitor), abergin (αvβ3 antagonist), S247 
(αvβ3/αvβ5 antagonist), ABT-510 (inhibitor derived from TSP-1), YH-16 (recombinant 
endostatin), angiostatin, PEG IFN-α  (a modified form of IFN-α with longer half life) (79, 86, 
90). The difficulty in completely eradicating solid tumour growth with anti-VEGF treatment 
alone reflects our incomplete understanding of angiogenesis signalling and highlights the 
need for new future targets to be developed.  
 
1.2.3.5 Models of angiogenesis 
In vitro angiogenesis assays are important for furthering our understanding of the molecular 
mechanisms involved in angiogenesis and useful in identifying new regulators of the 
angiogenesis cascade (91). The most commonly used in vitro assays involve looking at 
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isolated ECs in systems that aim to mimic each step of the angiogenesis cascade (migration, 
proliferation and tube formation). EC migration can be assessed by creating a ‘wound’ in a 
confluent monolayer of ECs and monitoring the rate and extent of wound closure. Moreover, 
chemotaxis can be examined using Boyden chemotaxis chambers, which involves the three-
dimensional movement of cells toward a gradient of chemotactic stimuli. The easiest method 
of analysing proliferation is to perform direct cell-counting assays, whereby cells are seeded 
and counted after a set period of time. Furthermore, plating ECs onto or into gelled matrices 
can stimulate EC tube formation and sprouting, thus creating a framework in which the 
differentiation stage of angiogenesis can be examined. Another form of tubule assay known as 
the organotypic assay involves co-culturing ECs with fibroblasts. The fibroblasts naturally 
produce extracellular matrix components such as collagen to act as scaffolding for the 3-
dimensional tube formation. Evidence shows that tubes that form in this assay contain lumens 
and that tube formation is dependent on VEGF (secreted by the fibroblasts) making it a more 
physiological representation of in vivo angiogenesis (92). Organ culture experiments such as 
aortic ring assays, where segments of the aorta are cultured in vitro in a 3-dimensional matrix, 
are the most representative of the in vivo situation since they encompass all the aspects of the 
angiogenic process such as proliferation, migration and tubular outgrowth. However, these 
assays are difficult to quantitate and determination of successful gene expression modulation 
is troublesome. Although these overly simplistic in vitro assays have many limitations and do 
not completely simulate the in vivo situation, they provide valuable information and are the 
essential first steps towards validating a potential new therapeutic target (93-95).  
 
In order to validate findings observed in vitro, animal models of angiogenesis are needed. 
Zebrafish, danio rerio, are small tropical freshwater fish that are increasingly being used for 
studying in vivo angiogenesis (91, 96). This model has many advantages over other models, 
for example, embryogenesis occurs outside the mother's body, embryos are transparent and 
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vascular development is very rapid. Thus real-time physiological blood vessel formation can 
be directly observed over a relatively short period of time (97). In addition, zebrafish gene 
expression can be modified with great ease making them model organisms for in vivo 
knockdown/overexpression studies (98). Other commonly used in vivo models of 
angiogenesis include the mouse Matrigel plug or sponge assay, corneal angiogenesis assay 
and chick chorioallantoic membrane assay (91, 93-95). 
 
1.3 Cell migration 
1.3.1 Overview  
Cell migration is essential to all multi-cellular organisms and is a highly orchestrated process 
that involves cell polarisation, protrusion, adhesion and retraction. To begin with, cells 
reorientate toward the direction of movement and establish front-rear polarity. Subsequent 
actin polymerisation at the front of the cell drives the extension of lamellipodia and filopodia. 
New focal adhesions are formed at the leading edge underneath these protrusions to enable 
the intracellular actin cytoskeleton to anchor to the ECM. In order to move forward, 
contraction of the actin cytoskeleton (mediated through the activation of myosin II in stress 
fibres) exerts force on focal adhesion sites. Focal adhesions then disassemble at the rear to 
allow the cell to retract the trailing edge (99-101).  
 
1.3.2 Cell polarisation  
In order for a cell to migrate, it firstly needs to asymmetrically remodel its molecular 
mechanisms in the direction of movement (figure 1.2A). In response to migration-promoting 
stimuli, cells redirect their intracellular vesicle trafficking to the cell front to augment cell-
surface receptors at the leading edge, thus aiding cells to chemically sense their direction 
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Figure 1.2 The major steps of cell migration. (A) During polarisation, the cell 
reorientates its cell shape in preparation for movement. During this process, the Golgi 
and microtubule organising centre (MTOC) are translocated to the front of the cell. (B) 
The cell then extends protrusions, driven by actin polymerisation, in the direction of 
migration such as lamellipodia (which initiate the formation of focal complexes at the 
front of the cell) and filopodia (which sense direction and probe the local environment). 
(C) Stress fibres that terminate at focal adhesion sites contract, enabling the cell to 
retract its trailing edge in order to propel forward. 
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(101). The polarisation of vesicular traffic has also been shown to be important for the 
delivery of adhesion and cytoskeletal proteins to the front of the cell, which are later needed 
for cell protrusion (102). To ensure that cells have a direct line of supply to the front of the 
cell, the Golgi apparatus translocates to the anterior side of the nucleus (103, 104). In this 
way, Golgi-derived vesicles can be rapidly transported to the leading edge. The microtubule 
organising centre (MTOC) also reorientates to face the cell front to provide structural stability 
to the asymmetrical cell shape and to promote cellular protrusion (103, 104). 
 
1.3.3 Actin dynamics 
Actin treadmilling is essential to many cellular processes, especially cell migration. 
Monomeric adenosine triphosphate (ATP)-bound globular actin subunits polymerise to form 
helical actin filaments (105). Filamentous actin (f-actin) is a polar structure; it has a fast 
growing end (the plus end) where actin monomers quickly bind and elongate filaments and a 
slow growing end (the minus end) where actin depolymerises (105). Upon binding to the fast 
growing end, ATP-bound globular actin subunits are converted to adenosine diphosphate 
(ADP)-bound monomers by slow hydrolysis and the release of inorganic phosphate (Pi) 
prompts depolymerisation at the slow growing end (100). Several types of proteins that bind 
to actin have been identified such as actin nucleators and cross-linkers, as well as components 
of adhesion complexes. Actin filaments can undergo constant rearrangement and adopt 
different functions depending on their structure and the type of actin-binding proteins that 
they are associated with (100, 101).  
 
In cell migration, once cells have acquired polarised morphology, they spread out cellular 
protrusions in the direction of migration (figure 1.2B). This process is driven by the dynamic 
growth of actin filaments, whereby actin filaments are arranged with their plus ends facing the 
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cell edge and polymerisation of these filaments drives the outward extension of the plasma 
membrane (105). Lamellipodia are flat, sheet-like protrusions, which are built of mesh-like 
networks of branched actin filaments. Lamellipodia formation induces integrin receptor 
clustering and the formation of nascent focal complexes (to anchor and stabilise protrusions to 
the ECM) (106, 107). Filopodia are finger-like structures that extend beyond the cell front and 
are filled with long, parallel bundles of actin filaments. Filopodia sense chemoattractant 
stimuli and explore the local environment for appropriate sites of adhesion. Although, actin 
filaments in lamellipodia and filopodia are nucleated through distinct mechanisms (Arp2/3 
complexes and formins, respectively), they co-exist at the leading cell edge (101, 107). 
 
1.3.4 Focal adhesions 
Focal adhesions are mechanosensory sites of cell adhesion to the underlying ECM. They 
structurally link the intracellular actin cytoskeleton to the ECM and serve as traction sites for 
migration as the cell moves forward over them. These links are mediated via ECM receptors 
known as integrins. Integrins are transmembrane heterodimers of α and β chains with large 
ligand-binding extracellular domains and short cytoplasmic domains. Pairing of different α 
and β subunit isoforms generates distinct receptors for specific ECM ligands (108). So far 
around 18 α and 8 β subunits have been identified in humans, which can combine to make 24 
different integrin receptors (109). Integrin activation typically occurs from the inside out but 
integrins can also serve as outside-in mechanosensors whereby information about the physical 
state of the ECM is transmitted into cells to alter actin cytoskeletal dynamics (101, 110). In 
outside-in signalling, the binding of ECM ligands to integrin receptors induces a 
conformational change. This unveils their cytoplasmic tails and stimulates the recruitment of 
adaptor molecules, scaffold and signalling proteins and actin filaments to the cytoplasmic 
domain (110, 111).  
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Focal adhesions are dynamic in their size, location and composition. In migrating cells, 
nascent ‘dot-like’ focal complexes appear at the cell’s leading edge and are linked to the actin 
filaments of lamellipodia and filopodia (figure 1.2B) (112). Focal complexes are short-lived 
and have a high rate of turnover since the dynamic flow of actin in cellular protrusions 
triggers their disassembly and assembly (113). However, some of these do not disassemble 
and go on to mature into larger complexes known as focal adhesions (figure 1.3). These are 
mainly found centrally and at the rear of motile cells. Focal adhesions are linked to the ends 
of stress fibres, so upon contraction of these fibres, they act as sites for force transmission 
(114-116). As traction forces move the migrating cell forwards, the trailing edge is retracted 
and focal adhesions at the back of the cell disassemble. These are then partly recycled 
(turned-over) to the front of the cell to form new focal complexes (see figures 1.2C and 1.3).  
 
It has been reported that focal adhesions are made up of over 100 different proteins and are 
structurally heterogeneous depending on their age and location (117). However, focal 
adhesions are composed of several fundamental components that are always present, some of 
which will be described below. A key event in activating integrins inside-out is the binding of 
talin to the cytoplasmic region of integrin receptors. Talin is a cytoskeletal adaptor molecule 
that physically couples integrins to actin filaments. Its N-terminus binds to the cytoplasmic 
tail of integrin β-chains (which increases their affinity for ECM ligands) and its C-terminal 
end contains binding sites for f-actin and vinculin, another cytoskeletal adaptor protein (118, 
119). Vinculin consists of globular head and tail domains (120). The head domain binds to 
talin and its tail domain contains binding sites for actin filaments and paxillin (121, 122). By 
binding to f-actin, vinculin strengthens the talin-mediated link between the actin cytoskeleton 
and the integrin receptor. Paxillin, a signal transduction adaptor protein, binds to the vinculin 
tail domain and contains tyrosine phosphorylation sites (121, 122). Non-receptor tyrosine 
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Figure 1.3 Focal adhesion turnover during cell migration. (1) New focal complexes 
at front of the cell dynamically turnover as the lamellipodium protrudes out. (2) Some 
of these do not disassemble but mature into focal adhesions, which attach to the ends of 
stress fibres. (3 & 4) In order to retract the trailing edge, stress fibres contract and cause 
focal adhesions to disassemble. (5) Stress fibres relax to allow the cell to protrude 
forward. (6) Some of the focal adhesion proteins are recycled to the front of the cell to 
make new focal complexes as the cell moves forward.  
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kinase, focal adhesion kinase (FAK) binds to talin and paxillin through its C-terminal focal 
adhesion targeting (FAT) domain (123). In response to integrin activation, FAK becomes 
autophosphorylated at Y397 (124). Activated FAK then phosphorylates several other focal 
adhesion proteins, including paxillin at Tyr118, which provides docking sites for other 
signalling molecules (125-127). This prompts the recruitment of other adaptor and signalling 
proteins to focal adhesions (such as Src kinase, p130CAS-CRK, G protein-coupled receptor 
kinase-interacting protein (GIT) and β-PIX), leading to their enlargement, maturation and 
increased strength (116, 124, 127). The basic molecular structure of a focal adhesion is 
illustrated in figure 1.4. 
 
1.3.5 Stress fibres and actomyosin contractility 
In order for a migrating cell to detach from the substrate, cytoskeletal contractility needs to 
exceed the adhesive strength of focal adhesions (128). This contractile force is generated by 
stress fibre contraction. Stress fibres are bundles of anti-parallel actin and bipolar non-muscle 
myosin II, also known as actomyosin (figures 1.2C and 1.5B) (129, 130). Myosin II is a 
molecular motor protein and is responsible for generating contractility by converting chemical 
energy (stored in ATP) into mechanical force (127, 131). Myosin II is divided into three 
structural domains; motor, regulatory and tail (illustrated in figure 1.5A). The motor domain 
contains the binding sites for ATP and actin and this is the region where ATP is hydrolysed 
into ADP and Pi for mechanical energy (127). The regulatory domain acts as a ‘lever arm’ for 
force generation and is associated with two myosin light chains (MLCs); essential and 
regulatory. The essential light chain helps to structurally support the globular head domain 
whereas the regulatory light chain is important for regulating myosin head function. The tail 
domain is a long α-helical coiled-coil region. Several myosins can assemble into bipolar 
myosin filaments through interactions between their tail domains (see figure 1.5B) (127). 
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Figure 1.4 Focal adhesion molecular composition. The extracellular domain of 
transmembrane αβ-integrin receptors bind to extracellular matrix (ECM) proteins. 
Numerous structural and signalling proteins bind to the intracellular domain of these 
heterodimers (only talin, vinculin, focal adhesion kinase (FAK) and paxillin are 
depicted), to form a physical link with intracellular actin filaments (f-actin).  
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Figure 1.5 The structure of myosin II and actomyosin. (A) Myosin II monomers 
consist of motor, regulatory and tail domains. The motor domain is made up of two 
globular myosin heads that contain actin binding sites and ATPase hydrolytic activity. 
The regulatory domain is comprised of the ‘lever arm’ and two myosin light chains; 
essential and regulatory. The tail domain represents the α-helical coiled coil region, 
which associates with other myosin monomers to form a bipolar structure. (B) 
Actomyosin bundles contain bipolar myosin filaments, which lie in between antiparallel 
bundles of actin filaments. Upon activation myosin II interacts with actin through its 
motor domain. The ATPase activity of the myosin heads induces a conformational 
change that allows myosin II to slide along the actin filaments towards the plus ends and 
‘pull’ to create actin cytoskeletal tension. 
 
 
A
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In the activated state, myosin heads that lack a bound nucleotide are locked onto actin 
filaments, which is often called rigor complex. Upon binding of ATP to the myosin head, a 
conformational change occurs that reduces the affinity of the myosin head for actin and 
allows it to move along the actin filaments toward the plus end. ATP is then hydrolysed into 
ADP and Pi, which results in myosin weakly binding to a new site on the actin filament. Pi 
release increases the strength of myosin binding to actin and when ADP is dissociated, again 
the myosin heads tightly lock onto the actin filament. The sliding of myosin II toward the plus 
end of actin filaments and the upstream tight binding exerts tension on the actin cytoskeleton, 
also known as actomyosin contractility (132). 
 
Tight control of actomyosin contractility is vital for detachment of the trailing edge during 
cell migration (116, 133). Myosin II activity is regulated by phosphorylation of the regulatory 
light chain (referred to as myosin light chain (MLC) hereafter). When MLC is 
unphosphorylated, the myosin heads of the motor domain exhibit an inactive conformation 
whereby they interact with one another in a way that blocks ATP hydrolysis and actin 
binding. Phosphorylation of MLC, at Thr18 and Ser19, disrupts the inhibitory head-head 
interactions, which unmasks the actin binding site and activates adenosine triphosphatase 
(ATPase) activity (127). Several kinases have been shown to phosphorylate MLC, these 
include Rho kinase (ROCK) and myosin light chain kinase (MLCK) (127, 134, 135). 
However, the activating signals for these kinases differ, for example, Ca2+-calmodulin 
activates MLCK but ROCK is activated downstream of RhoA, a Rho GTPase protein (127). 
ROCK can stimulate myosin II ATPase activity in two ways, by directly phosphorylating 
MLC or by inactivating MLC phosphatase, which dephosphorylates MLC (127). In motile 
cells, MLC phosphorylation in stress fibres results in increased transmission of tension to sites 
of adhesion, which is needed for cell body traction and the disassembly of focal adhesions at 
the cell rear (101). Evidence also shows that contractility is spatiotemporarily regulated 
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during cell migration, since the formation of cellular protrusions at the cell front needs low 
cellular tension but the rear requires high contractility (128). 
 
1.4 Rho GTPases 
1.4.1 Overview 
Rho guanosine triphosphatase (GTPase) proteins are molecular switches found in eukaryotic 
cells that control a wide array of signal transduction pathways. Among them Rac1, Cdc42 and 
RhoA are the best characterised. They cycle between inactive GDP-bound and active GTP-
bound conformations (136). Upon activation Rho GTPases bind to effector proteins, which 
control a myriad of cellular processes, such as cell polarity, migration, proliferation, gene 
transcription, cell adhesion and vesicular trafficking (136-138). Angiogenesis requires many 
of these diverse cellular events to occur appropriately and evidence shows that Rho GTPases 
are essential regulators of VEGF-dependant angiogenesis (139, 140).  
 
1.4.2 The small Rho GTPase family 
Rho GTPase proteins represent a subfamily within the Ras superfamily of small GTPases, 
which also include the Ras, Arf, Rab and Ran families (141, 142). To date, more than 150 
members of the small GTPase superfamily have been identified in mammals and around 23 of 
these are Rho GTPases (141). On the basis of amino acid sequence homology, Rho GTPases 
are classified into six subfamilies; Rho subfamily (RhoA, RhoB and RhoC), Rac subfamily 
(Rac1, Rac2, Rac3 and RhoG), Cdc42 subfamily (Cdc42, TC10/RhoQ, RhoJ/TCL, 
Wrch1/RhoU and Wrch2/RhoV), Rnd subfamily (Rnd1, Rnd2, Rnd3/RhoE, RhoD and 
Rif/RhoF), RhoBTB subfamily (RhoBTB1, RhoBTB2, RhoBTB3 and RhoH/TTF) and the 
Miro subfamily (Miro1/RhoT1 and Miro2/RhoT2) (143). The phylogenetic relationship 
between the Rho proteins is illustrated in figure 1.6. 
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Figure 1.6 Phylogenetic tree of the human small Rho GTPase family. The Rho 
family of small GTPases are divided into six subfamilies according to amino acid 
sequence homology. The blue coloured shapes indicate the classical Rho protein 
subfamily groups (Rho, Rac, Cdc42). The green coloured shapes represent atypical Rho 
protein subfamilies (Rnd, RhoBTB and Miro) that lack GTPase activity. Dendrogram 
adapted from Bustelo et al. (2007) (143). 
 
 
 
 
 
 
 
Figure 1.7 Core structural motifs of Rho GTPase proteins. Rho GTPase proteins 
typically contain a Rho domain, GTP/GDP binding regions, an effector domain, a C-
terminal hypervariable region and a CAAX (C-cysteine, A-aliphatic amino acid, X-any 
amino acid) box motif.  
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1.4.3 Rho GTPase structure  
Small Rho GTPases are highly conserved globular proteins made up of single six-stranded β 
sheets surrounded by five α-helices, with molecular masses of around 20-25 kDa (144). Rho 
proteins are defined by the presence of a Rho-type GTPase domain, which is typically 
sandwiched between short N- and C-terminal ends (142, 145). Rho proteins also contain 
amino acid residues responsible for guanosine triphosphate (GTP)/guanosine diphosphate 
(GDP) binding and GTPase activity (142). However, Rnd, RhoBTB and Miro subfamily 
members lack GTPase activity due to amino acid substitutions in their GTP/GDP binding 
regions and are considered atypical (figure 1.6) (145). Moreover, Rho GTPase proteins 
contain effector domains, important for activating downstream effector proteins (144).  
 
Although Rho GTPases share 30-50% homology (146), there is great diversity between them 
at the C-terminal end, which is known as the hypervariable region (147). In addition, Rho 
GTPase proteins typically contain a cysteine residue fourth from the C-terminal end, also 
known as the CAAX (C-cysteine, A-aliphatic amino acid, X-any amino acid) motif (145). 
Since small GTPases are hydrophilic and do not contain transmembrane domains, the CAAX 
motif can be isoprenylated by prenyltransferase enzymes to allow them to interact with 
membranes (145, 147). Although Rho proteins are structurally and biochemically related, 
variations in their C-terminal ends localises them to specific compartments within the cell, 
which is vital for their distinct biological functions (144, 147). Even closely related Rho 
proteins are localised to very different cellular regions, for example, Rac1 is largely located at 
the plasma membrane but its close relative, Rac2, mainly localises to endomembranes (142). 
The typical domain structure of a Rho GTPase protein (from Rho, Rac or Cdc42 subfamilies) 
is depicted in figure 1.7 
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1.4.4 The GTPase cycle 
Rho GTPases behave as ‘molecular switches’ that cycle between inactive GDP-bound and 
active GTP-bound states. Structural studies reveal that the exchange of GDP for GTP induces 
a conformational change in loop regions named switch I and switch II, which unmasks the 
effector domain (144, 146). Thus the conformation of GTP-bound Rho proteins allows them 
to interact with downstream effector proteins, which trigger various cellular responses, until 
GTP hydrolysis returns the switch back to the inactive state (137, 148).  
 
1.4.5 Regulation of GTPase activity 
The GTPase activation cycle is regulated by three classes of proteins; guanine nucleotide 
exchange factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide 
dissociation inhibitors (GDIs) (figure 1.8). GEFs promote the exchange of GDP for GTP and 
so activate the molecular switch, which leads to effector protein binding and propagation of 
downstream signalling (149, 150). GAPs inactivate Rho proteins by enhancing GTP 
hydrolysis, which leaves the molecule in the inactive GDP-bound state. This prevents effector 
binding and therefore shuts down signalling. GDIs bind to inactive GDP-bound forms of 
GTPases and prevent the exchange of GDP to GTP thus maintaining the inactive state. Since 
Rho GTPase activation is accompanied by intracellular translocation to membranes, GDIs 
also inhibit GTPase activity by masking their prenyl groups, which prevent them from 
localising to membranes (136). The human genome contains approximately 70 GEFs and 
around 80 GAPs for the Rho family of small GTPases, which demonstrates the complexity of 
Rho GTPase regulation in the cell (149). To date, only three GDIs for Rho proteins have been 
identified; RhoGDI-1, RhoGDI-2 and RhoGDI-3 (149, 151).  
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Figure 1.8 The GTPase cycle and its regulatory proteins. Rho GTPase proteins cycle 
between GDP-bound inactive and GTP-bound active states. In their active form, Rho 
GTPases can bind to effector molecules, which mediate downstream biological 
responses. Guanine nucleotide exchange factors (GEF) promote activation by catalysing 
the exchange of GDP for GTP. GTPase-activating proteins (GAP) inhibit Rho protein 
activation by enhancing the intrinsic GTPase activity to hydrolyse GTP into GDP, 
returning it to an inactive state. Guanine nucleotide dissociation inhibitors (GDI) 
maintain the GDP-bound form of GTPases, making it unable to interact with GEF 
proteins and cellular membranes. 
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1.4.6 Upstream activators 
Rho proteins are often activated by soluble serum components such as growth factors, 
hormones and cytokines. These soluble factors signal through cell surface receptors, such as 
receptor tyrosine kinases, G-protein coupled receptors and cytokine receptors (105). The 
downstream signalling pathways of these ligand-bound receptors can sequentially act upon 
GEFs or GAPs to control the activation state of Rho GTPases (152, 153). Rho proteins can 
also be activated downstream of cell adhesion molecules, integrin receptors and mechanical 
stresses (tension, compression or shear stress).   
 
1.4.7 Downstream effectors 
Once activated, Rho GTPases can interact with a spectrum of intracellular effector proteins to 
activate a wide variety of signaling pathways and cellular responses. Over 50 target effectors 
have been identified at present, which include serine/threonine kinases (e.g., ROCK), tyrosine 
kinases (e.g., Src), lipid kinases (e.g., phosphatidylinositol 4-phosphate (PIP) 5-kinase), 
lipases (e.g., phospholipase-C), oxidases (e.g., NADPH) and scaffold proteins (e.g., Wiskott-
Aldrich syndrome protein (WASP)) (143, 148, 154). Some of these downstream effectors can 
also sequentially activate further downstream proteins (155). Depending on their cellular 
context and the mechanism of activation, Rho proteins are capable of activating multiple 
types of effector proteins. Also distinct Rho proteins can activate identical effector proteins. 
This reflects the complex and diverse functional properties of Rho GTPases in cell biology.  
 
1.4.8 Functions of Rho GTPases 
Rho proteins are involved in regulating a plethora of biological processes such as cell cycle 
progression, gene transcription, cell polarity and vesicle trafficking (150). However, the major 
function of Rho GTPases is to regulate the assembly and organisation of the actin 
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cytoskeleton. Thus Rho proteins are essential mediators of cell processes that require 
cytoskeletal reorganisation such as cell motility and vascular remodeling. The role that Rho 
GTPases play in cell migration and in the vasculature will be discussed below. 
 
1.4.8.1 Rho GTPases in cell migration 
Cell migration is tightly controlled by the coordinated activity of Rho GTPase proteins (101, 
133). Cdc42 is a key regulator of directional sensing and is responsible for the reorientation of 
the MTOC and Golgi apparatus-derived vesicle trafficking during cell polarisation (156) 
Moreover, Rac1 and Cdc42 are known to promote actin polymerisation and membrane 
protrusion formation, both fundamental processes for cell motility (157). Cdc42 promotes 
filopodia formation at the leading cell edge, whereas Rac1 activation triggers the formation of 
lamellipodia (158). ROCK, is a downstream effector protein of  RhoA and activation of the 
RhoA-ROCK pathway stimulates the formation of stress  fibres (134, 148, 154, 159-162). 
Actomyosin contractility downstream of RhoA is important for traction of the cell body and 
detachment of the trailing edge (133, 163, 164). In addition, Rac1 and Cdc42 modulate the 
formation of focal complexes at the leading cell edge, whereas RhoA regulates the formation 
and maintenance of focal adhesions at the cell body and trailing edge through the downstream 
activation of FAK (165).  
 
Rho GTPases coordinate cell migration in a precise spatiotemporal manner. Rac1 and Cdc42 
both localise to the leading cell edge, although Cdc42 is also found at the Golgi apparatus. 
Unlike Cdc42 and Rac1, RhoA localises mostly to the cytosol at the cell body and the trailing 
cell edge (112, 163). In addition, the Rho proteins activate each other in a hierarchial fashion: 
active Cdc42 stimulates the activation of Rac1, which both transiently inhibit RhoA 
activation.  
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1.4.8.2 Rho GTPases in endothelial cells and angiogenesis 
Multiple reports have implicated Rho GTPase proteins as downstream effectors of VEGF-
A/VEGFR-2 signalling in ECs (30). VEGF-A stimulation leads to the activation of Rac1, 
Cdc42 and RhoA within 1-5 minutes of stimulation, indicating that the downstream effectors 
of Rho proteins function as key mediators of VEGF-dependant processes that drive 
angiogenesis (140, 166). Reports have suggested that Rho GTPase proteins are essential for 
every stage of the angiogenesis cascade (table 1.2).  
 
Rho proteins are capable of altering the expression and activity of pro-angiogenic and anti-
angiogenic factors. Rho GTPases have been shown to upregulate the expression of VEGF-A 
and FGF-2 in ECs (167). In addition, Rac1, Cdc42 and RhoA have been shown to induce the 
transcriptional expression and secretion of MMPs in mural cells. Rac1 and Cdc42 have also 
been shown to promote the transcription and activity of TIMPs to inhibit basement membrane 
degradation, which is essential for ECM remodeling in the later stages of angiogenesis (140).  
 
Given their role in regulating the actin cytoskeleton and cell motility, it is not surprising that 
Rho GTPases modulate EC migration and invasion. VEGF-A is known to induce Cdc42-
dependant filopodia, Rac1-induced lamellipodia and RhoA-mediated contractility in ECs (30, 
139, 140, 168). Rho proteins also have the ability to influence cell cycle regulation, which is 
essential for normal angiogenesis. Rac1, Cdc42 and RhoA have been shown to be essential 
for EC cycle progression from G1 (gap 1) to S (synthesis) phase (140). Furthermore, evidence 
shows that Rho GTPase activity is essential for EC morphogenesis, tube formation and 
capillary branching. Active forms of Rac1 and Cdc42 have been shown to increase EC lumen 
formation, microvessel branching and sprouting (140, 169-171). Studies have also shown a 
critical and selective role for RhoA activity in regulating angiogenesis. Some reports have 
suggested that RhoA inhibition impedes angiogenesis (172, 173), whereas some have claimed 
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Stage of 
angiogenesis 
Rac1 Cdc42 RhoA 
    
Matrix 
degradation 
 
Increases MMP 
exp. & secretion, 
promotes latent 
increase in TIMP 
exp. & activity 
Increases MMP 
exp. & secretion, 
promotes latent 
increase in TIMP 
exp. & activity 
Increases MMP 
exp. & secretion 
 
    
Migration Membrane 
protrusion, focal 
complex turnover 
Polarity, membrane 
protrusion, focal 
complex turnover 
Retraction, focal 
adhesion turnover 
    
Proliferation Promotes G1/S 
transition 
Promotes G1/S 
transition 
Promotes G1/S 
transition 
    
Tube formation  Promotes capillary 
& lumen formation 
Promotes capillary 
& lumen formation 
Promotes capillary 
formation & 
branching 
    
 
Table 1.2 Rho GTPase roles during angiogenesis. (exp.; expression) Adapted from 
Bryan et al. (2007) (140). 
 
that inhibition of RhoA signalling stimulates tube formation (92, 166, 174). Therefore, 
although it is clear that contractility is essential for EC motility and tubulogenesis, an over-
abundance of actomyosin contractility can also disrupt these processes.  
 
In recent years, a growing number of studies have also implicated Rho proteins as essential 
regulators of endothelial integrity and permeability (175-177). In EC monolayers, active 
RhoA binds to its effector protein ROCK and promotes an increase in stress fibre formation 
and actomyosin contractility. This contractile tension evokes the breakdown of cell-cell 
junctions, which leads to a disruption in the endothelial barrier and an increase in 
permeability (1, 178). A recent study by Tan et al. (2008) shows that specifically deleting the 
expression of Rac1 in ECs in mice (by using the Cre/Flox conditional knockout approach, 
under the control of Tie2 expression) causes embryonic lethally and defects in vascular 
development at around E9.5 (1, 171). Analysis of Rac1 deficient ECs revealed that cells failed 
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to form lamellipodia, required for proper cell-cell and cell-matrix interactions, resulting in 
impaired endothelial barrier function and vessel leakiness (171, 179). These findings provide 
evidence that Rac1 is essential for angiogenic vascular development and endothelium 
integrity through maintenance of adherens and tight junctions (180). As well as Rac1, Cdc42 
also participates in the recovery of endothelial barrier integrity (181-183). After stimulation 
with thrombin (a protease involved in blood clotting which induces RhoA-mediated 
permeability), Cdc42 activation is delayed by an hour which coincides with the repair of 
junctional complexes (182). As already mentioned, Cdc42 plays an essential role in Golgi-
derived vesicle trafficking. Thus, in response to breakdown of the endothelial barrier, Cdc42 
controls the transport of junctional complex proteins towards the plasma membrane, which 
help to repair intercellular junctions (175, 184, 185). It has been well documented that Rac1 
downregulates RhoA activity, which leads to reversal of the endothelial contractile response 
(186, 187). A recent study by Ramachandran et al. (2008) shows that expression of dominant 
active Cdc42 in ECs in vivo protects endothelial barrier integrity by inhibiting RhoA-
dependent permeability (183).  
 
Considering all the functions Rho GTPases regulate in ECs, it is not surprising that aberrant 
Rho GTPase signalling has been found to be involved in a wide range of vascular diseases 
such as atherosclerosis, hypertension and coronary/cerebral vasospasm (188, 189). In 
addition, Rho proteins and GEFs are found to be overexpressed in solid tumours (145, 190-
196). Therefore, Rho protein signalling pathways are attractive targets for future anti-cancer 
therapy. 
 
1 | Introduction 
 
 36 
1.5 RhoJ 
1.5.1 Overview 
RhoJ, also known as TC10-like (TCL) is a little studied Rho GTPase protein that belongs to 
the Cdc42 subfamily group and is phylogenetically most closely related to TC10/RhoQ and 
Cdc42, sharing 85% and 78% amino acid identity, respectively (197). RhoJ is encoded by five 
exons, which span over 85 kb on human chromosome 14, which is the largest gene encoding a 
Rho GTPase at present (197). RhoJ has a classical domain structure with conserved 
GTP/GDP binding regions, GTPase activity and a CAAX box motif (197, 198).  
 
1.5.2 Literature review of RhoJ 
Vignal et al. identified RhoJ as a new Rho protein that had high sequence homology to TC10 
and Cdc42 in 2000, (197). RhoJ was found to have a distinct mRNA expression pattern in 
mice compared to its closely related proteins; TC10 is found mainly in skeletal muscle, Cdc42 
is ubiquitously expressed, and according to Vignal et al., RhoJ is highly expressed in heart 
(197, 199). They also compared the biochemical kinetics of TC10 to RhoJ and found that in 
vitro RhoJ exchanges GDP into GTP 40% more rapidly than TC10, suggesting that RhoJ may 
be predominantly GTP-bound in vivo. (197). Moreover, TC10, Cdc42 and RhoJ share a 
highly conserved effector domain and are able to bind to identical downstream effector 
proteins, which contain Cdc42/Rac1 interacting binding motif (CRIB) domains (197). Rac1 
can also bind to effector proteins that contain CRIB domains, such as p21 activated kinase 
(PAK) and WASP. Despite its close relation to TC10 and Cdc42 and the ability to bind 
identical effector proteins, RhoJ overexpression did not induce filopodia formation like Cdc42 
and TC10 (112, 197, 199). Instead, REF-52 fibroblasts that expressed constitutively active 
RhoJ promoted actin-rich ruffles on the dorsal membrane, large cytoplasmic vesicles, stress 
fibre reduction and motile cellular morphology (197).  
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In 2002, Chiang et al. demonstrated that the mouse homologue of RhoJ (also called TC10β) 
was activated by insulin in 3T3-L1 adipocytes (200). More recently, Nishizuka and others 
(2003 and 2010) showed a vital role for TC10β in the program of adipocyte differentiation in 
mouse in vitro (201, 202). The expression level of mouse RhoJ rose when preadipocyte cells 
were induced to differentiate into adipocytes and the expression of TC10β in NIH-3T3 
fibroblasts, which normally do not differentiate into adipocytes, caused the accumulation of 
oil droplets and adipogenic markers (201).  
 
In 2003, Toledo et al. showed that RhoJ may also be involved in controlling early endocytosis 
(203). RhoJ was found to co-localise with early/sorting endosomes markers in HeLa cells 
expressing myc-tagged RhoJ (203). Knockdown of RhoJ expression in HeLa cells perturbed 
transferrin (Tf) trafficking, whereby Tf release was slowed down. Overexpression of 
constitutively active RhoJ promoted accumulation of Tf in early/sorting endosomes and the 
normal release of Tf, suggesting that RhoJ is involved in endocytic vesicle movement (203). 
 
Other studies have shown a role for RhoJ in f-actin reorganisation. Abe et al. (2003) reported 
loss of stress fibres in mouse fibroblasts that expressed dominant active RhoJ (198). In 
addition, Aspenstrom et al. (2004) observed lamellipodia formation and focal adhesion-like 
assemblies at the cell periphery of porcine aortic ECs that expressed constitutively active 
RhoJ (204). More recently, Billottet et al. (2008), showed that expression of the active form 
of RhoJ in porcine aortic ECs induced the formation of actin-rich adhesion assemblies known 
as podosomes (205). Thus like its famous siblings Rac1, Cdc42 and RhoA, RhoJ also plays a 
role in actin reorganisation in different cell types. 
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1.5.3 Discovery of RhoJ in endothelial cells 
Using a bioinformatics approach, whereby publicly available endothelial cDNA libraries were 
in silico subtracted from non-endothelial libraries, our laboratory previously identified RhoJ 
as being highly expressed by human ECs (206). This finding was confirmed by looking at the 
mRNA expression level of RhoJ in various primary cell lines using quantitative PCR (206). 
High levels of RhoJ mRNA was found in human umbilical ECs (HUVEC) and human dermal 
microvascular ECs (HDMEC) but not in other cell types such as fibroblasts, epithelial cells, 
hepatocytes, lymphocytes and keratinocytes (figure 1.9). The bioinformatic analyses also 
suggested that RhoJ is the most abundantly expressed Rho GTPase protein in human 
umbilical vein ECs (206). 
 
1.5.3.1 Hypothesis 
With increasing evidence showing that Rho proteins are involved in regulating angiogenesis, 
the hypothesis being tested is that RhoJ signalling is important for aspects of EC biology 
associated with the angiogenic process.  
 
1.6 Aims 
The overall aims of this project were to investigate the function of RhoJ in tubulogenesis and 
EC motility in vitro, to explore the role of RhoJ during zebrafish development and to 
determine its mammalian expression profile. The methodologies used for each of these aims 
are outlined below. 
 
1. Investigate the function of RhoJ in tubulogenesis and EC migration 
RNA interference (RNAi) was used to silence RhoJ expression in primary ECs and in vitro 
methods were used to test the impact of RhoJ knockdown on endothelial tube formation, 
1 | Introduction 
 
 39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 RhoJ is highly expressed in human endothelial cells. Quantitative PCR 
analysis of RhoJ mRNA expression in various normal human primary cell types: 
HUVEC; human umbilical vein endothelial cells, HDMEC; human dermal 
microvascular endothelial cells, MRC5; human lung fibroblasts, BECs; human 
bronchial epithelial cells, hepatocytes, peripheral blood lymphocytes and human adult 
epidermal keratinocytes. Graph taken from Herbert et al. (2008) (206). 
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migration and survival. The molecular mechanism of RhoJ function in EC motility was 
explored by analysing the effects of RhoJ knockdown/overexpression on aspects of cell 
migration, such as focal adhesion and stress fibre formation, and cell contractility. 
 
2. Characterise the role of RhoJ during zebrafish embryogenesis 
The temporal expression of RhoJ during zebrafish development was investigated using 
reverse transcription PCR analyses. The localisation of RhoJ expression during physiological 
embryonic angiogenesis was determined using in situ hybridization experiments. The function 
of RhoJ during zebrafish development was assessed by using morpholino technology to 
knockdown RhoJ expression in vivo. 
 
3. Determine the expression profile of RhoJ in mammals 
The localisation of RhoJ in human normal/cancerous tissues and mouse embryos during 
developmental angiogenesis was determined using in situ hybridization experiments. The 
tissue distribution profile of mammalian RhoJ was also examined using various cell lines and 
quantitative PCR/Western blotting analyses.  
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
Materials and methods 
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2.1 Commonly used solutions and media 
Buffers Constituents 
1 x Phosphate-buffered saline 
(PBS)  
10 mM Na2HPO4, 1.76 mM KH2PO4, 2.7 mM KCl and 0.14 
M NaCl, pH 7.4 
NP40 (lgepal) lysis buffer  1%  (v/v) NP40, 10 mM Tris pH 7.5, 150 mM NaCl, 1 mM 
EDTA pH 8, 0.01% (w/v) sodium azide and 1 x protease 
inhibitor cocktail  
2 x SDS-PAGE sample loading 
buffer 
100 mM Tris-HCl, pH 6.8, 20% (v/v) β-mercaptoethanol, 
4% (w/v) SDS, 0.2% (w/v) bromophenol blue, 20% (v/v) 
glycerol 
1 x Stacking gel buffer 125 mM Tris-HCl; pH 6.8, 0.1% SDS  
1 x Resolving gel buffer 375 mM Tris-HCl; pH 8.8, 0.1% SDS  
1 x SDS-PAGE running buffer  25 mM Tris, 250 mM glycine, 0.1% (w/v) SDS, pH 8.3 
1 x Western blotting transfer 
buffer 
6 mM Tris-base, 47.6 mM glycine, 20% (v/v) methanol, pH 
8.3 
Tris-Buffered Saline Tween-20 
(TBST) 
20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% (v/v) tween-
20 
Western blotting blocking buffer 5% (w/v) dried skimmed milk in TBST 
Tris-Borate-EDTA (TBE) 89 mM Tris, 89 mM Boric Acid, 2 mM EDTA 
Tris-Acetate-EDTA (TAE) 40 mM Tris, 20 mM Acetic Acid, 1 mM EDTA 
 
2.2 Commonly used reagents  
All reagents listed below were purchased from Sigma, UK unless otherwise stated. 
 
Ethylenediaminetetraacetic acid (EDTA) 
Protease inhibitor cocktail 
Bovine serum albumin (BSA) 
Sodium azide 
Paraformaldehyde (PFA) 
TritonX-100 
Ethanol/Methanol 
Acetic acid 
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Deionised formamide 
Citric acid 
20 x saline-sodium-citrate (SSC) 
N,N,N',N'-Tetramethylethylenediamine (TEMED) (Amresco, USA) 
Bromophenol blue 
Agarose 
Igepal (NP40) 
Tris-base 
Ammonium persulphate (Amresco, USA) 
Glycine 
Tween-20 
Heparin 
Proteinase K 
Sodium dodecyl sulphate (SDS) 
Sodium chloride (NaCl) 
β-mercaptoethanol 
Glycerol 
RNAse A 
Isopropanol 
Chloroform 
CHAPS 
Ponceau S 
Boric acid 
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2.6 Cell biology 
2.6.1 Cell culture  
Primary isolates Source 
Human umbilical vein endothelial cells (HUVEC) Isolated from umbilical cords obtained from 
Birmingham Women’s Hospital, 
Birmingham, UK 
Human pericytes from placenta (hPC-PL) Promocell, UK 
Human aortic smooth muscle cells (HASMC) TCS Cell Works, USA 
Cell lines Source 
Human microvascular endothelial cell line-1 
(HMEC-1) 
Ades et al. (1992) (207) 
Mouse subcutaneous endothelial cell line (sEND) Wagner et al. (1988, 1989) (208), (209) 
Materials Source 
Media 199  Cancer Research UK and Sigma, UK 
Dulbecco’s modified eagle medium  Sigma, UK 
Pericyte Growth Medium Promocell, UK 
Bovine brain extract Bovine brains were obtained from Pel-
Freez, USA. Brains were prepared as 
described by Maciag et al. (1979) (210). 
Fetal calf serum  PAA, The Cell Culture Co., UK 
L-glutamine Sigma, UK 
Heparin Sigma, UK 
Porcine skin gelatin  Sigma, UK 
Trypsin-EDTA Sigma, UK 
FastRead Haemocytometer Immune Systems, UK 
Tryphan Blue Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
USB 2.0 2M Xli camera Leica Microsystems, USA 
 
Human umbilical cords were obtained from Birmingham Women's Health Care NHS Trust at 
delivery after mothers had given informed consent. Human umbilical vein ECs (HUVECs) 
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were isolated from umbilical cords by using collagenase type IA by Mr. James Beesley 
(laboratory manager) according to a standard protocol (211). HUVECs were cultured to 
around 80-90% confluence in Media 199 containing 4 mM L-glutamine, 90 µg/mL heparin, 
10% (v/v) fetal calf serum (FCS) supplemented with bovine brain extract (prepared as 
described in (210)). Cells were plated in sterile plastic culture dishes that had been coated 
with 0.1% (w/v) gelatin. HUVEC were split at a ratio of 1:3 once cells were 80-90% 
confluent and were used between passages 1-6. Human pericytes derived from placenta (hPC-
PL) were cultured to 90% confluence in uncoated sterile plastic culture dishes. Cells were 
grown in medium provided by Promocell, UK and split at a ratio of 1:3 once cells were 90% 
confluent and used between passages 2-4. Human aortic smooth muscle cells (HASMC) were 
cultured to 90% confluence in Media 199 supplemented with 4 mM L-glutamine and 10% 
(v/v) FCS. HASMC were seeded onto sterile plastic culture plates that were coated with 0.1% 
(w/v) gelatin. Cells were split at a ratio of 1:3 once 90% confluence was reached and used 
between passages 2-4. Immortalised human microvascular EC line-1 (HMEC-1) was derived 
from primary human dermal microvascular ECs (HDMEC), which were transfected with 
simian vacuolating virus 40 T antigen (SV40-T) by Ades et al. (1992) (207). HMEC-1 were 
obtained from Professor Kay Davies (University of Oxford) and were cultured in 0.1% (w/v) 
gelatin coated sterile plastic culture dishes in Dulbecco’s modified eagle medium (DMEM), 4 
mM L-glutamine and 10% FCS until 90% confluent. Cells were then split at a 1:3 ratio when 
90% confluence was reached. An immortalised EC line derived from murine subcutaneous 
endothelium (sEND) was cultured in DMEM, 4 mM L-glutamine and 10% (v/v) FCS. This 
cell line expresses the polyoma virus middle T antigen, has a cobblestone-like morphology, 
expresses von Willebrand factor and causes hemangiomas in vivo (208), (209). Cells were 
plated in uncoated sterile plastic culture dishes and grown until confluent. sEND were split at 
a ratio of 1:10 once cells were 100% confluent.  
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All primary cells and cell lines were maintained in a humidified atmosphere with 5% CO2 at 
37°C. Once cells reached the desired confluence, cells were washed with 1 x phosphate-
buffered saline (PBS) and incubated for 5 minutes at 37°C with 1 x trypsin-EDTA solution. 
Once cells detached from the culture dish they were recovered in complete media, pelleted at 
350 RCF for 5 minutes and resuspended in fresh complete media. Cells were then plated out 
on to new sterile culture dishes for further cultivation.  
 
2.6.2 Transfection of siRNA into mammalian cells 
siRNA duplex Sequence Targeted nucleotides of coding 
region 
Source 
RhoJ duplex 1 5’-ccactgtgtttgaccacta-3’ 155-174 Eurogentec, 
UK 
RhoJ duplex 2 5’-agaaacctctcacttacga-3’ 455- 474 Eurogentec, 
UK 
Materials Source 
OptiMEM Invitrogen, UK 
Lipofectamine RNAi MAX Invitrogen, UK 
Negative control duplex Eurogentec, UK 
 
Small interfering RNA (siRNA) duplex 1 (D1) and duplex 2 (D2) were designed according to 
the criteria determined by Reynolds et al. (2004) (212), to the coding region of human RhoJ. 
A negative control duplex (NCD) was used that has no homology to any known sequence. 
The siRNA duplexes were made to working stocks of 20 µM in RNase-free water.  
 
For transfecting cells with siRNA in 10 cm culture dishes, 1 x 106 cells were seeded on to 
gelatin-coated dishes one day before transfection. The following day, D1, D2 or NCD was 
diluted in 680 µL of optiMEM to give a final siRNA concentration of 10 nM because it was 
the lowest concentration to consistently produce complete knockdown of RhoJ protein (see 
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appendix 1 for titration of siRNA duplexes). In a separate tube, 10% (v/v) lipofectamine 
RNAiMAX was prepared in a total volume of 120 µL of optiMEM. After mixing gently, both 
mixtures were incubated at room temperature for 10 minutes. Then the two mixtures were 
combined to give a total volume of 800 µL, gently flicked and incubated for a further 10 
minutes at room temperature. Meanwhile, the cells were washed twice with PBS before 
adding 3.2 mL optiMEM to the cells. The final transfection mix was then added to the plate to 
give a total volume of 4 mL. The plate was then tilted to ensure even distribution of the 
siRNA across the cell monolayer. Mock cells were transfected using the method above but 
with no siRNA included. The cells were incubated for 4 hours in 5% CO2 at 37°C. The 
siRNA-containing medium was then replaced with fresh media. Cells were assayed 48-72 
hours after the transfection. To transfect cells in 6 cm dishes, 6 well plates or 96 well plates 
the transfection mixes were scaled down according to the surface area of the culture dish 
being used. The table below shows the culture dish used for transfection and the number of 
cells transfected for each siRNA-knockdown experiment. Western blotting was performed for 
every transfection to validate successful knockdown of RhoJ protein. 
 
Assay Culture dish size Number of cells  
Two-dimensional Matrigel tube formation 10 cm plate 1 x 106 
Three-dimensional tube formation 10 cm plate 1 x 106 
Wound healing 6-well dish 3 x 105 
Boyden chamber chemotaxis 10 cm plate 1 x 106 
Dunn chamber chemotaxis 10 cm plate 1 x 106 
Proliferation 10 cm plate 1 x 106 
Cell cycle 96-well plate 2 x 103 
Apoptosis 6 cm plate 3.6 x 105 
Cell contraction assay 10 cm plate 1 x 106 
Immunofluorescence 6 cm plate 3.6 x 105 
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2.6.3 In vitro functional studies 
2.6.3.1 Tube formation 
Materials Source 
BD Matrigel, basement membrane matrix VWR, Canada 
Cytodex-3 Beads Amersham Pharmacia, UK 
Aprotinin Sigma, UK 
Fibrinogen Type I Sigma, UK 
Thrombin Sigma, UK 
 
2.6.3.1.1 Two-dimensional Matrigel tube formation  
To assay tube formation in two-dimensions, Matrigel was thawed overnight on ice at 4°C. 
The wells of a 12 well plate were wetted with PBS prior to adding 70 µL of Matrigel. The 
basement membrane extract was allowed to solidify at 37°C for 30 minutes. Cells were 
harvested and seeded at a density of 1.4 x 105 (cell density and Matrigel thickness was 
optimised by Dr. Victoria Heath) on top of the Matrigel layer in 1 mL of culture medium (see 
appendix 2 for diagram of set up). Cells were then incubated in 5% CO2 at 37°C for a further 
24 hours. Tube formation was observed by taking pictures at 10 and 24 hours post seeding 
using Leica DM IL microscope and USB 2.0 2M Xli camera. Quantitation was to count the 
number of nodes with either 1, 2, 3 or ≥4 branch points from five random fields of view for 
each condition at 10 and 24 hour time points. An example of node counting has been provided 
in appendix 2. 
 
2.6.3.1.2 Three-dimensional tube formation 
This method was adapted from that described by Nakatsu et al. (2007) (213). Two days after 
siRNA transfection, cells were harvested and counted to make a cell-bead suspension 
containing 106 HUVEC (a higher cell density was used because this ensured even coverage of 
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the beads) and 2,500 cytodex-3 micro-carrier beads in a final volume of 1.5 mL in sterile 
conical tubes. The mix was incubated for 4 hours in 5% CO2 at 37°C to allow the cells to 
adhere to the beads. During this incubation, every 20 minutes the tubes were flicked to ensure 
even coating of the beads with HUVEC. The coated beads were transferred to a T25 flask in 5 
mL of HUVEC media and incubated overnight. The coated beads were transferred to a 15 mL 
conical tube and allowed to settle for 10 minutes. After aspirating the supernatant, the beads 
were resuspended in 1 mL of 2.9 mg/mL fibrinogen solution containing 0.15 Units/mL 
aprotinin. Polymerisation was induced by mixing 0.5 mL of fibrinogen/bead suspension with 
6.2 µL of 0.625 Units/mL thrombin in a well of a 12-well plate. After a 10 minute incubation 
at room temperature, fibrin clots were generated and HUVEC media was added drop wise to 
the gel. The beads were incubated in 5% CO2 at 37°C and three-dimensional sprouting was 
observed over 7 days. Media was replaced every 2 days. To quantify sprouting, the number of 
sprouts per bead were counted, and beads were scored as having, <5, 5-10 or >10 sprouts. 
 
2.6.3.2 Cell migration 
Materials Source 
Mitomycin C Sigma, UK 
48-well Boyden chemotaxis chamber Neuro Probe, USA 
8µm pore polycarbonate nucleopore filters Neuro Probe, USA 
4',6-diamidino-2-phenylindole (DAPI) Sigma, UK 
Dunn chemotaxis chamber  Hawksley, UK 
Zeiss Axiovert 200 inverted high-end microscope Zeiss, UK 
Coolsnap Photometrics camera Photometrics, USA 
Image J software  National Institutes of Health 
Slidebook 4.2 software  Intelligent Imaging Innovations, USA 
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2.6.3.2.1 Scratch wound assay  
In 0.1% (w/v) gelatin coated 6 well plates, ECs were seeded at cell density of 3 x 105 and 
incubated overnight. Cells were then transfected with siRNA duplexes and two days later 
horizontal pen marks were made along the bottom of the wells. Scratches perpendicular to the 
pen marks were made with 200 µL sterile pipette tips. Cell debris was washed off and fresh 
media containing 2.5 µg/mL mitomycin C was added (concentration optimised by Dr. 
Victoria Heath). Mitomycin C is a cell division inhibitor and was added to ensure that cell 
proliferation did not contribute to wound closure. Cells were incubated in 5% CO2 at 37°C for 
a further 24 hours. Cell migration was observed by taking pictures at 0, 4, 12 and 24 hours 
using Leica DM IL microscope and USB 2.0 2M Xli camera. To quantify wound closure, the 
areas of wounds were measured using Image J software. For each condition, the wounds at 0 
hour time point were considered to have an area of 100%. The areas of the wounds at the 
subsequent time points therefore were divided by the area measured at 0 hour time point, and 
the percentage of the wound closure calculated.    
 
2.6.3.2.2 Boyden chamber chemotaxis 
Chemotaxis was assayed using a 48-well modified Boyden chamber (see appendix 3) (214) 
with 8 µm pore size polycarbonate nucleopore filters. Filters were coated with 0.1% (w/v) 
gelatin (recommended by Neuro Probe, USA) and placed over a lower chamber containing 30 
µL per well of complete HUVEC media, which is supplemented with 10% (v/v) FCS and 
bovine brain extract (see appendix 3 for optimisation). Cells were rested in serum-free media 
for 15 minutes before the assay to enhance the response to the chemoattractant. Cells were 
harvested and 2 x 104 cells (cell density recommended by Neuro Probe, USA) were seeded 
per well of the upper chamber in 50 µL of Media 199 consisting of only 4 mM L-glutamine, 
1% (v/v) FCS and no bovine brain extract. After 5 hours incubation in 5% CO2 at 37°C, the 
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filters were removed. Cells were fixed in 100% methanol and stained with 100 ng/mL DAPI 
for 1 minute at room temperature. The filters were then washed with tap water and placed 
onto a glass slide and non-migrated cells were wiped away with a wet cotton swab. Cells that 
migrated through the pores towards the chemoattractant were viewed using Axiovert 100M 
confocal microscope and LSM 510 software. The sum of migrated cells in five random areas 
for each well was calculated for at least nine replicate wells of each condition. A schematic of 
the Boyden chamber assay can be found in appendix 3. 
 
2.6.3.2.3 Dunn chamber chemotaxis 
Live chemotaxis was analysed using Dunn chambers (215) and time-lapse microscopy (see 
appendix 4 for a schematic of the Dunn chamber). Alexandra Mazharian from The University 
of Birmingham, UK optimised this assay. Two days after siRNA transfection, 105 HUVEC 
were plated onto 0.1% (w/v) gelatin coated coverslips (22 mm x 22 mm) and left to adhere for 
1 hour in 1% (v/v) FCS media with no bovine brain extract. The coverslips were then inverted 
onto the Dunn chamber. The chemoattractant (complete HUVEC media with 10% (v/v) FCS 
and bovine brain extract) was added to the outer well of the Dunn chamber. To set up a 
chemoattractant gradient, the inner ring was filled with control media (1% (v/v) FCS in Media 
199 containing 4 mM L-glutamine and no bovine brain extract). The Dunn chamber was 
placed in a humidified chamber on a heated stage at 37°C in 5% CO2 within an inverted 
microscope setup. Time-lapse images were digitally captured every 60 seconds for 4 hours. 
The cells that lay on the bridge between the two wells of the chamber were imaged using 
Axiovert 200 inverted high-end microscope, Coolsnap Photometrics camera and Slidebook 
4.2 software. Migration paths of the cells were mapped using Image J to visualise the 
direction of migration.  
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2.6.3.3 Cell growth and survival  
Materials Source 
Propidium iodide Sigma, UK 
Annexin V-FITC staining kit BD Pharmingen, UK 
10 x Binding Buffer (0.1 M Hepes pH 7.4, 1.4 M NaCl, 25 mM 
CaCl2) 
BD Pharmingen, UK 
Tumour necrosis factor-α (TNFα) Peprotech, UK 
FACS-Becton Dickson FACSCalibur Becton and Dickson, USA 
Acumen® eX3 microplate cytometer TTP Labtech Ltd, UK 
 
2.6.3.3.1 Proliferation  
Four hours after siRNA transfection, cells were harvested and 1.5 x 104 cells were seeded in 1 
mL of media per well of a 24 well plate. Four plates were prepared to count the cells 1-4 days 
after seeding. For each plate, cells from each condition were plated in triplicate. To determine 
cell growth, the cells were harvested 1-4 days after seeding and the number of cells obtained 
from each well was counted using a haemocytometer with tryphan blue and Leica DM IL 
light microscope.  
 
2.6.3.3.2 Cell cycle  
HUVEC were transfected with siRNA in a 96 well plate. Three days later, cells were washed 
gently with PBS and fixed with ice cold 85% (v/v) ethanol for 10 minutes at room 
temperature. The cells were washed with PBS once again before being permeabilised with 
0.1% (v/v) of triton-X-100 in PBS for 4 minutes at room temperature. Cells were then stained 
with 1 mg/mL propidium iodide (PI) in PBS containing 10 mg/mL RNAse A for 15 minutes 
at 37°C in the dark. Since PI can also bind to double-stranded RNA, it is necessary to treat the 
cells with RNAse for optimal DNA resolution. The plate was then scanned and the cell cycle 
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was analysed using an Acumen® eX3 microplate cytometer. This method was optimised by 
Dr. Zsuzsanna Nagy and colleagues (University of Birmingham). 
 
2.6.3.3.3 Apoptosis 
Three days after siRNA transfection, apoptosis was assessed using an annexin V-FITC 
staining kit according to the manufacturer’s instructions. Cells were stained in a volume of 
100 µL of 1 x binding buffer that contained 5 µL annexin V-FITC and 50 ng/mL PI. Cells 
were stained in the dark for 15 minutes before being analysed by FACS-Becton Dickson 
FACSCalibur to detect apoptosis. An aliquot of 10,000 cells were analysed per condition. 
Green fluorescence was detected using FL1 channel and red fluorescence was detected using 
FL3 channel. Cell Quest Software (version 3.1f) displayed the results as a bivariate dot plot of 
annexin V (FL1) and PI (FL3) fluorescence intensity. 
 
2.6.3.3.4 TNFα-induced apoptosis 
Tumour necrosis factor-α (TNFα) is a potent inducer of EC apoptosis (216, 217). TNFα was 
used as a positive control for detecting endothelial apoptosis. Two days after siRNA 
transfection, 5 x 104 cells were plated on to gelatin-coated 13 mm glass coverslips in a 24-
well plate. The following day, cells were washed with PBS and cells were treated with 0, 50, 
75 or 100 ng/mL of TNFα in fresh HUVEC media for 4 hours at 5% CO2 at 37°C. Dosage 
and incubation period was based on the studies of Petrache et al. (2001) (218). Following 
incubation, cells were fixed and stained with annexin V-FITC using the protocol stated in 
section 2.7.4. Changes made to the standard immunofluorescence protocol were that the cell 
permeabilisation step was omitted, 1 x binding buffer was used for annexin V binding and 
cells were not counterstained with DAPI. 
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2.6.3.4 Contractility 
Materials Source 
Cell contraction assay Cell Biolabs, Inc., UK 
Y27632 (ROCK inhibitor) Tocris Bioscience, UK 
H1152 (ROCK inhibitor) Tocris Bioscience, UK 
Blebbistatin (non muscle myosin II inhibitor) Tocris Bioscience, UK 
 
2.6.3.4.1 Cell contraction assay 
Using cell-populated collagen gels to measure contractility of human fibroblasts was first 
described by Bell et al. (1979) (219). Vernon and Sage (1996) (220) demonstrated that ECs 
also have the capability to contract collagen type I gels. To assay cell contraction, a collagen 
type I based cell contraction kit was set up according to the manufacturer’s instructions. 
Twenty-four hours after siRNA transfection, cells were harvested and resuspended in 
complete HUVEC medium at 3 x 106 cells/mL. The collagen gel lattice was prepared by 
mixing 1 part of cell suspension with 4 parts of ice-cold 3 mg/mL collagen gel solution. A 
volume of 0.5 mL of the cell-collagen mixture was added to each well of a 24 well plate and 
incubated for 1 hr at 37°C in 5% CO2. After collagen polymerisation, 1 mL of HUVEC 
medium was added drop wise to each collagen gel lattice. After two days, stress had 
developed in the collagen matrix. Therefore at this point, to initiate cell contraction, the 
attached collagen gels were gently released from the sides of the culture dishes with a sterile 
pipette tip. The degree of cell contraction was evaluated by measuring the diameter of the 
free-floating collagen gels after 5 days. 
 
2.6.3.4.2 Inhibition of Rho-kinase and non-muscle myosin II 
Rho-kinase (ROCK) inhibitors Y27632 and H1152 were used at a concentration of 10 µM. 
An inhibitor of non-muscle myosin II ATPase activity, blebbistatin, was used at a 
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concentration of 5 µM. The inhibitors were added to the media of in vitro functional assays 
such as two-dimensional Matrigel tube formation, wound healing, Boyden chemotaxis 
chamber and cell contraction assays. Drug concentrations were based on the work of 
Abraham et al. (2009) (221). 
 
2.7 Protein analyses 
2.7.1 Protein extraction  
For protein expression analysis, 48-72 hours after siRNA transfection, approximately 2 x 105 
cells were washed with PBS and lysed in 30 µL of NP40 (Igepal) lysis buffer. The lysates 
were vortexed for 10 seconds and left on ice for 30 minutes before being centrifuged at 
14,000 RCF for 10 minutes at 4°C. An aliquot of the supernatant was used to determine the 
protein concentration of the cell lysate using DC BioRad protein assay (BioRad Laboratories, 
UK) according to the manufacturer’s instructions. The remaining supernatant was transferred 
to a new tube containing an equal volume of 2 x SDS-PAGE sample buffer and stored at -
20°C.  
 
2.7.2 SDS-polyacrylamide gel electrophoresis  
Materials Source 
30% (w/v) Acrylamide/Bisacrylamide (5:1) National Diagnostics, UK 
Precision plus protein standard 250 – 10 kDa BioRad Laboratories, UK 
XCell SureLock™ Mini-Cell electrophoresis 
apparatus 
Invitrogen, UK 
 
To denature the proteins for SDS-polyacrylamide gel electrophoresis (SDS-PAGE), the cell 
lysate was boiled at 100°C for 5 minutes. Typically ~10 µg of protein lysate were separated 
by electrophoresis alongside protein standards (250-10 kDa) in  polyacrylamide gels prepared 
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using 30% (w/v) Acrylamide/Bisacrylamide (5:1), 1 x stacking gel buffer or 1 x resolving gel 
buffer, 10% (w/v) ammonium persulphate, TEMED in distilled H2O. Electrophoresis was 
performed in running buffer at 100 V using XCell SureLock™ Mini-Cell electrophoresis 
apparatus until the gel front had migrated to the bottom of the gel. The table below lists the 
volumes used to make a 12% resolving gel (6 mL) and a 5% stacking gel (2 mL). 
 
Resolving gel Volume (mL) 
H2O 2 
30% (w/v) Acrylamide/Bisacrylamide (5:1) 2.4 
Resolving gel buffer: 375 mM Tris-HCl; pH 8.8, 0.1% SDS 1.5 
10% ammonium persulphate 0.06 
TEMED 0.002 
Stacking gel Volume (mL) 
H2O 1.4 
30% (w/v) Acrylamide/Bisacrylamide (5:1) 0.33 
Stacking gel buffer: 125 mM Tris-HCl; pH 6.8, 0.1% SDS 0.25 
10% ammonium persulphate 0.02 
TEMED 0.002 
 
2.7.3 Western blotting 
Materials Source 
Polyvinylidene difluoride membranes Immobilon-P, Millipore, USA 
Chromatography paper (0.8 mm thickness) Whatman, UK 
Enhanced chemi-illuminescent substrate Amersham Biosciences, UK 
Hyperfilm ECL chemiluminescence film Amersham Biosciences, UK 
XCell II™ Blot Module wet transfer apparatus Invitrogen, UK 
 
Immediately after SDS-PAGE electrophoresis, proteins were transferred to polyvinylidene 
difluoride membranes. The polyvinylidene difluoride membranes were soaked in 100% 
methanol for 30 seconds and then soaked in transfer buffer for 5 minutes along with the SDS-
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PAGE gels and chromatography paper. Wet transfer was performed with XCell II™ Blot 
Module wet transfer apparatus at 30 V for 1 hour at 4°C. To check for successful transfer, the 
membranes were stained with Ponceau S and then blocked for 1 hour at room temperature in 
blocking buffer. The membrane was then incubated overnight at 4°C in primary antibody 
diluted in Tris-Buffered Saline Tween-20 (TBST) containing 3% (w/v) bovine serum albumin 
(BSA) and 0.01% (w/v) sodium azide. After washing the membrane 6 x 5 minutes with 
TBST, the appropriate secondary antibody conjugated to horseradish peroxidase (HRP) was 
diluted in blocking buffer and incubated with the membrane for 1 hour at room temperature. 
The membrane was then washed 6 x 5 minutes with TBST before being incubated for 1 
minute with enhanced chemiluminescent substrate (ECL) at room temperature. The 
membrane was then exposed to Hyperfilm-ECL high performance chemiluminescence film. 
 
2.7.4 Immunofluorescence 
Materials Source 
13 mm glass coverslips, thickness no. 1.5 VWR Canlab, Canada 
ProLong Gold Antifade reagent with DAPI® Invitrogen, UK 
Axiovert 100M confocal microscope/LSM 510 
software 
Carl Zeiss, Germany 
 
Cells were gently washed with PBS and fixed with 4% (w/v) paraformaldehye (PFA) in PBS 
for 15 minutes. The cells were washed again before being permeabilised with 0.1% (v/v) 
triton-X-100 in PBS for 4 minutes. The cells were blocked in blocking buffer (3% (w/v) BSA, 
10% (v/v) FCS, 0.1% (v/v) tween-20, 0.01% (w/v) sodium azide in PBS) for one hour at room 
temperature. The cells were then incubated for one hour at room temperature with the primary 
antibody diluted in blocking buffer. Cells were washed three times with PBS then incubated 
with the fluorophore conjugated secondary antibody and/or a protein-fluorophore conjugate 
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for 30 minutes at room temperature in blocking buffer. Cells were washed three times with 
PBS and once with H2O. Coverslips were mounted onto microscope slides using ProLong 
Gold Antifade reagent with DAPI® and left in the dark at room temperature overnight. The 
following day, the edges of the coverslips were sealed using clear nail-varnish and stored at -
20°C. Fluorescent staining was analysed using Axiovert 100M confocal microscope and LSM 
510 software (Zeiss).  
 
2.7.4.1 Wound healing  
In order to fluorescently stain proteins during wound healing, two days after siRNA 
transfection, 5 x 104 cells were seeded onto 13 mm gelatin-coated glass coverslips in 24-well 
plates. The following day, the cells were wounded by scraping across the surface with 2 µL 
sterile pipette tips and washed once with PBS. Fresh media was added and the wounds were 
allowed to heal for 6 hours in 5% CO2 at 37°C. The cells were then fixed and stained using 
the protocol above. Six hours was used as the time point for fixing because these wounds 
typically healed at 9 hours and six hours represented the 12-hour time point in the larger scale 
scratch wound assays. 
 
Annexin V-FITC was used to stain cells undergoing apoptosis in wound healing assays. As a 
positive control for this experiment, apoptosis was induced using TNFα as described in 
section 2.6.3.3.4.  
 
To visualise f-actin and focal adhesions during wound healing, cells were stained with 
primary anti-vinculin antibody and Alexa Fluor 488 secondary antibody and protein 
conjugate, phalloidin-TRITC. For f-actin quantification, LSM 510 confocal software was 
used to obtain the mean fluorescent intensity of the phalloidin-TRITC staining according to 
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the following equation: mean intensity  = sum of (number of +ve pixels x intensity 
levels)/number of +ve pixels. Counting the areas of vinculin staining using the cell-counter 
plugin tool of ImageJ quantitated the numbers of focal adhesions. In both cases, 30 cells were 
analysed either from the wound edge or monolayer. 
 
The Golgi apparatus was stained using Alexa Fluor 647 anti-GM130 antibody to determine 
whether cells were polarising in wound healing assays. To quantitate the position of the Golgi 
apparatus in migrating wound edge cells, cells were divided up into three 120° sectors 
centering on the nucleus, one of which faced the edge of the wound. Cells in which the Golgi 
apparatus was within the sector facing the wound were scored positive and counted.  
 
For specific antibody information, refer to section 2.3. 
 
2.7.4.2 Monolayer  
Two days after siRNA transfection, 3 x 104 cells were plated onto gelatin-coated 13 mm glass 
coverslips. The cells were incubated in 5% CO2 at 37°C and grown to 100% confluence for 7 
days. The cells were then fixed and stained using the protocol described in section 2.7.4 with 
anti-VE-Cadherin primary antibody and Alexa Fluor 488 secondary antibody. All PBS 
washes and incubations were made with PBS with calcium chloride and magnesium chloride 
(Sigma, UK) in order for the staining of VE-Cadherin with this antibody to work. For specific 
antibody information, refer to section 2.3. 
 
2.7.4.3 Subconfluent cells 
Two days after siRNA transfection, cells were harvested and seeded at 2 x 104 cells per 
gelatin-coated 13 mm glass coverslips. The cells were incubated in HUVEC medium for 4 
hours at 37°C in 5% CO2 to allow them for cells to adhere to the glass coverslips. The cells 
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were then fixed and stained according to the protocol described in section 2.7.4. Focal 
adhesions were stained by using either anti-vinculin, anti-phospho-FAK (pY397) or anti-
phospho-paxillin (Tyr118) primary antibodies. For all primary antibodies, the secondary 
antibody used was Alexa Fluor 488. For focal adhesion quantitation, 30 cells from each 
condition were picked at random and the staining of the focal adhesion marker was counted 
using the cell-counter plugin tool of ImageJ. For specific antibody information, refer to 
section 2.3. 
 
2.8 DNA protocols 
2.8.1 Gel electrophoresis 
Materials Source 
40% (w/v) Acrylamide/Bisacrylamide (29:1) BioRad Laboratories 
6 x gel-loading buffer Promega, UK 
100 bp/1kb DNA Ladders Promega, UK 
SYBR Safe DNA gel stain Invitrogen, UK 
Gene Genius Bio Imaging System and GeneSnap software Syngene, UK 
 
2.8.1.1 Neutral polyacrylamide gel electrophoresis 
To separate double stranded DNA, non-denaturing polyacrylamide gels were made with 1.66 
mL of 40% (w/v) acrylamide/bisacrylamide at a cross linker ratio of 29:1, 6.27 mL of H2O, 2 
mL of 5 x TBE, 70 µL of 10% (w/v) ammonium persulphate and 10 µL of TEMED. Gels 
were cast at 5% polyacrylamide with a separation range of 80–500 bp. Samples were loaded 
on to gel with 6 x gel-loading buffer alongside 100 bp/1 kb DNA ladders. The gels were run 
in 1 x TBE at 100 V using XCell SureLock™ Mini-Cell electrophoresis apparatus. Gels were 
stained after electrophoresis by immersion into 1 x TAE containing 2% (v/v) SYBR Safe 
DNA gel stain at room temperature for 1 hour.  
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2.8.1.2 DNA agarose gel electrophoresis 
DNA gel electrophoresis was performed in 1-2% (w/v) agarose gels made up with TAE buffer 
containing SYBR Safe DNA gel stain diluted at 1:10,000. Samples were loaded using 6 x gel 
loading dye and DNA ladders of 100 bp and 1 kb were used as size markers. The gels were 
run in 1 x TAE buffer at 80 V. Gels were visualised and imaged using Gene Genius Bio 
Imaging System (Syngene, Cambridge, UK).  
 
2.8.2 Cloning 
Materials Source 
GeneJET™ Plasmid Miniprep Kit Fermentas 
QIAfilter Plasmid Maxiprep Kit  Qiagen, UK 
QIAEX II Agarose Gel Extraction kit Qiagen, UK 
QIAquick PCR Purification Kit  Qiagen, UK 
ZeroBlunt® TOPO® Cloning kit Invitrogen, UK 
10 x BSA New England BioLabs, UK 
T4 ligase /10 x T4 ligase buffer  New England BioLabs, UK 
HindIII /10 x buffer 2 New England BioLabs, UK 
Not1/10 x buffer 3 New England BioLabs, UK 
EcoR1/EcoR1 buffer Fermentas 
BamH1/BamH1 buffer Fermentas 
 
2.8.2.1 Restriction digests and gel purification 
Restriction enzyme digestion of purified RT-PCR-amplified DNA or host plasmid vector 
DNA was performed in a total volume of 50 µL. This consisted of 5 µL of 10 x enzyme 
buffer, 5 µL of 10 x BSA, 37.5 µL of 5 µg plasmid or PCR product DNA diluted in DEPC 
treated-H20 and 2.5 µL of restriction enzyme at 20,000 U/mL. The mixture was then 
incubated for 2.5 hours at 37°C. The digested DNA fragments were run in broad lanes on a 
1% (w/v) agarose gel and purified with QIAEX II agarose gel extraction kit according to 
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manufacturer’s instructions.  
 
2.8.2.2 DNA ligation 
DNA inserts were ligated with appropriate plasmids using T4 ligase enzyme at 400,000 U/ml. 
A reaction volume of 20 µL was set up with 2 µL of enzyme, 2 µL 10 x T4 ligase buffer and 
16 µL of insert:vector mix at a ratio of 3:1. Control ligations lacking insert were also 
prepared. Ligations were incubated at room temperature for 1 hour.  
 
2.8.2.3 Extraction of plasmid DNA 
For bacterial colony screening, 10 different colonies after heat-shock transformation of 
bacteria were incubated overnight at 37°C in 2 mL Luria-Bertani (LB) broth medium 
containing the required antibiotic. Plasmid DNA from 2 mL overnight cultures was isolated 
using the GeneJET™ Plasmid Miniprep Kit according to manufacturers instructions. To 
generate a large amount of plasmid DNA, corresponding bacteria of the miniprep incubation 
were incubated overnight in 200 mL of LB-broth medium with the same concentration of 
antibiotics. Plasmid DNA was purified using QIAfilter Plasmid Maxiprep Kit according to the 
manufacturer’s instructions.  
 
2.8.2.4 DNA sequencing 
All cloned constructs were verified by sequencing using the plasmid to profile service of the 
University of Birmingham according to their instructions.  
 
2.9 Microbiology 
Materials Source 
Escherichia coli subcloning efficiency™ DH5α™  Invitrogen, UK 
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α-select competent cells gold efficiency Bioline, UK 
Cellstar incubator  Borolabs Ltd., UK 
Orbital shaker  Sanyo Gallenkamp, UK 
Ampicillin 100 µg/mL Sigma, UK 
Kanamycin 50 µg/mL Sigma, UK 
Liquid SOC medium  Invitrogen, UK 
Buffers Constituents 
LB broth 1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) 
NaCl in H20 
LB agar 1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) 
NaCl, 0.1% (w/v) bacto-agar in H20 
 
2.9.1 Bacterial culture 
Bacteria (Escherichia coli (E.coli) subcloning efficiency DH5α™ or α-select competent cells 
gold efficiency) were cultured at 37°C either as colonies on LB-agar plates in a Cellstar 
incubator or in LB-broth medium in an orbital shaker.  
 
2.9.2 Heat-shock transformation of bacteria 
Plasmid DNA or 5 µL of a ligation mix were added to 25 µL of chemically competent E.coli 
subcloning efficiency DH5α™ or α-select gold efficiency bacteria. Cells were incubated for 
15 minutes on ice, then at 42°C for 30 seconds and placed on ice again for 2 minutes. After 
adding 500 µL LB-broth medium, cells were incubated at 37°C shaking for 1 hour and plated 
on LB-agar plates containing the required antibiotic. The plates were then incubated at 37°C 
overnight.  
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2.9.4 Preparation of glycerol stocks 
500 µL cultures of E.coli cells transformed with plasmids of interest in LB-broth medium 
were mixed with the same volume of 30% (v/v) glycerol solution in a cryotube. The tube was 
placed in a dry ice/isopropanol bath until the bacteria were frozen and then stored at –80°C. 
 
2.10 RNA analyses 
2.10.1 RNA extraction 
To extract total cellular RNA, approximately 2 x 105 cells in a well of a 6 well dish were 
lysed with 1 mL of TRI reagent (Sigma, UK). Cells were homogenised by pipetting up and 
down using a 1 mL pipette then incubated for 5 minutes at room temperature. The 
homogenate was then transferred into a new tube containing 200 µL chloroform (Sigma, UK). 
Tubes were shaken vigorously for 15 seconds, incubated for 10 minutes at room temperature 
and centrifuged at 12,000 RCF for 15 minutes at 4°C. Following centrifugation, the mixture 
separated into a lower red phenol-chloroform phase, interphase and a colorless upper aqueous 
phase. The upper aqueous phase containing the RNA was removed and mixed with 0.5 mL 
isopropanol and incubated for 10 minutes at room temperature. To precipitate the RNA, the 
solution was centrifuged at 12,000 RCF for 10 minutes at 4°C. The supernatant was removed 
and the pellet was washed with 1 mL of 75% (v/v) ethanol and centrifuged at 12, 000 RCF for 
5 minutes at 4°C. The ethanol wash was removed and the RNA pellet was briefly air-dried. 
RNA was dissolved in water made RNAse-free by diethyl pyrocarbonate (DEPC) treatment. 
To check RNA quality, total RNA was run on a 1% (w/v) agarose gel and the RNA 
concentration was measured by using NanoDrop ND-1000 spectrophotometer (Labtech, UK). 
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2.10.2 Generation of cDNA 
Materials Source 
High capacity cDNA Archive Kit Applied Biosystem, USA 
SuperScript III First-Strand Synthesis System Invitrogen, UK 
 
Total complementary DNA (cDNA) was generated from RNA using High Capacity cDNA 
Archive kit (RNA obtained from primary cells or cell lines) or SuperScript III First-Strand 
Synthesis System kit (RNA obtained from whole zebrafish embryos) according to the 
manufacturer’s instructions. Both kits use random hexamer primers to generate cDNA. In 
each case, 3 µg of isolated RNA was converted to cDNA in a reaction volume of 30 µL. For 
reverse transcription PCR, each RNA sample was also used to generate a reverse transcription 
control (reaction without reverse transcriptase enzyme). 
 
2.10.3 Real time quantitative PCR 
Materials Source 
SensimixTM Quantace, UK 
Universal ProbeLibrary set, Human Roche Applied Science, UK 
Rotor-Gene RG-3000 qPCR machine Corbett Research Ltd, Australia 
Rotor-Gene 6 software Corbett Research Ltd, Australia 
 
Real time quantitative PCR (qPCR) was performed using a probe-based system developed by 
Exiqon and Roche Applied Science. Forward and reverse primers were designed using the 
Roche web based tool, which if possible would position the PCR product across an exon 
boundary. cDNA was diluted twenty fold and 10 µL of this was used for every 25 µL of PCR 
reaction mix (12.5 µL of 2 x qPCR Master mix, 1 µL of 10 µM forward primer, 1 µL of 10 
µM reverse primer, 0.25 µL of the corresponding probe and 0.25 µL of deionised water). The 
PCR was conducted using an initial denaturing interval at 95°C for 10 minutes followed by 40 
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cycles of 95°C for 15 seconds and 60°C for 45 seconds using Rotor-Gene RG-3000. 
Expression levels were determined by comparing the results to standard curves generated by 
Rotor-Gene 6 software from serial dilutions that were made of a known amount of cDNA. To 
accurately quantify gene expression, the expression level of the gene of interest was divided 
by the expression level of the housekeeping gene. This method of normalisation permits 
accurate comparison of expression of the gene of interest between different samples.  
 
2.10.4 Reverse transcription PCR 
Materials Source 
Phusion High-Fidelity DNA Polymerase  New England BioLabs , UK 
5 x High-Fidelity Buffer New England BioLabs, UK 
100mM Deoxynucleotide triphosphate mix Bioline, UK 
PTC-225 Peltier Thermal Cycler for RT-PCR MJ Research, UK 
 
To generate inserts for cloning into various vectors, reverse transcription PCR (RT-PCR) was 
performed in a total volume of 50 µL. 50 µL reaction mixes contained the following: 34 µL of 
water, 10 µL of 5 x Phusion High Fidelity Buffer, 1 µL of 10 mM dNTP mix, 1 µL of each 
primer (50 µM) and 1 µL of Phusion High-Fidelity DNA Polymerase. Finally 2 µL of 
template was added. For the no template control, template was omitted. PCR reactions were 
performed using Peltier Thermal Cycler set at an initial denaturation step of 98ºC for 30 
seconds, then 24 cycles of denaturation at 98°C for 30 seconds, annealing at 58-60°C for 30 
seconds (this step is primer dependant) and 72°C for x minutes (where x  =  the length in 
kilobases of the region to be amplified). A final extension step of 72ºC for 10 minutes was 
included. PCR products for cloning were purified using QIAquick PCR Purification Kit 
according to the manufacturer’s instructions. The whole PCR product was loaded on to an 
agarose gel and gel electrophoresis was performed as mentioned in section 2.8.1.2. The band 
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of interest was cut out and obtained for cloning using QIAEX II Agarose Gel Extraction kit 
from Qiagen. 
 
To investigate whether RhoJ was expressed in zebrafish cDNA, reverse transcription PCR 
(RT-PCR) was performed in a total volume of 20 µL. The reaction mixes contained the 
following: 8.5 µL of water, 4 µL of 5 x Phusion High Fidelity Buffer, 4 µL of 1 mM dNTP 
mix, 0.5 µL of each primer (10 µM) and 0.5 µL of Phusion High-Fidelity DNA Polymerase. 
Finally 2 µL of template was added. For the no template control, template was omitted. PCR 
reactions were performed using Peltier Thermal Cycler set at an initial denaturation step of 
98ºC for 30 seconds, then 30 cycles of denaturation at 98°C for 10 seconds, annealing at 60°C 
for 30 seconds and 72°C for 30 seconds. A final extension step of 72ºC for 10 minutes was 
included. PCR products were loaded on to agarose gels and gel electrophoresis was performed 
as mentioned in section 2.8.1.2. Bands were visualised and imaged using Gene Genius Bio 
Imaging System (Syngene, Cambridge, UK). 
 
2.10.5 In situ hybridization 
2.10.5.1 DEPC treatment  
Diethyl Pyrocarbonate (DEPC) (Sigma, UK) is a non-specific inhibitor of RNAses. DEPC 
treatment to water and PBS solutions involved adding 0.1% (v/v) DEPC to water and shaking 
vigorously for 15 seconds. The solution was then kept at room temperature for up to 16 hours 
before autoclaving. 
 
2.10.5.2 Riboprobe synthesis 
Materials Source 
QIAquick PCR purification kit Qiagen 
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10 x DIG RNA Labeling Mix Roche Applied Science, UK 
10 x Transcription Buffer Roche Applied Science, UK 
SP6 RNA polymerase Roche Applied Science, UK 
T7 RNA polymerase Roche Applied Science, UK 
RNAse inhibitor  Roche Applied Science, UK 
DNAse I Fermentas, UK 
Mini Quick Spin Columns Roche Applied Science, UK 
 
Plasmids containing the coding region of the gene of interest were linearised to generate 
templates for sense and antisense probe generation. The linearised DNA was then purified 
from the enzymatic reaction with QIAquick PCR purification kit according to the 
manufacturer’s instructions and the concentration of DNA was measured using NanoDrop 
ND-1000 spectrophotometer. 1 µg of linearised DNA was transcribed and labelled with 
digoxigenin using 2 µL of 10 x transcription buffer, 2 µL 10 x DIG labelling mix, 1 µL 
T7/SP6 RNA polymerase, 1 µL RNAse inhibitor and the volume was made up to 20 µL with 
nuclease-free water. The reaction mix was incubated at 37°C for 2.5 hours. After in vitro 
transcription, 1 µL of DNAse I was added to the reaction mix to digest the linearised DNA. 
To determine if the reaction was successful, 1 µL of the reaction mix was loaded on a 1% 
(w/v) agarose gel and then the probe was purified using mini quick spin columns. The 
concentration of RNA was then measured using NanoDrop ND-1000 spectrophotometer.  
 
2.10.5.3 Whole-mount in situ hybridization 
Materials Source 
C57BL6 mice  Biomedical Services Unit at The University of 
Birmingham.  
AB wild-type zebrafish Strain from Max Planck Institute of Developmental 
Biology, Germany.  
Glutaldehyde Sigma, UK 
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Boehringer blocking reagent Roche Applied Science, UK 
Torula RNA Sigma, UK 
Heat inactivated goat serum Sigma, UK 
BM Purple substrate Roche Applied Science, UK 
Leica MZ16 stereomicroscope/USB 
2.0 2M Xli camera 
Leica Microsystems, USA 
Buffers Constituents 
Phosphate buffered saline tween-20 
(PBST) 
0.01 M phosphate buffer, 0.0027 M KCl and 0.137 
M NaCl, pH 7.4 with 0.1% tween-20 
Hybridization buffer  
 
50% deionised formamide, 1% (w/v) blocking 
reagent, 5 x SSC, 0.1 mg/mL heparin, 1 mg/mL 
torula RNA, 0.1% (w/v) CHAPS, adjusted to pH 5.5 
with 1 M citric acid 
Maleic Acid Buffer– tween 20 
(MABT) 
0.1 M Maleic acid, 0.15 M NaCl, pH 7.5 using 
NaOH 
Antibody buffer  10% (v/v) heat inactivated serum, 1% (w/v) 
blocking reagent in MABT 
AP1 buffer 0.1 M NaCl, 0.1 M Tris pH 9.5, 50 mM MgCl2 
Stop solution  100 mM Tris pH 7.4, 1 mM EDTA 
 
2.10.5.3.1 Zebrafish embryo preparation 
Wild-type zebrafish AB strain was obtained from Max Planck Institute of Developmental 
Biology, Germany. Dr. Rajeeb Swain from University of Birmingham maintained the fish 
strain using the facilities at the Biomedical Services Unit (BMSU) at the University of 
Birmingham. The fish were raised at 28°C on a 14 hour light and 10 hour dark cycle. The 
night before eggs were required, tanks were filled with room temperature water. Male and 
female fish were added to the tanks but separated from one another by a divider in the tank. 
The next morning, the dividers were removed and fertilised eggs were collected from the 
bottom of the tanks 30 minutes–1 hour after mating. These embryos were then grown in 
Hank’s buffer at 28°C to different stages up until 48 hours post fertilisation (hpf). To prevent 
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pigmentation from forming and thus reducing transparency of the fish, 1 mL of 50 x 
propylthiouracil (PTU) was added to 10 mL of Hank’s buffer containing 24 hpf embryos. 
Embryos for in situ hybridization experiments were dechorionated and fixed in 4% (w/v) PFA 
at 4°C overnight whilst gently rocking. The embryos were then washed with DEPC-treated 
PBS before being dehydrated through sequential 5 minute incubations at room temperature in 
1 mL 25%, 50%, 75% and then 100% (v/v) methanol in DEPC-treated PBS with 0.1% (v/v) 
tween-20 (PBST) and stored at -20°C until needed. 
 
2.10.5.3.2 Zebrafish whole-mount in situ hybridization 
Zebrafish whole-mount in situ hybridization protocol was adapted from the protocol 
described by Patient et al. (2005) (222). Embryos stored in 100% methanol were rehydrated 
back through sequential 5 minute incubations at room temperature in 1 mL 75%, 50% and 
then 25% (v/v) methanol in PBST and then 5 minutes in 100% PBST with gentle rocking for 
all incubations. Embryos at 24 hpf were then digested with 10 µg/mL of proteinase K in 
PBST for 20 minutes (48 hpf embryos were incubated with 10 µg/mL of proteinase K in 
PBST for 30 minutes) at room temperature before being re-fixed in 4% (w/v) PFA in PBS for 
20 minutes. The embryos were washed 5 x 5 minutes with PBST. The embryos were then 
equilibrated into hybridization buffer with a 5 minute wash with 50% PBST/50% 
hybridization buffer followed by 1 hour in 100% hybridization buffer at 65°C. This was 
replaced with fresh hybridization buffer for another 2 hours before adding 1 mL of fresh 
hybridization buffer containing 500 ng of riboprobe to the embryos and incubating overnight 
at 65°C.  
 
The following day, the riboprobe mix was removed and the embryos were washed at 65°C 
with all saline-sodium citrate (SSC) buffer solutions containing 0.1% (v/v) tween-20 as 
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follows: 10 minutes incubations at room temperature in 100%, 75%, 50% and 25% 
hybridization buffer in 2 x SSC. The embryos were then washed once for 10 minutes at 65°C 
with 2 x SSC and 4 x 15 minutes at 65°C with 0.2 x SSC. The embryos were washed further 
with 5 minute incubations at room temperature in 25%, 50%, 75% and 100% MABT in 0.2 x 
SSC. Embryos were then washed in 100% MABT for 5 minutes at room temperature. 
Embryos were blocked for 1 hour at room temperature with gentle agitation in antibody 
buffer, which consisted of 2% (w/v) Boehringer blocking reagent (BBR) and 5% (v/v) heat 
inactivated goat serum in MABT. This was replaced with fresh antibody buffer containing 
150 mU/mL anti-digoxigenin antibody conjugated to alkaline phosphatase and embryos were 
left in this buffer overnight at 4°C with gentle agitation.  
 
The embryos were brought back to room temperature for 1 hour then washed 8 x 15 minutes 
with MABT. Embryos were washed 2 x 10 minutes in AP1 buffer at room temperature. The 
AP1 buffer was replaced with 1 mL of BM purple and incubated in the dark until a purple 
signal developed. The reaction was stopped by washing the embryos 2 x 15 minutes in stop 
solution at room temperature and dehydrated through a methanol series to 100% methanol as 
detailed above. Embryos were viewed and imaged using Leica MZ16 stereomicroscope and 
USB 2.0 2M Xli camera and stored at 4°C indefinitely. 
 
2.10.5.3.3 Zebrafish sections 
Twenty-four hours post fertilisation zebrafish embryos used in whole-mount in situ 
hybridization experiments were sent to Cancer Research UK (London central services) where 
they were paraffin wax embedded, formalin fixed and cut into 1 µm transverse sections. 
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2.10.5.3.4 Mouse embryo preparation 
Mouse embryos were collected from matings of C57Bl6 mice at embryonic day (E) 9.5. 
Embryos were staged by assigning noon of the day that a vaginal plug is found as E0.5. 
Biomedical Services Unit (BMSU) at the University of Birmingham set up the matings and 
culled the pregnant female mice on E9.5. Once culled, the embryos from the pregnant mother 
were extracted immediately. The embryos were dissected from the mother by removing the 
uterus and trimming the mesometrium. The decidual swelling was then removed from the 
uterus and placed in ice cold PBS. The embryos were carefully removed from the deciduas 
before removing the thin Deichert’s membrane from the embryos. The embryos were 
immediately transferred to freshly prepared 4% (w/v) PFA and incubated at 4°C overnight 
whilst gently rocking. The embryos were then washed with DEPC-treated PBS before being 
dehydrated through sequential 5 minute incubations at room temperature in 1 mL 25%, 50%, 
75% and then 100% (v/v) methanol in PBST and stored at -20°C.  
 
2.10.5.3.5 Mouse whole-mount in situ hybridization 
Mouse whole-mount in situ hybridization protocol was adapted from the protocol described 
by Piette et al. (2008) (223). The mouse embryos were rehydrated back through sequential 5 
minute incubations at room temperature in 1 mL 75%, 50% and then 25% (v/v) methanol in 
PBST and then 5 minutes in 100% PBST with gentle rocking for all incubations. The embryos 
were then digested with 10 µg/mL of proteinase K in PBST for 15 minutes at room 
temperature and washed once with 2 mg/mL glycine in PBST. Embryos were rinsed once 
with PBST and washed a further 2 x 5 minutes with PBST before being re-fixed in 4% (w/v) 
PFA/0.2% (v/v) glutaldehyde in PBS for 20 minutes. The embryos were washed 2 x 5 
minutes with PBST and washed once with 50% hybridization buffer/50% PBST for 3 minutes 
at room temperature. The embryos were washed once in 100% hybridization buffer for 3 
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minutes at room temperature. This was then replaced with 400 µL of fresh hybridization 
buffer and the embryos were prehybridized at 65°C for 3 hours. 500 ng of riboprobe was 
added to 100 µL of hybridization buffer and denatured at 95°C for 5 minutes. This riboprobe-
hybridization buffer mix was added to the embryos to bring to a total volume of 500 µL of 
hybridization buffer and embryos were incubated overnight at 65°C.  
 
The following day, the riboprobe mix was removed and the embryos were washed in 800 µL 
of hybridization buffer for 5 minutes at 70°C. Added to this solution was 400 µL of 2 x SSC 
pH 4.5 which was incubated for 5 minutes at 70°C (this step was repeated 3 times leading to a 
total volume of 2 mL). The mix was removed and the embryos were incubated in 2 x SSC pH 
7/0.1% (w/v) CHAPS for 30 minutes at 70°C. The embryos were then washed with MABT in 
the following order: 2 x 10 minutes with MABT at room temperature, 2 x 30 minutes MABT 
at 70°C, 2 x 10 minutes PBS at room temperature and finally for 5 minutes in PBST. Embryos 
were blocked in antibody buffer for at 2 hours at 4°C. This was removed and replaced with 
antibody buffer containing preblocked 1500 mU/mL anti-digoxigenin conjugated to alkaline 
phosphatase antibody and incubated overnight at 4°C whilst rocking gently.  
 
Embryos were rinsed and then washed 4 x 45 minutes with 4 mL of PBST/0.1% (w/v) BSA at 
room temperature. Embryos were then washed 2 x 30 minutes in PBST and then 2 x 10 
minutes in AP1 buffer at room temperature. The AP1 buffer was replaced with 1 mL of BM 
purple and incubated in the dark until a purple signal developed. The reaction was stopped by 
washing the embryos 2 x 15 minutes in stop solution at room temperature and dehydrated 
through a methanol series to 100% methanol as detailed above. Embryos were viewed and 
imaged using Leica MZ16 stereomicroscope and USB 2.0 2M Xli camera and stored at 4°C 
indefinitely.  
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2.10.5.4 Fluorescent in situ hybridization on human tissue sections 
Materials Source 
Paraffin embedded tissue sections Cancer Research UK histology service, 
UK or Superbiochips Inc., Korea 
Histoclear National Diagnostics, UK 
Sodium phosphate Sigma, UK 
Dextran sulphate Sigma, UK 
Hybriwell hybridization sealing systems  Invitrogen, UK 
PCR express thermal cycler Thermo Hybaid, UK 
ProLong Gold Antifade reagent with DAPI® Invitrogen, UK 
Axiovert 100M confocal microscope/LSM 510 
software 
Carl Zeiss, Germany 
Buffers Constituents 
Phosphate buffered saline – tween 20 (PBST) 0.01 M phosphate buffer, 0.0027 M KCl 
and 0.137 M NaCl, pH 7.4 with 0.1% 
(v/v) Tween-20 
Hybridization buffer 50% (v/v) deionised formamide, 2 x 
SSC, 0.005 M sodium phosphate, 10% 
(w/v) dextran sulphate, 500 ng 
digoxigenin labelled riboprobe in 
nuclease-free H2O 
Blocking buffer 1/20 fetal calf serum in PBST 
 
Following removal of paraffin with Histoclear for 3 x 5 minutes, tissues were rehydrated back 
through sequential 5 minute incubations at room temperature in 100%, 75%, and then 25% 
(v/v) ethanol in H2O. Tissues were then washed for 1 minute in H2O and 10 minutes in PBS at 
room temperature. Tissues were re-fixed in 4% (w/v) PFA in PBS for 10 minutes at room 
temperature. Sections were then washed for 30 minutes with PBS at 37°C to ensure the right 
temperature for digestion. The tissue sections were then digested with 0.2% (v/v) trypsin in 
PBS for 10 minutes at 37°C. Following digestion, sections were rinsed once with PBS and 
then dehydrated through sequential 5 minute incubations at room temperature in 25%, 75% 
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and then 100% (v/v) ethanol in H2O. Slides were allowed to air dry for 3 minutes before 
adding 50 µL of hybridization buffer per slide. Sections were completely covered with 
RNAse-free hybriwell hybridization sealing systems. The probe was then denatured by 
heating the slide to 80°C for 75 seconds using PCR Express Thermal Cycler before being 
incubated overnight at 37°C. The following day, the hyrbiwells were removed and sections 
were gently rinsed in 2 x SSC with 0.1% (v/v) tween-20. Tissues were then washed in 0.1 x 
SSC for 30 minutes at 68°C. Tissues were treated with 0.1 mg/mL RNAse A for 15 minutes at 
room temperature then rinsed three times with PBST. Sections were blocked in blocking 
buffer for 1 hour at room temperature. Tissue sections were then probed with 20 µg/mL of 
Ulex europeaus agglutinin I (UEAI) conjugated to fluorescein and 1 µg/mL anti-digoxigenin 
conjugated to rhodamine in blocking buffer for 1 hour at room temperature. Sections were 
rinsed three times with PBST and then once with H2O. Slides were permanently mounted 
with Anti-Fade Prolong Gold with DAPI and sections were analysed using Axiovert 100M 
laser scanning confocal microscope.  
 
2.11 In vivo studies 
Materials Source 
Fli1-GFP transgenic zebrafish Strain obtained from Brant M. Weinstein 
(224) 
Phenol red Sigma, UK 
50 x Propylthiouracil (PTU) Sigma, UK 
Hank’s buffer Sigma, UK 
Microinjection apparatus Narishige, Japan  
Morpholino  Sequence 
Zebrafish RhoJ translation blocker  5’-tacttttcgagctgagtgtaggcat-3’ 
Zebrafish RhoJ splice blocker – targeting 
Exon2 Intron2 splice junction 
5’-ccttaggagaattaactcacttgtc-3’ 
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Fli1-GFP transgenic zebrafish were obtained from Brant M. Weinstein (224) and maintained 
by Dr. Rajeeb Swain as described in 2.10.5.3.1. For zebrafish in vivo gene silencing, a 
translation blocker morpholino was designed to be complementary to the translational start 
site and a splice blocker morpholino was designed to be complementary to exon2 intron2 
splice junction for zebrafish RhoJ. Morpholinos were designed and synthesised by Gene Tool, 
USA. Morpholinos were injected with phenol red as an injection indicator into the yolk of one 
to four cell stage Fli1-GFP transgenic embryos which were then cultured at 28°C in Hank’s 
buffer. Embryos were fixed at 26 hpf with 4% (w/v) PFA after being dechorionated. A Leica 
DMRE fluorescent microscope was then used to analyse the morpholino injected Fli1-GFP 
transgenic embryos. The effect of morpholino knockdown on vessel formation was 
quantitated by scoring the embryos according to whether the vasculature was affected (under-
developed intersegmental arteries) or unaffected.  
 
2.12 Statistical analyses 
All experiments were repeated at least 3 times with similar results unless otherwise stated. 
Data are plotted with error bars representing the standard error of the mean. A Shapiro-Wilk 
normality test was performed on data sets to confirm a normal distribution. In order to test for 
significant differences in data, P values were determined by using GraphPad Prism 5 
software. One-way analysis of variance (ANOVA) was used to test the significance of 
experiments. If the calculated P value was less than 0.05, then the hypothesis that the means 
of at least two subgroups differed significantly was accepted. If the ANOVA test was positive 
(P<0.05) then a Tukey’s post hoc test for multiple pair-wise comparisons of means were 
performed and significance levels were determined at 0.05 (95%) confidence intervals. P 
values <0.05 were considered significant (*), <0.01 highly significant (**) and 0.001 
extremely significant (***). 
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3.1 Introduction 
Angiogenesis is the process of generating new blood vessels from the existing vasculature. 
This process is vital to embryogenesis and adult physiology, such as in female menstruation 
and wound-healing, but also contributes to many pathological diseases including the growth 
and metastasis of solid tumours (225). The principal cells involved in this process are ECs, 
which line all blood vessels and capillaries. To achieve the new formation of a blood vessel, 
ECs of a pre-existing mature vessel degrade the ECM and migrate through the degraded 
matrix towards angiogenic stimuli. Behind this migrating front, ECs proliferate to provide the 
necessary number of cells to make a new vessel. This new outgrowth of ECs then reassemble 
and reorganise into a three-dimensional tubule structure (226). Rho GTPases regulate many 
essential aspects of cell physiology such as cell growth, adhesion, migration and control of 
actin dynamics (140). Evidence shows that RhoA, Rac1 and Cdc42 mediate EC processes that 
are crucial for angiogenesis to occur (139). Expanding our knowledge of the molecular 
regulatory mechanisms underlying these processes is necessary to further understand the 
biology of physiological and pathological angiogenesis. 
 
RhoJ, a member of the Cdc42 subfamily group, has previously been shown to be involved in 
in vitro differentiation of 3T3 L1 adipocytes, early endocytosis and filamentous actin 
rearrangement (197, 198, 201, 203, 204). Using a combination of bioinformatic and 
expression analyses using reverse transcription and quantitative PCR, our laboratory 
previously identified RhoJ as being highly expressed by ECs (206). The aim of this study was 
to further explore the role of RhoJ in ECs, with specific interest in the processes that occur 
during angiogenesis.  
 
3 | The role of RhoJ in endothelial cell tube formation and migration 
 
 82 
To study RhoJ function, its expression was knocked down in human umbilical vein ECs 
(HUVEC) or immortalised human microvascular ECs using siRNA technology. To silence 
RhoJ expression, the regulatory cellular pathway known as RNA interference was exploited 
by using RhoJ-specific synthetic siRNA (227). Upon entry into cells by lipofection, siRNA 
are assembled into endoribonuclease-containing complexes, known as RNA-induced 
silencing complexes (RISC) and unwind to become single stranded. The siRNA strand 
incorporated into RISC pairs to its complementary mRNA sequence, which results in its 
cleavage and degradation. This blocks the translation of mRNA into protein thus silencing its 
expression in the cell. 
 
Key aspects of the angiogenic process were assessed by in vitro methods to test the impact of 
siRNA mediated RhoJ knockdown on endothelial tube formation, migration, growth and cell 
death. Tube formation was assessed using Matrigel and 3-dimensional sprouting bead assays. 
Scratch wound and Boyden chamber assays were used to examine EC migration. Cell-
counting assays and flow cytometry analyses were used to assess cell proliferation and 
survival. In summary, this chapter aims to investigate the function of RhoJ in human ECs in 
vitro. 
 
3.2 Results 
3.2.1 RNA interference-mediated knockdown of RhoJ in vitro 
In order to investigate the role of RhoJ in EC biology, RNAi was used to specifically 
knockdown the expression of RhoJ in human ECs and then their function in various assays 
was tested. Two RhoJ specific siRNA duplexes, duplex 1 (D1) and duplex 2 (D2) were 
designed to different nucleotide sequences within the coding region of human RhoJ. A 
negative control siRNA duplex (NCD) that has no homology to any known human sequence 
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was used to demonstrate that the effects of RhoJ knockdown were solely due to RhoJ specific 
siRNA, and not due to effects that are associated with the delivery of double stranded RNA 
into cells. In addition, cells were mock transfected with transfection reagent only to show that 
the transfection process did not induce any non-specific effects.  
 
Cells are able to evoke an innate immune interferon response to high concentrations of siRNA 
duplexes (228), since double stranded RNA can be present in certain virus-infected cells. 
SiRNA duplexes at high concentrations can also trigger off-target effects such that they can 
knock down other mRNAs with high silencing efficacy (229). In order to minimise the 
induction of the interferon response and off-target effects, a low siRNA concentration of 10 
nM was chosen to knockdown RhoJ in ECs because it was the lowest concentration to 
consistently produce complete knockdown of RhoJ protein (see appendix 1 for titration of 
siRNA duplexes). To check for successful knockdown of RhoJ message in HUVEC 
transfected with D1 or D2 at 10 nM; RNA was extracted from the cells two days after 
transfection and reverse-transcribed into cDNA, then real-time quantitative PCR was 
performed to quantify the expression level of RhoJ relative to housekeeping control, β-actin. 
Transfection of D1 or D2 at 10 nM successfully reduced RhoJ mRNA expression in HUVEC 
by approximately 90% compared to NCD and mock-transfected conditions (figure 3.1A).  
 
During an interferon response to double stranded RNA, cells induce the expression of type 1 
interferons (IFN), IFN-α and IFN-β. These are a group of cytokines that in turn induce 
production of 2', 5’-oligoadenylate synthetase 1 (OAS1) and IFN-stimulated gene of 20 kDa 
(ISG20). OAS1 is an enzyme involved in the OAS pathway that is responsible for degrading 
viral and cellular RNA, thus inhibiting virus replication and promoting the death of infected 
cells (230). ISG20 is a 3’-5’ exonuclease protein that can inhibit viral replication by also 
degrading viral RNA (231). Detecting the up-regulation of OAS1 and ISG20 mRNA can be 
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Figure 3.1 Successful RhoJ knockdown at mRNA and protein level and lack of 
interferon response in RhoJ-specific siRNA transfected cells. Human umbilical vein 
endothelial cells were either mock transfected or transfected with negative control 
duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM. (A-B) Two days 
after transfection, RNA was extracted and converted into cDNA. Expression levels of 
RhoJ and interferon response-induced genes (OAS1 and ISG20) were determined by 
quantitative PCR and normalised to β-actin expression levels. (C) Cells were harvested 
and lysed 2-7 days after transfection and Western blotting was performed using anti-
RhoJ and anti-tubulin antibodies to determine the stability of RhoJ knockdown over 7 
days using 10 nM siRNA. 
 
A 
C 
B 
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used as an indication that the interferon response has been activated. It was important to check 
whether RhoJ specific duplexes induced an interferon response because activated interferons 
can trigger undesirable side effects and alter normal cell behaviour and function (232). To 
determine whether transfection of RhoJ specific duplexes at 10 nM elicited an interferon 
response, the mRNA expression levels of OAS1 and ISG20 in RhoJ-depleted cells was 
investigated.  Two days after transfection, RNA was extracted and reverse-transcribed into 
cDNA. Real-time quantitative PCR was performed to quantify the expression level of OAS1 
and ISG20 in the transfected cells relative to housekeeping control, β-actin. The expression 
level of OAS1 and ISG20 when normalised to β-actin was not markedly increased in D1 or 
D2 transfected cells compared to NCD and mock transfected cells (figure 3.1B). The similar 
levels of OAS1 and ISG20 expression in all conditions indicated that an interferon response 
was not activated by transfection of D1 and D2 at 10 nM. 
 
RhoJ was knocked down at the protein level and the duration of RhoJ depletion over 7 days 
was examined using D1 or D2 at 10 nM. HUVEC were mock transfected or transfected with 
NCD, D1 or D2. Cells were then lysed 2-7 days after transfection and Western blots were 
performed. RhoJ protein was successfully knocked down using 10 nM of D1 or D2, with 
knockdown lasting over the entire 7-day period (figure 3.1C).  
 
These data confirm that these RhoJ-specific duplexes do not induce an interferon response 
and that RhoJ is successfully depleted at the mRNA and protein level using a low siRNA 
duplex concentration of 10 nM. This concentration was used in all in vitro assays to assess the 
function of RhoJ in ECs and Western blotting was performed for every experiment to validate 
knockdown of RhoJ protein. 
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3.2.2 The effect of RhoJ knockdown on endothelial tube formation 
RhoJ was found to be more highly expressed in ECs than in other cell types and since 
capillary tube formation represents a specialised EC function, the role of RhoJ in endothelial 
tube formation was explored. Matrigel, a solubilised basement membrane extract derived 
from mouse Engelbreth–Holm–Swarm sarcoma was used to induce EC differentiation into 
tube-like structures in vitro. Matrigel is rich in extracellular proteins that are present in 
vascular basement membranes in vivo such as collagen IV, laminin, heparan-sulphate 
proteoglycans and entactin (33). Kubota et al. (1988) was the first to reveal that plating ECs 
onto a reconstituted basement membrane does not induce proliferation but stimulates 
attachment, migration and differentiation of ECs into interconnecting capillary-like structures 
in a way that mimics the in vivo situation (233, 234). Ultrastructurally it has been shown that 
the ECs in tube-like structures are attached to one another by tight junctions (235). However 
there is still dispute over whether these tube-like structures possess lumens, for example, 
Grant et al. (1991) confirmed the presence of lumens in ‘tubules’ on Matrigel using electron 
microscopy, however this was not observed by Bikfalvi et al. (1991) (170, 236). The in vitro 
Matrigel tube formation assay is considered a model of microvessel development and 
regarded as representative of the differentiation stage of angiogenesis (95). 
 
To investigate the effect of RhoJ knockdown on tube formation in vitro; HUVEC were mock 
transfected or transfected with NCD, RhoJ specific D1 or D2 and two days later cells were 
harvested and seeded on to a thin layer of gelled Matrigel. The formation of capillary-like 
structures were observed at 10 and 24 hours post-seeding. Mock and NCD treated cells 
differentiated into organised and well-connected capillary-like networks (figure 3.2A). In 
comparison, cells lacking RhoJ formed networks that showed fewer connections between 
branches indicating broken connections or connections not being made. They also appeared 
less stable since more cell retraction was observed at 24 hours. To quantify the effect of RhoJ 
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Figure 3.2 Impaired tubule formation with RhoJ knockdown in human umbilical 
vein endothelial cells. Human umbilical vein endothelial cells were either mock 
transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or 
RhoJ duplex 2 (D2) at 10 nM. (A) Two days later, cells were plated on to Matrigel and 
imaged at 10 and 24 hours. Scale bar = 200 µm. (B) Matrigel assays were quantified by 
counting the number of nodes with 1, 2, 3 or ≥4 branches from five random fields of 
view. Values represent the means from three independent experiments. Error bars depict 
the standard error of the mean. One-way ANOVA showed a significant effect of RhoJ 
knockdown on two-dimensional tubule formation at 10 and 24 hours (P<0.0001). 
Tukey’s multiple comparison test was used to compare D1 or D2 with NCD (** = 
P<0.01, *** = P<0.001). 
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Figure 3.3 Impaired tubule formation with RhoJ knockdown in the microvascular 
cell line HMEC-1. Human microvascular endothelial cells were either mock transfected 
or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 
2 (D2) at 10 nM. (A) Two days after transfection, cells were plated on to Matrigel and 
incubated for a further 24 hours. Pictures were taken at 10 and 24 hours. Scale bar = 
200 µm. (B) Matrigel assays were quantified by counting the number of nodes with 1, 2, 
3 or ≥4 branches from five random fields of view. Values represent the means of five 
fields of view from one experiment. Error bars depict the standard error of the mean. 
One-way ANOVA showed a significant effect of RhoJ knockdown on two-dimensional 
tubule formation at 10 and 24 hours (P<0.0001 for all nodes). Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (* = P<0.05, ** = P<0.01, 
*** = P<0.001). 
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Figure 3.4 Reduced sprouting with RhoJ knockdown in human umbilical vein 
endothelial cells. Human umbilical vein endothelial cells were either mock transfected 
or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 
2 (D2) at 10 nM. (A) Two days after transfection, cells were seeded onto cytodex beads 
and embedded into fibrin gels for 7 days. Images represent sprouting of tubes from 
beads at 7 days. Scale bar = 200 µm. (B) The number of sprouts per bead were counted 
and beads were scored as having, <5, 5≥10 or >10 sprouts. Values represent pooled data 
from three independent experiments. One-way ANOVA showed a significant reduction 
of sprouting with RhoJ knockdown (P<0.0001). Tukey’s multiple comparison test was 
used to compare D1 or D2 with NCD (*** = P<0.001).  
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knockdown on Matrigel-induced tube formation, the numbers of nodes with 1, 2, 3 or ≥4 
tubule branches were counted (nodes with 1 branch indicated an unconnected end). RhoJ 
knockdown produced a significant increase in unconnected ends and a significant reduction in 
nodes containing 3 or more branch points at 10 and 24 hours (figure 3.2B).  
 
Since HUVEC are macrovascular ECs, it was important to determine how RhoJ knockdown 
would affect tube formation in microvascular derived ECs, for this purpose the human 
microvascular EC cell line-1 (HMEC-1) was used. Knockdown of RhoJ in HMEC-1 cells also 
impaired tube formation on Matrigel, resulting in more unconnected branches and fewer 
complex nodes (figure 3.3). In vivo angiogenesis occurs in three-dimensions, and so the effect 
of RhoJ silencing on three-dimensional tube formation was analysed using a sprouting bead 
assay (213). There has been some dispute over whether lumens are present in the tube-like 
structures found in two-dimensional Matrigel assays. However, Bayless and colleagues 
(2000) have confirmed the presence of a lumen in capillary-like structures formed in three-
dimensional fibrin matrices (237) thus the sprouting bead assay more closely mimics the in 
vivo situation.  
 
The sprouting bead assay involved siRNA transfection of HUVEC to knockdown RhoJ and 
two days later cells were harvested and coated onto microcarrier beads. Coated beads were 
then embedded into a fibrin matrix gel and three-dimensional tube sprouting was monitored 
over 7 days. By 7 days, mock and NCD transfected cells had migrated into the fibrin gel and 
differentiated to form tubes (figure 3.4A). In contrast, cells lacking RhoJ formed fewer and 
shorter tubes. To quantify the effect of RhoJ knockdown on three-dimensional sprouting, the 
number of sprouts per bead were counted and beads were scored as having, <5, 5≥10 or >10 
sprouts. A significant reduction in three-dimensional tube formation was found with RhoJ 
knockdown (figure 3.4B). 
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3.2.3 The effect of RhoJ knockdown on endothelial chemokinesis and chemotaxis 
Endothelial migration is essential to angiogenesis. Hence, in order to investigate the cause for 
the impaired tube formation with RhoJ knockdown, scratch wound assays were performed to 
examine the chemokinetic motility of RhoJ-depleted cells. Scratch wound assays involve 
gently scraping away cells in a confluent cell monolayer to create a ‘wound’. The cells at the 
edge of the scratch then migrate into the denuded area in order to ‘heal the wound’ and re-
form the monolayer.  
 
HUVEC were mock transfected or transfected with NCD, RhoJ specific D1 or D2. Two days 
after siRNA transfection a scratch was made and the ability of the cells to close the wound 
was assessed over 24 hours. The healing of wounds normally depends on a combination of 
cell migration and proliferation (238). Mitomycin C is an antibiotic that binds to DNA and 
works by blocking DNA synthesis and inhibiting cell growth (239). Mitomycin C was 
included in the migration assay to ensure that cell division did not contribute to the closure of 
the wound. By 24 hours, the denuded area was completely filled with mock and NCD 
transfected HUVEC (figure 3.5A). However, cells with reduced RhoJ expression did not 
migrate to close the scratch and at 24 hours a region of the scratch still remained evident. To 
quantify wound closure, Image J software was used to measure the area of the scratch at 
different time points. A significant reduction in endothelial chemokinetic migration with RhoJ 
knockdown was found at 24 hours (figure 3.5B). This experiment was also repeated using 
immortalised HMEC-1 cells and a similar reduction of random cell motility was found with 
knockdown of RhoJ (figure 3.6A-B).  
 
In angiogenesis, gradients of secreted signalling proteins such as chemokines, cytokines and 
growth factors guide growing blood vessels through EC chemotaxis (43). Therefore a 
chemotaxis assay using a Boyden chamber (214) was used to assess the effect of RhoJ 
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knockdown on chemotaxis. Boyden chambers consist of upper and lower wells separated by a 
micro-porous membrane filter. The chemoattractant is placed in the lower wells and cells are 
added to the top wells. After a period of incubation, the cells that migrated towards the 
chemoattractant are counted on the lower surface of the membrane. 
 
HUVEC were mock treated or transfected with NCD, RhoJ specific D1 or D2. Two days 
later, cells were harvested and seeded into upper chamber wells with media containing 1% 
fetal calf serum (FCS). A 8 µm pore size filter was coated with a gelatin matrix, to more 
closely mimic the in vivo environment and was used to separate the upper chamber from the 
lower chamber, which was filled with media containing 10% FCS supplemented with bovine 
brain extract and heparin. Cells were allowed to migrate towards the serum-rich media for 5 
hours then non-migrated cells were wiped away. Migrated cells attached to the other side of 
the filter were fixed and stained with DAPI revealing the migratory response to the 
chemoattractant. To quantify chemotaxis, the sum of migrated cells in five random areas for 
each well was calculated for at least nine replicate wells of each condition. A significant 
reduction in chemotaxis towards serum-rich media was observed with RhoJ knockdown 
compared to mock and NCD transfected wells (figure 3.5C). RhoJ siRNA treated HMEC-1 
cells also displayed reduced migration towards FCS in the Boyden chamber assay (figure 
3.6C). 
 
3.2.4 The effect of RhoJ knockdown on endothelial cell proliferation and apoptosis 
The formation of new micro-vessels from pre-existing mature vessels is dependent not only 
on cell migration and tube formation but also on endothelial proliferation. A method used to 
measure cell proliferation in vitro is a direct cell-counting assay. These assays involved 
equally plating cells from each condition straight after siRNA transfection. Proliferation was 
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Figure 3.5 Reduced cell motility with RhoJ knockdown in human umbilical vein 
endothelial cells. Human umbilical vein endothelial cells were either mock transfected 
or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 
2 (D2) at 10 nM. (A) Two days after transfection, scratches were made and imaged at 0, 
4, 12 and 24 hours. Scale bar = 200 µm. (B) The percentage of wound remaining was 
measured and plotted. Values represent the means from three independent experiments. 
Error bars depict the standard error of the mean. One-way ANOVA showed a 
significant effect of RhoJ knockdown on chemokinesis at 24 hours (P<0.0001). Tukey’s 
multiple comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). 
(C) Two days after transfection, a Boyden chamber chemotaxis assay was performed 
and the number of migrated cells quantified. Values represent the means from three 
independent experiments with nine or more replicates in each experiment. Error bars 
depict the standard error of the mean. One-way ANOVA showed a significant reduction 
of chemotaxis to fetal calf serum in RhoJ-depleted cells (P<0.0001). Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). 
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Figure 3.6 Reduced cell motility with RhoJ knockdown in the microvascular cell 
line HMEC-1. Human microvascular endothelial cells were either mock transfected or 
transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 
(D2) at 10 nM. (A) Two days after transfection, scratches were made and imaged at 0, 
4, 12 and 24 hours. Scale bar = 400 µm. (B) The percentage of wound remaining was 
measured and plotted. Values represent wound closure from one experiment. (C) Two 
days after transfection, a Boyden chamber chemotaxis assay was performed and the 
number of migrated cells quantified. Values represent the means of one experiment with 
nine replicates. Error bars depict the standard error of the mean. One-way ANOVA 
showed a significant reduction of chemotaxis to fetal calf serum in RhoJ-depleted cells 
(P<0.0001). Tukey’s multiple comparison test was used to compare D1 or D2 with 
NCD (*** = P<0.001). 
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then allowed to occur for a period of time before cells were harvested and counted. Cells were 
harvested and counted 1-4 days post seeding. A significant reduction in cell growth 2-4 days 
after seeding was found with RhoJ knockdown (figure 3.7A). 
 
Cell division is regulated by the cell cycle, which consists of interphase gap 1, synthesis and 
gap 2 and mitosis. RhoA, Rac1 and Cdc42 have been shown to play a critical role in the 
signalling cascades controlling cell cycle and cell proliferation (240, 241). A reduction in cell 
proliferation is often due to cell cycle defects or delays. Therefore, in order to explain the cell 
growth reduction found with RhoJ knockdown, the effect of reduced RhoJ expression on the 
cell cycle was assessed. HUVEC were transfected with RhoJ specific D1 or D2, NCD, or 
mock transfected. Three days later the cells were fixed, permeabilised and DNA was stained 
with propidium iodide (PI). The cells were then scanned and the cell cycle was analysed using 
an Acumen® eX3 microplate cytometer. PI is used in cell cycle analysis to quantitatively 
evaluate DNA content in cells. Thus, phases of the cell cycle can be analysed by measuring 
the fluorescent intensity of PI staining. The cytometer produces a graph that shows the 
percentage of cells found in G1 (gap 1), S (synthesis) and G2/M (gap 2/mitosis) phases 
according to their DNA content (PI staining). SiRNA-mediated knockdown of RhoJ did not 
significantly change the proportion of cells in each phase of the cell cycle when compared to 
mock and NCD conditions (figure 3.7B). This result suggests that the reduced cell 
proliferative effects seen with RhoJ knockdown are not likely to be due to deregulation of the 
cell cycle. 
 
Decreased proliferation may be due to cytotoxic rather than cytostatic effects. Apoptosis 
related changes in cell morphology can be analysed to discover how many cells in a given 
population are apoptotic or have already undergone apoptosis. In early apoptosis, a 
phospholipid, phosphatidylserine, is translocated from the inner to the outer leaflet of the 
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Figure 3.7 Reduced cell growth and increased cell death with RhoJ knockdown.
Human umbilical vein endothelial cells were either mock transfected or transfected with 
negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM. 
(A) Cell growth was assessed by cell counting 1-4 days after transfection. Values 
represent the means of one experiment with three replicates. Error bars depict the 
standard error of the mean of triplicates for each time point. Similar data were obtained 
in four independent experiments. One-way ANOVA showed a significant reduction of 
cell proliferation with RhoJ knockdown (P<0.0001, days 2-4). Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). (B) Three 
days after transfection, cells were stained with propidium iodide and the cell cycle was 
analysed by an Acumen® eX3 microplate cytometer. Values represent the percentage of 
cells in G1, S and G2/M stages of the cell cycle from three independent experiments, 
each with 12 or more replicates. Error bars represent the standard error of the mean. 
One-way ANOVA showed that RhoJ knockdown did not have a significant effect on 
cell division (ns: not significant). (C) Three days after transfection, cells were stained 
with annexin V and propidium iodide and analysed by a fluorescence activated cell 
scanner. Results are displayed as a bivariate distribution of annexin V (FL1) and 
propidium iodide (FL3) fluorescence intensity The percentage of cells stained double 
positive for both annexin V and propidium iodide are indicated in red. Similar data were 
obtained in three independent experiments. 
C
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plasma membrane; making it detectable with annexin V conjugated to fluorescein (FITC), a 
protein with high affinity for this phospholipid (242). The loss of integrity of the plasma 
membrane in late apoptosis alters the permeability of the cell, enabling PI to enter and stain 
the nucleic acid (243). 
 
To determine whether silencing RhoJ induces EC death, RhoJ siRNA treated HUVEC were 
stained with annexin V and PI and analysed by flow cytometry. The results were displayed as 
a bivariate distribution of annexin V (FL1) and PI (FL3) fluorescence intensity. Cells in the 
lower-left quadrant were viable cells that were unstained for both annexin V and PI. Cells in 
the lower-right quadrant were early apoptotic that stained positive for annexin V but negative 
for PI. Cells in upper-right quadrant represent the late apoptotic cell population that stained 
positive for both annexin V and PI.  In figure 3.7C, cells found in the upper-right quadrant 
that were undergoing apoptosis or already dead is displayed as a percentage (in red). RhoJ 
reduced populations showed a 2-fold increase in cell death (9.2%) compared with mock 
(4.5%) and NCD transfected (5.9%) populations. However these increases in cell death are 
still relatively low. 
 
Since knockdown of RhoJ reduces EC motility and increases cell death, it was important to 
determine whether the reduced motility of RhoJ-depleted cells found in figures 3.5 and 3.6 
were due to cells undergoing apoptosis. In order to investigate whether an increase in 
apoptosis was impeding migration of RhoJ-depleted cells, cells at the wound edge of a scratch 
wound assay were analysed for apoptosis. Two days after siRNA transfection, scratch wound 
assays were set up on gelatin-coated glass coverslips. Scratch wounds on glass coverslips 
were made on a smaller scale due to scraping with a smaller pipette tip. Wounds made on 
glass coverslips typically healed after nine hours in control cells (not shown). Cells were fixed 
but not permeabilised and stained with annexin V-FITC in order to visualise apoptotic cells at 
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Figure 3.8 Apoptosis was not detected at the wound edge with RhoJ knockdown. 
Human umbilical vein endothelial cells were either mock transfected or transfected with 
negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM. 
Two days after transfection, scratch wound assays were set up on fully confluent glass 
coverslips. Scratches were allowed to heal for 6 hours before staining with annexin V-
FITC to visualise cells undergoing apoptosis. Dotted white lines indicate the wound 
edge. As a positive control for detecting endothelial apoptosis, wildtype cells were 
treated with 0, 50, 75 or 100 ng/mL of tumour necrosis factor-alpha (TNFα) for 4 hours 
and stained with annexin V-FITC. Scale bar = 100 µm. Similar data were obtained in 
three independent experiments.  
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the wound margin six hours after the scratches were made. Tumour necrosis factor-α (TNFα) 
is a potent inducer of EC apoptosis (216, 217). As a positive control for detecting endothelial 
apoptosis, untransfected HUVEC were treated with varying amounts of TNFα and stained 
with annexin V-FITC. RhoJ-depleted cells at the wound margin were not found to be 
apoptotic (figure 3.8). Although there is a weak level of background staining, the cells are 
negative for annexin V. The cells treated with TNFα showed positive staining for annexin V 
that increased in intensity as the amount of TNFα increased. This was most likely due to cells 
gradually losing membrane integrity and annexin V-FITC being able to enter cells and stain 
intracellular phosphatidylserine as well as extracellular. These data suggest that although 
siRNA-knockdown of RhoJ does induce a small rise in apoptosis, the motility defects 
displayed by RhoJ-depleted cells are not apoptosis-related.  
 
3.2.5 Summary 
SiRNA mediated silencing of RhoJ in HUVEC cells did not induce an interferon response and 
knockdown of RhoJ protein continued over 7 days using RhoJ-specific siRNA duplexes at a 
low concentration of 10 nM. Knockdown of RhoJ in HUVEC impaired tube formation in two 
and three-dimensional tube formation assays. RhoJ-specific siRNA-treated HUVEC displayed 
reduced chemokinesis, chemotaxis and cell growth. RhoJ knockdown in human microvascular 
HMEC-1 cells also resulted in impaired tube formation and cell motility defects. An increase 
in apoptosis was detected with RhoJ knockdown, with no effect on the cell cycle, but this 
increase in cell death did not explain the reduced chemokinesis of RhoJ depleted cells. 
 
3.3 Discussion 
Impaired tubule formation was observed when RhoJ was silenced in two-dimensional 
Matrigel tube formation assays (figure 3.2). Reduced connections between branches and 
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retraction of tubules at later time points were found with silencing of RhoJ in both HUVEC 
and HMEC-1. In three-dimensional sprouting bead assays, which are more representative of 
physiological capillary formation, the number of sprouting tubules found when RhoJ 
expression was knocked down in HUVEC was significantly reduced (figure 3.4). These data 
suggest that RhoJ GTPase activity is important for in vitro endothelial tube formation. This 
would be consistent with the previous finding of Connolly et al. (2002) which showed that 
inactivating GTPase function of small Rho proteins using toxin B 10463, from Clostridium 
difficile bacterium, inhibited tube formation on Matrigel in a dose-dependant manner (170).  
 
Interestingly, in our Matrigel assays, RhoJ depleted cells were able to align themselves into 
short cord-like structures but these primitive tube-like structures failed to form extensive 
branched capillary networks like control cells. Connolly et al. (2002) also studied the cellular 
changes that occurred in HUVEC when in contact with Matrigel (170). They demonstrated 
that microtubule dynamics and cellular protrusions, such as lamellae and membrane ruffles, 
were required for the initial alignment of cells into short cord-like aggregates but the 
extension of these short tube-like structures into interconnected lumen-containing tubules was 
mainly regulated by tight control of cell migration and actomyosin contractility (170). Thus 
our data indicates that RhoJ is not required for the initial alignment of ECs into primitive 
cords through the use of cellular protrusions but is essential for the second stage of 
differentiation where cells migrate into complex branched tubule networks.  
 
RhoJ knockdown also induced chemokinetic and chemotactic motility defects in HUVEC and 
HMEC-1 (figure 3.5 and 3.6). In the scratch-wound assay, RhoJ depleted cells displayed 
reduced migration compared to control cells. In the Boyden chamber assay, RhoJ silencing 
significantly reduced the number of cells that migrated through filter pores towards the 
chemoattractant. Since Rho GTPases are mostly known to be involved in regulating 
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cytoskeletal actin dynamics (139), it was not surprising that RhoJ knockdown impaired cell 
motility. Moreover, the impaired tube formation found with RhoJ knockdown could be 
explained by the reduced cell motility. Branching of tubules to form interconnected networks 
is a process heavily dependent on EC migration (170). Since tubule branching was 
significantly impaired when RhoJ was knocked down in Matrigel assays, it is reasonable to 
surmise that the cell migratory defects of RhoJ knocked cells may have caused the ineffective 
tube formation. Therefore, these data suggest that RhoJ may play a critical role in EC 
migration, which is not only important for physiological angiogenesis but also vital to the 
repair of injuries to the endothelium. 
 
EC proliferation and apoptosis are also fundamental aspects of EC biology. Angiogenesis 
requires quiescent ECs to become proliferative in order to have enough ECs to remodel the 
vasculature (71). On the other hand, Segura et al. (2002) showed that apoptosis occurs inside 
tubules to create lumens and inhibiting programmed cell death in ECs impairs in vitro and in 
vivo angiogenesis (244). Thus angiogenesis requires the subtle balance between EC growth 
and death. RhoJ knockdown was shown to reduce EC growth and increase apoptosis (figure 
3.7). However the cell cycle was not affected suggesting that RhoJ is not required for cell 
cycle regulation unlike its closely related family member Cdc42 (163). Since RhoJ 
knockdown did not impair cell division, it is most likely that the reduced number of viable 
cells found in the cell-counting assays was due to cells apoptosing more.  
 
The increase in apoptosis could be another possible explanation for the defective tube 
formation found with RhoJ knockdown. The lack of branching and connectivity of RhoJ 
depleted networks may have been due to too many cells apoptosing. However, the increase in 
apoptosis was only a small degree more than control cells. In line with what is already known 
about the functions of Rho GTPase proteins, it is probable that RhoJ is regulating cell 
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locomotion, by modulating actin reorganisation, than apoptosis. Thus RhoJ signalling may not 
be directly regulating apoptosis but may occur as a secondary phenotype to accumulated 
cytoskeletal problems. Consistent with this theory, RhoJ-depleted cells at the wound edge of a 
scratch-wound assay were not found to be undergoing apoptosis (figure 3.8). This suggests 
that RhoJ knockdown-induced motility defects were not apoptosis-related. However, later 
time points were not checked and it is possible that apoptosis might have occurred at the late 
stages of wound healing (due to cytoskeletal defects) thus contributing to the phenotype. In 
support of this, Chen et al. (1997) showed that non-motile cell shape and increased cellular 
tension is capable of switching proliferative ECs into programmed cell death (245). This may 
be the case for RhoJ knockdown cells; where changes in cell locomotion induce some cells 
but not all to apoptose. In summary, the increase in cell death may not be directly modulated 
by RhoJ but may be an independent motility-induced phenotype. The combination of both 
impaired motility and the small increase in apoptosis are likely to contribute to the profound 
defective tube formation in the Matrigel and sprouting bead assays.  
 
In previous studies, the overexpression of dominant active RhoJ in REF-52 fibroblasts was 
found to induce the production of dynamic actin-rich dorsal ruffles across the top surface of 
the cell (197). Dorsal ruffles are dynamic actin ‘waves’ that have been shown to mediate the 
disassembly of actin stress fibers and prepare static cells for subsequent movement (246, 
247). Similarly in another study, immortalised porcine aortic endothelial (PAE) cells 
expressing constitutively active RhoJ were found to display lamellipodia and focal adhesion-
like structures at the cell periphery (204). More recently, dominant active overexpression of 
RhoJ in immortalised PAE cells promoted the formation of podosomes (205). Podosomes are 
dynamic actin-rich cell-matrix adhesion structures found on the ventral surface of highly 
motile cells. They are thought to stimulate the activity of matrix metalloproteinases and cell 
invasion (248, 249). These data all show that RhoJ activity induces reorganisation of 
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filamentous actin and cell-matrix adhesions. The present study is consistent with and extends 
past findings since we have shown that knocking down RhoJ interferes with EC migration, 
which is a process extremely reliant on the normal control of actin reorganisation and cell-
matrix adhesions. Furthermore, we have shown that RhoJ’s role in EC migration is important 
for in vitro tubulogenesis. 
 
Most previous studies performed on RhoJ used ectopic overexpression of wild type or mutant 
RhoJ (197, 198, 204). However, in 2003, de Toledo group used siRNA technology to knock 
down RhoJ in HeLa cells (203), and RNAi was also used to knockdown RhoJ in immortalised 
mouse preadipocyte cells (3T3 L1) by Kawaji and colleagues in 2010 (202). Although we are 
not the first to knockdown RhoJ using siRNA, our studies are unique compared to previous 
research since we have assessed the impact of RhoJ reduction in primary human ECs, which 
are cells that endogenously express relatively high levels of RhoJ. The use of primary cells 
instead of immortalised cell lines provides a more normal physiological system to study the 
effects of gene silencing on cell behaviour.  
 
Using RhoJ specific siRNA duplexes, we were able to successfully transfect primary human 
umbilical vein ECs (HUVEC) and knockdown RhoJ message/protein using a low dose of 10 
nM (figure 3.1). Additionally, using RhoJ specific duplexes at this concentration did not 
induce expression of interferon response genes and protein knockdown persisted over 7 days. 
In the present study, sufficient controls were utilised to ensure that phenotypic changes 
observed with RhoJ knockdown were specific to loss of RhoJ function. For example, cells 
were transfected with a negative control siRNA duplex (NCD) that did not have sequence 
homology to any human gene. This duplex was used at the same concentration used for RhoJ 
specific duplexes in all experiments and was also shown not to upregulate the expression of 
interferon response genes (figure 3.1).  In addition, two different siRNA duplexes (D1 and 
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D2) that targeted two different regions of RhoJ coding region were used. Both D1 and D2 
duplexes induced the same phenotypes, which implied that effects found were specific to 
reduction of RhoJ and not off-target effects. Moreover, transfection of NCD did not induce 
the same phenotypes as RhoJ specific duplexes, further supporting that these effects were 
specific to loss of RhoJ.  Although, using multiple siRNA duplexes to one target is the most 
widely accepted control to enhance confidence in RNAi data (250), future work could include 
siRNA rescue experiments to provide final confirmation that the observed effects are due to 
specifically knocking down RhoJ. This can be achieved by expressing wild type RhoJ with 
one or more silent point mutations within the target regions of the RhoJ specific duplexes to 
create a form resistant to RNAi knockdown.  
 
The main limitation of the methodology used in this chapter is the use of HUVEC since 
angiogenesis occurs only in microvascular ECs and HUVEC are macrovascular. The most 
appropriate cell type to use in angiogenesis research are human microvascular ECs (HMEC) 
since these are capillary ECs and of human origin, however these cells are costly to maintain 
and often difficult to source. Umbilical cords were easy to obtain and isolate by our group and 
for these reasons, HUVEC were used routinely in our laboratory. However, it was important 
for us to confirm the physiological relevance of RhoJ and investigate whether RhoJ 
knockdown had the same effect in microvascular ECs as in HUVEC. Thus key aspects of 
angiogenesis such as tube formation and migration were also assessed in an immortalised 
human microvascular EC line (HMEC-1). The phenotypic changes that were observed in 
HUVEC after loss of RhoJ were also found in HMEC-1 cells. Since the phenotypes were 
repeated in capillary ECs, this suggests that RhoJ may function in ECs from different vascular 
beds.  
 
3 | The role of RhoJ in endothelial cell tube formation and migration 
 
 106 
In conclusion, since Rho GTPase proteins are well known for their regulatory effects on cell 
motility, and the data described in this chapter suggest that RhoJ may play a critical role in 
EC migration, the function of RhoJ in aspects of cell locomotion were examined in detail and 
this work is described in chapter 4.  
 
 
 
  
 
 
  
 
 
 
  
 
 
 
RhoJ modulation of actomyosin contractility and 
focal adhesion numbers  
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4.1 Introduction 
Cell migration can be thought of as a cyclic process. The initial response of a cell to a 
migration-promoting stimulus is to polarise and extend protrusions, either as filopodia or 
lamellipodia, in the direction of migration. Cell polarity and filopodia formation is known to 
be regulated by Cdc42 while lamellipodia formation has been shown to be under the control 
of Rac1 (163). The formation of these protrusions is driven by actin polymerisation and is 
stabilised by adhering to the ECM through focal adhesions. Focal adhesions are large, 
dynamic protein complexes that are often heterogeneous structures, varying in size, strength 
and organisation (108). Focal adhesions act at traction sites for migration as the cell moves 
forward over them and are dissembled at the cell rear, allowing the cell to detach (251). Thus, 
focal adhesions play a critical role in mechanotransduction and their coordinated assembly 
and turnover are essential to cell locomotion.  
 
The turnover of focal adhesions requires myosin-induced contractility. Migrating cells must 
be able to detach from the ECM. The ends of stress fibres are attached to focal adhesion sites 
and are composed of actin and myosin bundles, known as actomyosin (252). To retract the 
trailing edge, cells need to exert force to focal adhesion sites at the cell rear to disassemble 
adhesions through coordinated contraction of actomyosin bundles (253). Actomyosin 
contraction is mediated primarily by myosin II activity, which is regulated by phosphorylation 
of myosin light chain (MLC). Rho kinase (ROCK) acts downstream of RhoA and is known to 
phosphorylate a number of targets including MLC (134). Therefore, RhoA is known to 
positively regulate stress fibre formation via activation of ROCK (161, 162, 254).  
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Small Rho GTPases are key regulators of cell migration. Cdc42 and Rac1 are generally 
proposed to function at the leading edge to induce cell polarisation and actin protrusions, 
whereas RhoA is believed to mainly act at the cell body to facilitate contraction (101).  
 
RhoJ was previously shown to modulate filamentous actin formation through overexpression 
of dominant active or inactive RhoJ (197, 198, 204). In addition, siRNA-mediated knockdown 
of endogenous RhoJ protein in human ECs was shown to impair endothelial tube formation 
and migration (chapter 3). The aim of the experiments described in this chapter was to 
investigate how RhoJ causes defects in cell motility in human ECs. To study this, aspects of 
cell locomotion were examined in detail. HUVEC were either treated with RhoJ-specific 
siRNA to knockdown RhoJ or transduced with lentivirus constructs to overexpress dominant 
active or wild type RhoJ. The role of RhoJ in EC polarisation, cell-matrix and cell-cell 
adhesion and stress fibre formation was assessed using immunofluorescence and confocal 
microscopy. To analyse the morphology of cells during chemotaxis when silencing or 
overexpressing RhoJ, Dunn chemotaxis chamber assays were performed using time-lapse 
microscopy. The effect of RhoJ knockdown and overexpression on endothelial actomyosin 
contraction was measured using collagen type I gel contraction assays and pharmacological 
inhibition of ROCK and myosin II. 
 
In summary, this chapter aims to explore the molecular mechanism by which RhoJ is 
regulating human EC migration. 
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4.2 Results 
4.2.1 RhoJ regulation of focal adhesion formation 
Focal adhesions are large, dynamic protein complexes through which the intracellular 
cytoskeleton connects to the ECM. The dynamic assembly and disassembly of focal 
adhesions plays a central role in cell migration (108). Vinculin is a cytoskeletal focal adhesion 
protein that binds to actin directly. Paxillin binds to the tail domain of vinculin (122) and 
provides a platform for protein tyrosine kinases such as FAK. FAK phosphorylates paxillin at 
Tyr118, providing a docking site for recruitment of other signalling molecules to focal 
adhesions, leading to their maturation (126). FAK Y397 autophosphorylation site is required 
for adhesion strengthening (255). 
 
To elucidate the underlying cause for reduced movement in cells lacking RhoJ (chapter 3), 
focal adhesion markers, vinculin, phospho-paxillin and phospho-FAK, were used to 
investigate the effects of RhoJ knockdown on focal adhesion formation. HUVEC were either 
mock transfected, transfected with NCD, RhoJ specific D1 or D2. After two days, cells were 
adhered to gelatin-coated glass coverslips at a low density and were stained with anti-
vinculin, anti-phospho paxillin (Tyr118) and anti-phospho FAK (Y397) antibodies to 
visualise focal adhesions. To quantify focal adhesion formation, the numbers of focal 
adhesions per cell were counted for each focal adhesion marker. Cells with reduced RhoJ 
expression displayed more vinculin, phospho-paxillin and phospho-FAK positive focal 
adhesions that also appeared slightly denser than control transfected HUVEC (figure 4.1). The 
quantitation confirmed that RhoJ-depleted cells had significantly increased numbers of 
vinculin, phospho-paxillin and phospho-FAK stained focal adhesions (figure 4.1B). This 
increase in focal adhesions may account for the impediment in cell motility in the RhoJ 
knockdown cells (chapter 3). 
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Figure 4.1 RhoJ knockdown increases focal adhesion numbers in sparsely plated 
cells. Human umbilical vein endothelial cells were either mock transfected or 
transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 
(D2) at 10 nM. (A) Two days later, cells were plated at low density on to glass 
coverslips and stained to visualise focal adhesions using vinculin, phospho-paxillin 
(Try118) and phospho-FAK (Y397) antibodies. Scale bar = 20 µm. (B) The numbers of 
focal adhesions found per cell were quantified for 30 cells from three independent 
experiments and displayed as box and whisker plots. The box contains the middle 50% 
of the data and the median is shown by the line in the box. The upper edge of the box 
represents the 75th percentile (upper quartile) and the lower edge of the box indicates the 
25th percentile (lower quartile) of the data. The whiskers represent the maximum and 
minimum values of the data. One-way ANOVA showed a significant increase of focal 
adhesion numbers with RhoJ knockdown (P<0.0001 in each case). Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). 
A
B
4 | RhoJ modulation of actomyosin contractility and focal adhesion numbers 
112
Figure 4.2 Knockdown of RhoJ increases the number of focal adhesions at the 
wound edge but not in the monolayer. Human umbilical vein endothelial cells were 
either mock transfected or transfected with negative control duplex (NCD), RhoJ duplex 
1 (D1) or RhoJ duplex 2 (D2) at 10 nM. (A) Two days after transfection, scratch wound 
assays were set up on fully confluent glass coverslips and wounds were allowed to heal 
for 6 hours before staining with anti-vinculin to visualise focal adhesions. Scale bar = 
10 µm. (B) The numbers of focal adhesions in cells at the wound edge or in the 
monolayer were quantified for at least 30 cells from three independent experiments and 
displayed as a box and whisker plots. The box contains the middle 50% of the data and 
the median is shown by the line in the box. The upper edge of the box represents the 
75th percentile (upper quartile) and the lower edge of the box indicates the 25th
percentile (lower quartile) of the data. The whiskers represent the maximum and 
minimum values of the data. One-way ANOVA showed a significant increase of focal 
adhesion numbers with RhoJ knockdown at the wound edge (P<0.0001) but not in the 
monolayer (ns: not significant). Tukey’s multiple comparison test was used to compare 
D1 or D2 with NCD (*** = P<0.001). 
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ECs in vessels are normally found as a monolayer surrounded by other ECs. Hence it was 
important to know whether focal adhesion numbers were also affected with RhoJ knockdown 
in an endothelial monolayer. However, to form a new microvessel ECs can differentiate to 
become tip cells, which guide newly formed sprouts towards a chemoattractant gradient. Tips 
cells are not completely surrounded by other ECs and have now been shown to have distinct 
signalling pathways controlling their migration (256).  
 
To assess whether RhoJ knockdown differentially affected focal adhesion numbers in ECs 
depending on their cellular context, cells at the wound edge of a scratch wound were 
compared to those found within a monolayer. HUVEC were siRNA transfected with NCD, 
RhoJ specific D1 or D2 or mock transfected. Two days later, scratch wound assays were set 
up on gelatin-coated glass coverslips. Six hours after the scratches were made, cells were 
fixed, permeabilised and stained with anti-vinculin antibodies. To quantify focal adhesion 
numbers, the number of focal adhesions found per cell either at the wound edge or in the 
monolayer was counted. SiRNA mediated knockdown of RhoJ resulted in increased focal 
adhesion numbers in cells at the edge of a scratch compared with control transfected cells 
(figure 4.2A). However no differences were observed in cells within the monolayer. Counting 
focal adhesions confirmed that RhoJ knockdown significantly increased the number of focal 
adhesions per cell at the migrating front of a scratch wound but RhoJ knockdown did not 
significantly affect focal adhesion formation of cells in the monolayer (figure 4.2B). 
 
4.2.2 RhoJ regulation of stress fibre formation and actomyosin contractility 
Since Rho GTPases have been shown to control the actin cytoskeleton and focal adhesions are 
physically linked to the actin cytoskeleton, experiments were performed to investigate how 
RhoJ knockdown might affect filamentous actin (f-actin) organisation in sparsely plated ECs. 
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Two days after siRNA transfection, HUVEC were adhered to gelatin-coated glass coverslips 
at a low density and were stained with phalloidin-TRITC to detect f-actin. Control transfected 
HUVEC displayed actin protrusions and moderate numbers of stress fibres (figure 4.3A). 
However, cells with reduced RhoJ expression appeared to have less protrusions and more 
stress fibres. To quantify stress fibre formation, LSM 510 confocal software was used to 
obtain the mean fluorescent intensity of the phalloidin-TRITC staining per cell. RhoJ 
knockdown significantly increased actin staining intensity indicating that RhoJ-depleted cells 
have increased numbers of stress fibres (figure 4.3B).  
 
As mentioned earlier, ECs exist in vivo as a monolayer, except for when endothelial tip cells 
are leading the end of an angiogenic sprout. To assess whether RhoJ knockdown affected 
stress fibre formation in ECs depending on their cellular setting, cells at the wound edge of a 
scratch wound were compared to those found within a monolayer. HUVEC were either mock 
transfected, transfected with NCD, RhoJ specific D1 or D2. Two days later, scratch wound 
assays were set up on gelatin-coated glass coverslips. Six hours after the scratches were made, 
cells were fixed, permeabilised and stained with phalloidin-TRITC. To quantify stress fibres, 
the mean fluorescent intensity of the phalloidin-TRITC staining per cell either at the wound 
edge or in the monolayer was measured. SiRNA-mediated knockdown of RhoJ resulted in 
increased stress fibres in cells at the edge of a scratch compared with control transfected cells 
(figure 4.4A). 
 
As before, no differences were observed in cells within the monolayer. RhoJ knockdown 
significantly increased actin intensity at the migrating front of a scratch wound but RhoJ 
knockdown did not significantly affect stress fibre formation of cells in the monolayer (figure 
4.4B). These data suggest that increased stress fibres in RhoJ-depleted cells may be the cause 
for the motility defects found in RhoJ knockdown cells. 
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Figure 4.3 RhoJ knockdown increases stress fibre formation in sparsely plated 
cells. Human umbilical vein endothelial cells were either mock transfected or 
transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 
(D2) at 10 nM. (A) Two days after transfection, cells were plated at low density on to 
glass coverslips and stained with phalloidin-TRITC to visualise filamentous actin (f-
actin). Scale bar = 20 µm. (B) The mean fluorescent intensity of f-actin staining per cell 
were quantified for 30 cells from three independent experiments and displayed as box 
and whisker plots. The box contains the middle 50% of the data and the median is 
shown by the line in the box. The upper edge of the box represents the 75th percentile 
(upper quartile) and the lower edge of the box indicates the 25th percentile (lower 
quartile) of the data. The whiskers represent the maximum and minimum values of the 
data. One-way ANOVA showed a significant increase in the intensity of f-actin staining 
in RhoJ-depleted cells (P<0.0001). Tukey’s multiple comparison test was used to 
compare D1 or D2 with NCD (*** = P<0.001).
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Figure 4.4 Knockdown of RhoJ increases stress fibre formation at the wound edge 
but not in the monolayer. Human umbilical vein endothelial cells were either mock 
transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or 
RhoJ duplex 2 (D2) at 10 nM. (A) Two days after transfection, scratch wound assays 
were set up on fully confluent glass coverslips and allowed to heal for 6 hours before 
staining with phalloidin-TRITC to visualise filamentous actin. Scale bar = 10 µm. (B) 
The mean fluorescent intensity of filamentous actin staining per cell of cells at the 
wound edge or in the monolayer were quantified for at least 30 cells from three 
independent experiments and displayed as a box and whisker plots. The box contains 
the middle 50% of the data and the median is shown by the line in the box. The upper 
edge of the box represents the 75th percentile (upper quartile) and the lower edge of the 
box indicates the 25th percentile (lower quartile) of the data. The whiskers represent the 
maximum and minimum values of the data. One-way ANOVA showed a significant 
increase in the intensity of filamentous actin staining in RhoJ-depleted cells at the 
wound edge (P<0.0001) but not in the monolayer (ns: not significant). Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (*** = P<0.001).  
B
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 In order to visualise the migratory behaviour of cells lacking RhoJ in response to a 
chemoattractant gradient during chemotaxis, a Dunn chemotaxis chamber assay was set up 
where the cells could be observed microscopically in real time, something that could not be 
done with a Boyden chamber. The Dunn chamber consists of two concentric circles ground 
into one face of a glass slide, referred to as the inner and outer wells. A ring-shaped ridge, 
referred to as the bridge, separates the two wells. The bridge is 20 µm lower than the rest of 
the glass slide. The outer well contains the chemoattractant and the inner well contains control 
media. A linear gradient of the chemoattractant forms by diffusion across the bridge between 
the two wells. Cells seeded onto a glass coverslip are inverted onto the slide. The cells that lie 
directly over the bridge of the chamber between the two wells can be observed using live 
imaging microscopy and their migratory paths towards the gradient can be mapped.  
 
Two days after HUVEC were siRNA transfected, cells were plated sparsely onto coverslips 
and left to adhere for 1 hour in low-serum media before loading on to the Dunn chamber. The 
outer wells were filled with media containing 10% FCS supplemented with bovine brain 
extract. Inner wells were filled with 1% FCS media. The Dunn chamber was placed in a 
humidified chamber on a heated stage at 37°C in 5% CO2 using an inverted microscope setup. 
Time-lapse images were digitally captured every minute for 4 hours. Migratory paths of 
individual cells were tracked and plotted as direction plots. The majority of the mock and 
NCD transfected cells migrated towards the chemoattractant, which is located at the top of the 
plots (figure 4.5A). However RhoJ knocked down cells did not migrate towards the direction 
of the chemoattractant and did not considerably move away from their point of origin. The 
time-lapse images in figure 4.5B show that the control-transfected cells were polarised, 
elongated and migrated towards the chemoattractant. However RhoJ-depleted cells were 
round in shape, unpolarised and displayed dynamic blebbing of their plasma membrane, 
which occurred constantly throughout the 4-hour period. Blebs arise from rapid detachment of 
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Figure 4.5 Cells with reduced RhoJ expression demonstrate defective 
morphological polarisation and bleb-like membrane protrusions in the presence of 
a chemoattractant gradient. Human umbilical vein endothelial cells were either mock 
transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or 
RhoJ duplex 2 (D2) at 10 nM. Two days after transfection, cells were plated onto 
gelatin-coated coverslips and inverted onto the Dunn chemotaxis chamber. Cell 
polarisation and migration towards 10% fetal calf serum and bovine brain extract was 
monitored over 4 hours using time-lapse microscopy. (A) The migratory tracks of 10 or 
more cells are displayed as direction plots with the source of the chemoattractant 
located at the top of the plots. (B) Frames of cells at 0, 60, 120, 180 and 240 min are 
shown. Outlines of the cells at 0 (red), 60-180 (grey) and 240 (green) min reveal the 
migratory paths of the cells outlined in white. Yellow arrows indicate the source of the 
chemoattractant and white arrowheads indicate bleb-like protrusions. Scale bar = 10 
µm. Similar data were obtained in three independent experiments.  
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the actomyosin cortex from the plasma membrane. Blebs inflate over ~30 seconds to form 
spherical protrusions that are filled with cytosol (257, 258). When blebs stop expanding, blebs 
are retracted as the contractile actin cortex reassembles under the membrane (259). Membrane 
detachment from the actin cortex and bleb inflation are thought to occur as a result of 
increased intracellular pressure generated by increased actomyosin contraction since 
blebbistatin-mediated inhibition of myosin II ATPase was shown to prevent bleb formation 
(260).  
 
Since membrane blebbing is driven by actomyosin contractility and RhoJ knockdown was 
shown to increase stress fibre formation, the effect of RhoJ depletion on contractility was 
investigated by measuring endothelial contractility using a gel contraction kit. The use of cell-
populated collagen type I gels to measure contractility of human fibroblasts was first 
described by Bell et al. (1979) (219). Vernon and Sage in 1996 then demonstrated that ECs 
also have the ability to contract collagen type I gels (220). In order to assay cell contraction, 
siRNA transfected HUVEC were harvested and embedded into type I collagen gels. Two days 
later, when stress had developed in the collagen matrices, the collagen gels were gently 
released from the sides of the culture dishes using a sterile pipette tip to initiate cell 
contraction. The degree of cell contraction was evaluated by measuring the diameter of the 
free-floating collagen gels after five days. Blebbistatin is an inhibitor of myosin II ATPase 
activity and binds specifically to the ATP binding region of myosin II heads and blocks the 
release of Pi hence inhibiting actomyosin contractility (261, 262). Thus for each condition, a 
negative control was added where blebbistatin was used to inhibit actomyosin contractility. 
RhoJ knockdown significantly decreased the diameter of collagen gels indicating that cells 
with reduced RhoJ expression have increased actomyosin contractility (figure 4.6A). 
Contraction of the collagen gels was reversed by adding blebbistatin, thus providing further 
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Figure 4.6 RhoJ knockdown increases actomyosin contractility. Human umbilical 
vein endothelial cells were either mock transfected or transfected with negative control 
duplex (NCD), RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM. (A) Two days after 
transfection, collagen gel contraction assays were set up and the diameters of cell-
populated collagen gels were measured 7 days later. For each condition a control was 
added where non-muscle myosin II was inhibited by blebbistatin. Values represent the 
means of three independent experiments. Error bars depict the standard error of the 
mean. One-way ANOVA showed that knockdown of RhoJ significantly decreased the 
diameter of collagen gels (P<0.0001), which was reversed with blebbistatin (ns: not 
significant). Tukey’s multiple comparison test was used to compare D1 or D2 with 
NCD (*** = P<0.001). (B) One day after transfection, cells were replated on to 
Matrigel. 24 hours later, cell lysates were prepared and blotted for phospho and total 
myosin light chain (MLC). Performed by Dr. Sabu Abraham and Dr. Georgia Mavria 
(Institute of Molecular Medicine, Leeds, UK and Institute of Cancer Research, London, 
UK). Permission for the use of their figure in this thesis was given. Similar data were 
obtained in three independent experiments 
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evidence that RhoJ-depleted cells contracted the collagen gels via increased actomyosin 
contractility.  
 
Rho-kinase (ROCK) is a serine/threonine kinase and is an effector molecule of RhoA (263). 
ROCK phosphorylates myosin light chain (MLC), which in turn increases actomyosin 
contractility (263). Cells undergoing actomyosin contraction would be expected to have 
increased levels of phosphorylated MLC. Dr. Sabu Abraham and Dr. Georgia Mavria 
(collaborators from the Institute of Molecular Medicine, Leeds, UK and Institute of Cancer 
Research, London, UK) checked the levels of phospho-MLC in RhoJ knockdown cells 
undergoing differentiation on Matrigel. This experiment involved knocking down RhoJ and 
plating cells on to Matrigel for 24 hours before harvesting and lysing the cells. Western 
blotting was performed using phospho-MLC (ser19/thr18) antibodies to detect the levels of 
phosphorylated MLC or pan-MLC antibodies to detect total levels of MLC. Knockdown of 
RhoJ increased phospho-MLC levels in cells plated on to Matrigel, indicating that these cells 
have increased actomyosin contractility (figure 4.6B). This data was included in this thesis to 
further support the data in figure 4.6A showing that RhoJ knocked down cells have increased 
actomyosin contractility. Dr. Sabu Abraham and Dr. Georgia Mavria gave full consent for the 
use of their data in this thesis. 
 
The effects of overexpressing wild type RhoJ or constitutively active RhoJ (permanently 
locked in the GTP-bound active form) on cell motility and contractility was also assessed. 
Cells that expressed GFP, GFP-tagged wild type RhoJ (GFP-wtRhoJ) or GFP-tagged 
dominant active mutant (Q79L) of RhoJ (GFP-daRhoJ) were generated by Mrs. Katarzyna 
Leszczynska  (University of Birmingham, UK). Recombinant lentiviral particles containing 
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Figure 4.7 Overexpression of dominant active RhoJ increases cell motility and 
reduces actomyosin contractility. Human umbilical vein endothelial cells were 
lentivirally transduced to express GFP, GFP-wtRhoJ or GFP-daRhoJ (A) Cells were 
plated onto gelatin-coated coverslips and inverted onto the Dunn chemotaxis chamber. 
Cell polarisation and migration towards 10% fetal calf serum and bovine brain extract 
was monitored over 4 hours using time-lapse microscopy. The migratory tracks of 10 or 
more cells are displayed as direction plots with the source of the chemoattractant 
located at the top of the plots. (B) Frames of cells at 0, 60, 120, 180 and 240 min are 
shown. Outlines of the cells at 0 (red), 60-180 (grey) and 240 (green) min reveal the 
migratory paths of the cells outlined in white. Yellow arrows indicate the source of the 
chemoattractant. Scale bar = 10 µm. Similar data were obtained in three independent 
experiments. (C) Collagen gel contraction assays were set up and the diameter of cell-
populated collagen gels were measured 7 days later. For each condition a control was 
added where non-muscle myosin II was inhibited by blebbistatin. Values represent the 
means of three independent experiments. Error bars depict the standard error of the 
mean. One-way ANOVA showed that overexpression of dominant active RhoJ 
significantly increased the diameter of collagen gels (P<0.0183). Tukey’s multiple 
comparison test was used to compare GFP-wtRhoJ or GFP-daRhoJ with GFP control (* 
= P<0.05). (D) Western blots of GFP, GFP-wtRhoJ and GFP-daRhoJ cell lysates blotted 
with GFP, RhoJ and tubulin antibodies. (e): endogenous. Performed by Mrs. Katarzyna 
Leszczynska from The University of Birmingham, UK. Full consent for the use of this 
figure was given.  
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either GFP, GFP-wtRhoJ or GFP-daRhoJ were produced by transient transfection of 
HEK293T cells. The lentiviral supernatants were collected and concentrated before stably 
transducing into HUVEC. Cells from each condition were then purified by selection of GFP 
positive cells using flow cytometric sorting to ensure that every cell used in assays were 
successfully infected with either GFP, GFP-wtRhoJ or GFP-daRhoJ lentivirus vectors. 
 
In order to observe the morphology and the chemotactic response of cells overexpressing wild 
type or dominant active RhoJ during live chemotaxis, a Dunn chemotaxis chamber assay was 
set up. GFP, GFP-wtRhoJ and GFP-daRhoJ cells were plated sparsely onto coverslips and left 
to adhere for 1 hour in low-serum media before loading on to the Dunn chamber. The outer 
wells were filled with media containing 10% FCS supplemented with bovine brain extract and 
inner wells were filled with 1% FCS media. Time-lapse images of cells that lay directly over 
the bridge between the two wells at 37°C in 5% CO2 were digitally captured every minute for 
4 hours. Most of the cells expressing GFP alone migrated towards the FCS gradient (figure 
4.7A). Cells expressing GFP-wtRhoJ and GFP-daRhoJ also migrated successfully towards the 
chemoattractant however GFP-daRhoJ cells moved a greater distance towards the FCS 
suggesting that these cells have increased motility. GFP-wtRhoJ and GFP-daRhoJ cells 
polarised and extended towards the chemoattractant in a similar way to control cells (figure 
4.7B). Moreover, GFP-daRhoJ cells generally extended out long cellular protrusions in an 
attempt to connect to one another in similar way to how ECs connect in tube forming assays 
on Matrigel.  
 
To investigate the effect of wild type RhoJ or constitutively active RhoJ overexpression on 
actomyosin contraction, cells expressing either GFP, GFP-wtRhoJ or GFP-daRhoJ were 
embedded into type I collagen gels. Two days later, gel contraction was initiated by pulling 
away the collagen gels from the sides of the culture dishes with a sterile pipette tip. The 
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degree of cell contraction was evaluated by measuring the diameter of the free-floating 
collagen gels after five days. For each condition, a negative control was added where 
blebbistatin was used to inhibit actomyosin contractility. Overexpression of dominant active 
RhoJ significantly increased the diameter of collagen gels in comparison to control indicating 
that GFP-daRhoJ cells have decreased actomyosin contractility (figure 4.7C). Although the 
mean diameter of the collagen gels containing GFP-wtRhoJ cells was higher than GFP 
control, the means were not statistically different from each other. The expression of the GFP, 
GFP-wtRhoJ and GFP-daRhoJ was confirmed by western blotting (figure 4.7D). Cell lysates 
from HUVEC expressing GFP, GFP-wtRhoJ or GFP-daRhoJ were blotted with GFP, RhoJ or 
tubulin antibodies. This Western blot was performed by Mrs. Katarzyna Leszczynska (The 
University of Birmingham, UK) and full consent for the use of figure 4.7D in this thesis was 
given. 
 
Data in figure 4.8 shows that cells with reduced RhoJ expression did not polarise their cell 
shape in the direction of migration indicating that these cells may not have the ability to detect 
chemoattractant stimuli in order to migrate directionally. Polarised cells reorganise the 
position of the Golgi apparatus towards the direction of movement (103). Nobes and Hall 
(1999) showed that Cdc42 activity is required for Golgi reorientation and that the 
reorientation of the Golgi towards the direction of migration is an essential process for 
directional cell movement (165). To determine whether knocking down RhoJ affects cell 
polarisation, the position of the Golgi apparatus in RhoJ-depleted cells at the wound edge was 
assessed. Two days after transfection, scratch wound assays were set up on fully confluent 
glass coverslips. Six hours later, cells were fixed, permeabilised and stained with anti-GM130 
(a cis-Golgi matrix protein (264)) and DAPI. To quantify the number of polarised wound 
edge cells, cells were divided up into three 120° sectors centering on the nucleus, one of 
which faced the edge of the wound. Cells in which the Golgi apparatus was found within the 
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sector facing the wound were scored positive and counted. Staining of the Golgi in cells at the 
wound edge and an example of how cells were scored as positive are shown in figure 4.8A. 
Quantitation of the the wound edge cells revealed that RhoJ-depletion did not alter the 
reorientation of the Golgi apparatus which suggests that cells with reduced RhoJ expression 
are capable of sensing the edge of a scratch (figure 4.8B).   
 
ECs are connected to one another through cell-cell adherens junctions, which are important 
for contact inhibition regulation, permeability and the organisation of new vessels during 
angiogenesis (265). VE-Cadherin is expressed at adherens junctions and is known to 
modulate endothelial permeability and barrier function downstream of RhoA and Rac1. RhoA 
inhibition has been shown to increase junctional localisation of VE-Cadherin whereas 
inhibition of Rac1 shows the converse (177). The effect of RhoJ knockdown on cell-cell 
junctions was also investigated by analysing the expression of VE-Cadherin at cell-cell 
junctions. HUVEC were transfected with NCD, RhoJ specific D1 or D2 or mock transfected. 
Cells were grown to confluence on glass coverslips and seven days later, cells were fixed, 
permeabilised and stained with anti-VE-Cadherin and DAPI. Expression of VE-Cadherin at 
cell-cell junctions did not appear to be altered by RhoJ knockdown (figure 4.9). 
 
4.2.3 Rescue of motility defects in RhoJ siRNA-treated cells 
4.2.3.1 Inhibition of Rho-kinase activity 
The activation of ROCK, which is downstream of RhoA, modulates the rearrangement of the 
actin cytoskeleton and focal adhesions by inducing contraction of actomyosin fibres (134, 
159). Since RhoJ knockdown was shown to increase stress fibre formation (figure 4.3), 
actomyosin cell contraction and MLC phosphorylation (figure 4.6), it was hypothesised that 
knockdown of RhoJ causes an increase in ROCK activity, which in turn increases phospho-
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Figure 4.8 Knockdown of RhoJ does not affect polarisation of the Golgi apparatus 
in a scratch wound assay. Human umbilical vein endothelial cells were either mock 
transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or 
RhoJ duplex 2 (D2) at 10 nM. Two days after transfection, scratch wound assays were 
set up on fully confluent glass coverslips and allowed to heal for 6 hours before fixing 
and staining with anti-GM130 and DAPI. The white boxes represent a polarised cell 
with the Golgi apparatus located within the 120° sector facing the wound edge. Dotted 
white lines indicate the edge of the scratch. Scale bar = 20 µm. (B) The percentage of 
cells at the scratch margin with the Golgi apparatus facing the wound edge was 
calculated from 50 cells from three independent experiments. Error bars show the 
standard error of the mean. Analysis using one-way ANOVA showed that knockdown 
of RhoJ did not affect Golgi reorientation in migrating cells (ns: not significant). 
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Figure 4.9 Knockdown of RhoJ does not affect the localisation of VE-Cadherin at 
cell-cell junctions. Human umbilical vein endothelial cells were either mock 
transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 (D1) or 
RhoJ duplex 2 (D2) at 10 nM. Transfected cells were grown to confluence on glass 
coverslips and were then stained with anti-VE-Cadherin and DAPI. Scale bar = 50 µm. 
Similar data were obtained in three independent experiments 
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MLC levels and actomyosin contractility resulting in impaired tube formation and motility 
defects. Thus it was thought that inhibition of ROCK would ameliorate the RhoJ knockdown-
mediated defects in cell motility and tube formation. To test this hypothesis, ROCK was 
inhibited using a selective ROCK inhibitor, Y27632 (266), in RhoJ knocked down cells. 
These cells were then assayed in Matrigel tube formation, scratch wound and Boyden 
chamber chemotaxis assays. Assays were set up as previously described except where 
required Y27632 was added to the media at 10 µM at the beginning of every assay.  
 
Twenty-four hours post seeding on to Matrigel, cells with reduced RhoJ expression treated 
with Y27632 produced well-connected and stable capillary-like networks (figure 4.10A). 
These tubule networks displayed reduced numbers of unconnected branches and increased 
numbers of complex nodes (nodes with 3 or more branch points) to similar levels found in 
NCD control (figure 4.10B). In wound healing, ROCK inhibited RhoJ-depleted cells 
completely closed the scratch by 24 hours at a similar rate to NCD treated cells (figure 
4.10C). The significant reduction in chemokinetic migration with RhoJ knockdown at 24 
hours was reversed with inhibition of ROCK (figure 4.10D). In the Boyden chamber assay, as 
expected, knockdown of RhoJ alone resulted in a significant reduction in chemotactic 
migration towards serum-rich media. However with ROCK inhibition in RhoJ knocked down 
cells, the migratory response towards the chemoattractant gradient was similar to NCD 
control (figure 4.10E).  
 
ROCK was also inhibited using H1152 (267), which is an inhibitor that has an unrelated 
chemical structure to Y27632. Although Y27632 is known to inhibit ROCK with high 
potency, like all pharmacological inhibitors, it can exhibit off-target effects (268). To confirm 
that the phenotypic effect of Y27632 in the assays above was due to ROCK inhibition, it was 
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Figure 4.10 Inhibition of ROCK using Y27632 restores tube forming and motility 
defects in cells with reduced RhoJ expression. Human umbilical vein endothelial 
cells were either mock transfected or transfected with negative control duplex (NCD), 
RhoJ duplex 1 (D1) or RhoJ duplex 2 (D2) at 10 nM. Two days after transfection, cells 
were either treated with or without Y27632 (A) Pictures of Matrigel assay at 10 and 24 
hours. Scale bar = 200 µm. (B) Matrigel assays were quantified by counting the number 
of nodes with 1, 2, 3 or ≥4 branches from five random fields of view. Values represent 
the means from three independent experiments. Error bars depict the standard error of 
the mean. One-way ANOVA showed that RhoJ knockdown significantly impaired two-
dimensional tubule formation (P<0.0001 for all nodes except node 2), which was 
reversed with Y27632 treatment. Tukey’s multiple comparison test was used to 
compare D1 or D2 with NCD (* = P<0.05, ** = P<0.01, *** = P<0.001). (C) Scratch 
wounds at 0, 4, 12 and 24 hours. Scale bar = 200 µm. (D) The percentage of wound 
remaining was measured and plotted. Values represent the means from three 
independent experiments. Error bars depict the standard error of the mean. One-way 
ANOVA showed a significant reduction of chemokinesis at 24 hours with RhoJ 
knockdown (P<0.0001), which was reversed with inhibition of ROCK. Tukey’s 
multiple comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). 
(E) Quantitation of cell migration using Boyden chemotaxis chamber. Values represent 
the means from three independent experiments with nine or more replicates in each 
experiment. Error bars depict the standard error of the mean. One-way ANOVA showed 
a significant reduction of chemotaxis to fetal calf serum in RhoJ-depleted cells 
(P<0.0001), which was reversed with ROCK inhibition. Tukey’s multiple comparison 
test was used to compare D1 or D2 with NCD (*** = P<0.001).  
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important to use another ROCK inhibitor from a structurally distinct chemical series. 
Inhibitors of different structure that share one target are predicted to have different off-target 
effects. Therefore if using inhibitor H1152 resulted in the same phenotypic effects as Y27632, 
it can be assumed that it is due to the fact that they both inhibit ROCK.  
 
With H1152 treatment tube formation and cell motility defects observed with RhoJ 
knockdown were restored in a similar way to Y27632 treatment (figure 4.11). These data 
suggest that the RhoJ knockdown mediated effects on tube formation and motility are due to 
increased ROCK activity. 
 
4.2.3.2 Inhibition of myosin II ATPase activity 
Activated ROCK increases myosin II ATPase activity in two ways, phosphorylation of MLC 
and inactivation of MLC phosphatase. Non-muscle myosin II interacts with actin filaments in 
an ATP-dependant manner. At the start of the cycle, myosin heads lacking a bound nucleotide 
are locked onto actin filaments. ATP binds to the myosin head and induces a conformational 
change that reduces the affinity of the myosin head for actin and allows it to move along the 
filaments. ATP is then hydrolysed into ADP and inorganic phosphate (Pi), which results 
in myosin weakly binding to a new site on the actin filament. Pi release increases the strength 
of myosin binding to actin and ADP is dissociated leaving the myosin head again locked 
tightly to the actin filament, generating actomyosin contractility (132).  
 
Blebbistatin is an inhibitor of myosin II ATPase activity (261, 262). Blebbistatin binds 
specifically to the ATP binding region of myosin II heads and blocks the release of Pi hence 
inhibiting actomyosin contractility. The tube forming and motility defects found in RhoJ 
knockdown cells were rescued when ROCK was inhibited (figures 4.10 and 4.11). These 
experiments demonstrated that RhoJ-siRNA treated cells have increased ROCK activity but 
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Figure 4.11 Inhibition of ROCK using H1152 restores tube forming and motility 
defects in RhoJ-depleted cells. Human umbilical vein endothelial cells were either 
mock transfected or transfected with negative control duplex (NCD), RhoJ duplex 1 
(D1) or RhoJ duplex 2 (D2) at 10 nM. Two days later, cells were either treated with or 
without H1152 (A) Pictures of Matrigel assay at 10 and 24 hours. Scale bar = 200 µm. 
(B) Matrigel assays were quantified by counting the number of nodes with 1, 2, 3 or ≥4 
branches from five random fields of view. Values represent the means from three 
independent experiments. Error bars depict the standard error of the mean. One-way 
ANOVA showed that RhoJ knockdown significantly impaired two-dimensional tubule 
formation (P<0.0001 for all nodes except node 2), which was reversed with H1152 
treatment. Tukey’s multiple comparison test was used to compare D1 or D2 with NCD 
(* = P<0.05, ** = P<0.01, *** = P<0.001). (C) Scratches wounds at 0, 4, 12 and 24 
hours. Scale bar = 200 µm. (D) The percentage of wound remaining was measured and 
plotted. Values represent the means from three independent experiments. Error bars 
depict the standard error of the mean. One-way ANOVA showed a significant reduction 
of chemokinesis at 24 hours with RhoJ knockdown (P<0.0001), which was reversed 
with inhibition of ROCK. Tukey’s multiple comparison test was used to compare D1 or 
D2 with NCD (*** = P<0.001). (E) Quantitation of cell migration using Boyden 
chemotaxis chamber. Values represent the means from three independent experiments 
with nine or more replicates in each experiment. Error bars depict the standard error of 
the mean. One-way ANOVA showed a significant reduction of chemotaxis to fetal calf 
serum in RhoJ-depleted cells (P<0.0001), which was reversed with ROCK inhibition. 
Tukey’s multiple comparison test was used to compare D1 or D2 with NCD (*** = 
P<0.001).  
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different substrates can be phosphorylated by ROCK as well as MLC. To elucidate whether 
the defects found in RhoJ knockdown cells were directly due to an increase in actomyosin 
contractility, blebbistatin was used to specifically inhibit the ATPase activity of myosin II. 
These experiments were carried out in a similar fashion to the ROCK inhibition assays 
described previously except blebbistatin was added at a concentration of 5 µM.  
 
In tube formation, cells with reduced RhoJ expression treated with blebbistatin produced 
well-linked and stable tubule networks (figure 4.12A). These networks no longer appeared 
weak and unconnected as shown with RhoJ knockdown alone and instead were similar to the 
tubule networks created by NCD cells. Blebbistatin treatment in RhoJ-depleted cells reduced 
the number of unconnected branches and increased the number of nodes with 3 or more 
branch points at 10 and 24 hours to similar levels found in NCD control. In wound healing, 
blebbistatin treatment in RhoJ-depleted cells resulted in complete closure of the wound at 24 
hours at a similar rate to NCD treated cells (figure 4.12C). The significant reduction in 
migration with RhoJ knockdown alone was fully restored when myosin II ATPase activity 
was inhibited (figure 4.12D). In the Boyden chamber assay, knockdown of RhoJ alone 
resulted in a significant reduction in chemotactic migration towards serum-rich media (figure 
4.12E). However with blebbistatin treatment in RhoJ knocked down cells, the migratory 
response towards the chemoattractant gradient was restored back to normal.  
 
Inhibition of actomyosin contractility ameliorated the cell motility and tube formation defects 
found in RhoJ knocked down cells. These data produced similar results to when ROCK was 
inhibited in RhoJ-depleted cells (figures 4.10 and 4.11). These data suggest that tube 
formation and motility defects found with RhoJ knockdown are due to increased ATPase 
activity of myosin II resulting in increased actomyosin contractility, which is a downstream 
effect of increased ROCK activity.  
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Figure 4.12 Inhibition of myosin II using blebbistatin restores tube forming and 
motility defects in RhoJ-depleted cells. Human umbilical vein endothelial cells were 
either mock transfected or transfected with negative control duplex (NCD), RhoJ duplex 
1 (D1) or RhoJ duplex 2 (D2) at 10 nM. Two days after transfection, cells were either 
treated with or without blebbistatin (A) Pictures of Matrigel assay at 10 and 24 hours. 
Scale bar = 200 µm. (B) Matrigel assays were quantified by counting the number of 
nodes with 1, 2, 3 or ≥4 branches from five random fields of view. Values represent the 
means from three independent experiments. Error bars depict the standard error of the 
mean. One-way ANOVA showed that RhoJ knockdown significantly impaired two-
dimensional tubule formation (P<0.0001 for all nodes except node 2), which was 
reversed with blebbistatin treatment. Tukey’s multiple comparison test was used to 
compare D1 or D2 with NCD (* = P<0.05, ** = P<0.01, *** = P<0.001). (C) Scratch 
wounds at 0, 4, 12 and 24 hours. Scale bar = 200 µm. (D) The percentage of wound 
remaining was measured and plotted. Values represent the means from three 
independent experiments. Error bars depict the standard error of the mean. One-way 
ANOVA showed a significant reduction of chemokinesis at 24 hours with RhoJ 
knockdown (P<0.0001), which was reversed with blebbistatin treatment. Tukey’s 
multiple comparison test was used to compare D1 or D2 with NCD (*** = P<0.001). 
(E) Quantitation of cell migration using Boyden chemotaxis chamber. Values represent 
the means from three independent experiments with nine or more replicates in each 
experiment. Error bars represent standard error of the mean. One-way ANOVA showed 
a significant reduction of chemotaxis to fetal calf serum in RhoJ-depleted cells 
(P<0.0001), which was reversed with blebbistatin treatment. Tukey’s multiple 
comparison test was used to compare D1 or D2 with NCD (*** = P<0.001).  
E D
 
!
!"
4 | RhoJ modulation of actomyosin contractility and focal adhesion numbers 
 
 144 
4.2.4 Summary 
RhoJ silencing increased the number of focal adhesions and stress fibres in wound edge cells 
but not in cells found in the monolayer. In the presence of a chemoattractant gradient, RhoJ-
depleted cells produced bleb-like membrane protrusions and showed impaired cellular 
morphology. In contrast, cells overexpressing RhoJ, either wild type or dominant active, were 
highly motile in the Dunn chamber chemotaxis assay. RhoJ knockdown increased cellular 
contraction and the converse was seen with cells overexpressing dominant active RhoJ. 
Furthermore, increased levels of phospho-MLC were detected in cells lacking RhoJ on 
Matrigel. RhoJ knockdown did not affect directional sensing or the expression of VE-
Cadherin at cell-cell junctions in the monolayer. Tube forming and migration phenotypes 
(introduced in chapter 3) were reversed when ROCK or myosin II ATPase activity was 
inhibited in cells with reduced RhoJ expression. 
 
4.3 Discussion 
SiRNA-mediated knockdown of RhoJ in primary ECs was found to impede EC motility in 
chapter 3. Subsequently, cells lacking RhoJ were found to display more focal adhesions than 
mock or NCD-transfected cells (figure 4.1). It is likely that the significant increase in focal 
adhesion numbers perturbed the normal cyclic process of focal adhesion assembly and 
disassembly, thereby causing motility to become impaired in RhoJ depleted cells. In addition, 
the increase in focal adhesions may have induced tighter adhesion to the matrix substrate 
rendering RhoJ knocked down cells immobile. Studies have shown that activation of FAK 
increases cell-matrix adhesion strength (255, 269). Since RhoJ siRNA treated cells displayed 
increased numbers of phospho-FAK containing focal adhesions, it is likely that these cells had 
stronger adherence to the ECM. Moreover, the focal adhesions in RhoJ knocked down cells 
were vinculin, phospho-paxillin and phospho-FAK positive (figure 4.1) showing that RhoJ 
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knockdown did not affect the assembly of these proteins into focal adhesion complexes. 
However, the increase in their numbers is indicative of problems with disassembly and 
turnover. Thus RhoJ may have an important role in focal adhesion turnover in ECs but in 
order to confirm this theory, the rate of focal adhesion turnover would need to be measured.  
  
Stress fibers are physically linked to focal adhesions via the actin binding site on the vinculin 
tail domain (121). Forces generated in stress fibres, by the pulling of myosin II on actin 
filaments, are exerted on focal adhesions in order for cells to move (270). Considering their 
connection, it was not surprising that RhoJ knockdown also induced an increase in stress 
fibres (figure 4.3). Stress fibres are bundles of actin and non-muscle myosin II filaments, 
which have contractile activity and regulate tension within cells (129-131). Therefore since 
RhoJ siRNA treated cells had increased stress fibres, it was logical to assume that these cells 
would also have increased actomyosin contractility. As expected, cells with reduced RhoJ 
expression were found to contract collagen gels significantly more than controls cells (figure 
4.6A). Conversely, cells expressing dominant active RhoJ contracted the collagen gels 
significantly less than control cells (figure 4.7C).  
 
In line with our findings, RhoJ-silenced cells on Matrigel were also found to have increased 
levels of phosphorylated MLC (figure 4.6B). MLC can be phosphorylated by a number of 
kinases including RhoA-dependent ROCK and calcium-dependent MLC kinase, which result 
in increased myosin II ATPase activity and stress fiber contractility (127, 254). Using two 
structurally unrelated inhibitors of ROCK, the tube forming and motility defects of RhoJ 
siRNA treated cells were reversed to phenotypes equivalent to that seen in negative control 
duplex treated cells (figures 4.10 and 4.11). These data strongly suggest that the increase in 
phospho-MLC was due to an increase in ROCK activity, which in turn increased the ATPase 
activity of myosin II. The present study also demonstrates that the direct inhibition of non-
4 | RhoJ modulation of actomyosin contractility and focal adhesion numbers 
 
 146 
muscle myosin II using blebbistatin also reversed the effect of RhoJ knockdown on scratch 
wound closure and tube formation (figure 4.12). Inhibiting the function of non-muscle myosin 
II in alternative ways resulted in the rescue of RhoJ knockdown phenotypes. This suggests 
that phenotypes induced by loss of RhoJ were due to increased actomyosin contractility, 
mediated through increased ROCK activity. These data indicate that RhoJ negatively 
regulates stress fibre formation and actomyosin contractility. 
 
Interestingly, the increased stress fibre and focal adhesion phenotype was only evident in 
sparsely plated cells or cells at the migration front of scratch wound assays but not within 
monolayers (figures 4.1 to 4.4). This suggests that RhoJ plays a critical role in migrating cells 
but the cells within the monolayer may not be dependent on RhoJ for maintenance of focal 
adhesions or stress fibres. The lack of phenotype in the monolayer may be due to signalling 
from neighbouring cells, through intact cell-cell contacts, which suppress the phenotypes of 
RhoJ knockdown and compensate for the loss of RhoJ.  
 
In chapter 3, the reduced migration of RhoJ depleted cells in the scratch wound assay, was 
more evident at later time points (figures 3.5A-B and 3.6A-B). RhoJ depleted cells were able 
to migrate to some extent initially but by 24 hours migration was significantly reduced. Since 
we have found that cells in a monolayer do not express the RhoJ knockdown phenotype, RhoJ 
knockdown cells at the wound edge may have retained the ‘monolayer phenotype’ during 
initial wound closure and migrated normally at first. However, only after the cells started to 
move and reduced contact with neighboring cells, focal adhesions and stress fibres may have 
begun to accumulate, which caused motility to slow.  
 
This may also explain why initial tube formation was not largely affected by RhoJ 
knockdown but the secondary stage was (figures 3.2 to 3.4). Perhaps RhoJ knockdown did not 
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affect the initial phase since motility is not required (170). However in the secondary phase, 
when migration is essential, the loss of RhoJ resulted in excessive contractility and focal 
adhesion numbers, which inhibited migration and the extension of primitive cords. The weak 
connections made in RhoJ knockdown conditions also appeared to retract by 24 hours (figures 
3.2A-B and 3.3A-B), this is consistent with our finding that these cells have increased 
contractility (figure 4.6A). In addition, the observations that RhoJ knocked down cells on 
Matrigel have increased levels of phosphorylated MLC (figure 4.6B) and inhibition of ROCK 
or myosin II ATPase activity ameliorates the motility and tube formation defects, strongly 
suggest that actomyosin contractility was increased in these cells through increased ROCK 
activity (figures 4.10 to 4.12). Moreover, it has previously been shown that increased 
actomyosin contractility is capable of inducing cell death during tube formation (92).  
 
Cell–cell adhesions are essential for normal tube formation (265, 271). Altered cell-cell 
adhesions could also produce the same effect as RhoJ knockdown on tube formation. 
Although, we found no mis-localisation of the adherens junctional protein VE-Cadherin in a 
monolayer of RhoJ siRNA treated cells (figure 4.9), we cannot formally rule out a cell-cell 
adhesion defect because cells within a monolayer appear to suppress RhoJ knockdown 
phenotypes. In future studies, it would be interesting to examine the expression of VE-
Cadherin in RhoJ knocked down cells on Matrigel.  
 
In agreement with our observations, a past study reported stress fibre loss in mouse fibroblast 
cells expressing dominant active mutant of RhoJ (198). In further support of our findings, 
Vignal et al. (2000) showed that constitutively active RhoJ expression in rat embryonic 
fibroblasts induced the formation of actin-rich ruffles on the dorsal membrane (197). These 
‘waves’ are known to disassemble stress fibres and promote actin reorganization (246, 247). 
Therefore, it is possible that RhoJ knockdown might have prevented dorsal ruffling, which 
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resulted in the accumulation of stress fibre bundles and increased actomyosin contractility. 
This group also observed a significant increase of stress fibres in fibroblasts expressing 
dominant negative RhoJ and conversely a reduction in cells expressing dominant active RhoJ 
(197). Our work agrees with these past studies but we are the first to show a role for 
endogenous RhoJ in primary ECs. Moreover, dominant active RhoJ induced lamellipodia 
formation in porcine aortic ECs stably expressing the human platelet-derived growth factor β-
receptor (204). In agreement with this finding, our observations were that RhoJ depleted cells 
were typically more rounded and poorly spread, however, control cells were polarised and 
presented polygonal protrusions such as lamellipodia. The extension of lamellipodia is 
stimulated by integrin engagement (106). Perhaps the inhibition of focal adhesion turnover by 
RhoJ knockdown prevented the spreading of these cells. Moreover, Wakatsuki et al. (2003) 
demonstrated that cell spreading is inversely related to myosin II activity and that increased 
actomyosin contractility (driven by RhoA) hinders lamellipodia and filopodia formation. (99). 
Additionally, they showed that during cell spreading, RhoA activity is low while the activity 
of Rac1 and Cdc42 is high. Low RhoA activity has also been shown to induce high turnover 
of focal adhesions in fibroblast cells (106, 272). Therefore, perhaps the lack of RhoJ 
signalling triggered circular, non-polarised cell shapes due to these cells having increased 
RhoA signalling. Thus it may be possible for RhoJ activity to be conversely correlated to that 
of RhoA, whereby high RhoJ activity could increase focal adhesion turnover rate and reduce 
actomyosin contractility, and visa versa. Our data suggests that RhoJ may negatively regulate 
the RhoA signalling pathway.  
 
Consistent with chapter 3, RhoJ knockdown diminished cell migration toward a gradient of 
chemoattractant in the Dunn chemotaxis chamber (figure 4.5A). Conversely, cells 
overexpressing wild type or dominant active RhoJ were capable of moving toward the 
chemical stimuli and migrated further than control cells toward the chemoattractant (figure 
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4.7A). These data further support the data in chapter 3, which suggest that RhoJ is important 
for EC motility. Consistently, RhoJ siRNA treated cells were also non-polarised, poorly 
spread and had circular cell shapes in the Dunn chamber. Intriguingly however, cells lacking 
RhoJ also constantly produced and retracted bleb-like plasma membrane protrusions (figure 
4.5B). This was not observed in other situations such as in the scratch wound or Matrigel 
assays suggesting that perhaps the presence of a serum gradient may have somehow induced 
the cells to bleb. Cells overexpressing wild type or constitutively active RhoJ demonstrated 
the opposite morphology, whereby cells were polarised, elongated and extended long cellular 
protrusions (figure 4.7B), suggesting that these cells were highly motile. In addition, in 
normal cell culture conditions, cells expressing dominant active RhoJ were also found to 
undergo extensive tubulogenesis (data not shown). This is compatible with a recent study that 
shows that reduced contractility results in high EC motility and morphogenesis (174).  
 
Bleb formation corresponds with high myosin II activity and myosin II inhibition prevents 
blebbing (260, 273, 274).  Blebs are thought to be a mechanical response to a localised 
increase in intracellular pressure, which is exerted through actomyosin contractility (257, 
275). During the last decade, it has started to emerge that cell movement does not exclusively 
involve the extension of lamellipodia but can also require membrane blebbing (260). Normal 
blebbing occurs at the leading edge of a cell and the cell is then thrust forward by a 
subsequent contraction of the cell body (260). Many types of cells have been shown to utilise 
polarised blebbing as an alternative to lamellipodial migration such as zebrafish germ cells, 
tumour cells and depending on their environment, neutrophils and leukocytes (273, 274, 276). 
Moreover, zebrafish germ cells have been shown to display blebbing at the leading edge 
following stimulation by a chemoattractant gradient (276).  
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Our hypothesis is that increased contractility in RhoJ siRNA treated cells may have hindered 
spreading and by compensating for the lack of lamellipodia, these cells may then have 
attempted to migrate through blebbing in response to the chemoattractant gradient. However, 
due to unlocalised and sustained actomyosin contractility, the blebbing was not polarised but 
apparent all round the cell circumference. Moreover, RhoJ depleted cells were found to 
successfully reorientate their Golgi apparatus toward the wound edge in scratch wound assays 
(figure 4.8), indicating that these cells had the ability to sense direction and migration-
promoting stimuli but were unable to physically polarise their cell shape to move. Moreover, 
cells lacking RhoJ did not move a great deal from their points of origin and from our findings 
we can argue that this may have been due to these cells having increased adherence to the 
ECM as well as too much widespread intracellular tension. Many studies have shown that 
increased RhoA-ROCK-myosin signalling is essential for blebbing (277, 278). This coincides 
with our theory that RhoJ may be negatively regulating the RhoA pathway in some way, thus 
loss of RhoJ leads to accumulated contractile tension that spreads across the entire cell. 
 
In conclusion, RhoJ negatively modulates focal adhesion numbers and actomyosin 
contractility in ECs in vitro and may be essential for endothelial motility and angiogenesis in 
vivo. However, there is a complex interplay and reciprocal regulation between focal adhesion 
maturation, turnover, and actomyosin contractility. Studies have shown that focal adhesion 
disassembly, size and distribution is dependent on the controlled activity of myosin II (116, 
279). Conversely, components of focal adhesions have been shown to regulate contractility. 
At present, we do not know which process RhoJ affects directly. To determine whether 
increased contractility is the cause or consequence of defective focal adhesion turnover, the 
downstream effector proteins that GTP-bound RhoJ binds to would need to be identified.  
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To assess the biological relevance of RhoJ function in angiogenesis, it is necessary to study 
the role of RhoJ in vivo. By understanding the function of RhoJ in vivo, insights can be gained 
on the role of RhoJ in pathological angiogenesis in diseases such as psoriasis, arthritis, 
atherosclerosis and cancer metastasis. Future in vivo experiments may include knockdown or 
overexpression of RhoJ in murine Matrigel plug or sponge assays and the use of tumour 
models to assess the role of RhoJ in tumour angiogenesis. Currently, our group is in the 
process of generating a RhoJ knockout mouse. It would be interesting to see if these mice 
display any vascular defects and also to analyse the ECs from these mice at the cellular level. 
Furthermore, the role of RhoJ in zebrafish was already explored and this work is described in 
chapter 5.  
 
 
 
  
 
 
  
 
 
 
  
 
 
 
 
RhoJ in zebrafish development 
C h a p t e r  f i v e  
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5.1 Introduction 
Zebrafish, danio rerio, are small teleost tropical fish that are often used as model systems for 
studying aspects of developmental biology including in vivo angiogenesis. The advantages of 
using zebrafish are that protein expression can be easily knocked down using morpholino 
technology and the transparency of the embryos greatly facilitates visualisation of blood 
vessel formation (95).  
 
Zebrafish embryonic development is described in six broad periods of embryogenesis and 
each period is subdivided into stages, which are named according to their morphological 
features: the zygote (1-cell), cleavage (2-cell to 64-cell), blastula (128-cell to 30% epiboly), 
gastrula (50% epiboly to bud), segmentation (1-4 somites to 26+ somites) and pharyngula 
(prim-5 to long-pec) periods. In segmentation, somitogenesis occurs, which is the formation 
of somites from the presomitic mesoderm. At the final stages of the segmentation period, the 
primary vessels, the dorsal aorta and cardinal vein begin to form. During pharyngula period, 
angiogenesis occurs and the circulatory system begins to develop (280).  The sprouting of the 
intersegmental arteries from the dorsal aorta occurs around 22 hours post fertilisation (hpf). 
These arteries sprout dorsally and once reached the level of the dorsal neural tube, the vessels 
connect from anterior and posterior sides to form the future dorsal longitudinal anastomotic 
vessel (DLAV) (224). 
 
Having discovered that RhoJ is both highly expressed in human ECs and regulates endothelial 
motility and tube formation in vitro (chapters 3 and 4), it was important to discover the role of 
RhoJ in vivo, and zebrafish were chosen initially for this purpose. With zebrafish RhoJ being 
a hypothetical protein, the sequence and expression of RhoJ in zebrafish was firstly validated. 
The expression profile of RhoJ was also examined using reverse transcription PCR to 
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determine the temporal regulation of RhoJ expression, which would give an insight into the 
possible functions of RhoJ during zebrafish development. Furthermore, the tissue distribution 
profile of zebrafish RhoJ during normal embryonic angiogenesis was determined using 
whole-mount in situ hybridization experiments. Morpholinos are synthetic complementary 
antisense oligonucleotides that can either block translation or modify pre-mRNA splicing in 
order to knockdown gene function (98). Thus in order to investigate the function of RhoJ in 
zebrafish embryos, morpholino antisense oligonucleotides were used to knockdown RhoJ 
function in vivo.  
 
To conclude, this chapter aims to investigate the expression profile and function of RhoJ 
during zebrafish embryonic development. 
 
5.2 Results 
5.2.1 Validation of RhoJ mRNA expression and sequence in zebrafish  
Zebrafish RhoJ was a hypothetical protein and its sequence had been predicted by homology 
with mammalian RhoJ. Figure 5.1 shows the alignment of RhoJ’s amino acid sequence in 
human, mouse and zebrafish. The proteins have conserved exon structures and highly 
conserved primary sequences, which diverge only at the N- and C-termini. Protein sequence 
analysis by ClustalW program (Network Protein Sequence Analysis tool) showed that human 
and mouse RhoJ amino acid sequences were 93% identical and human and zebrafish RhoJ 
amino acid sequences were 76% identical.  
 
With zebrafish RhoJ expression and sequence being hypothetical, it was thus important to 
determine if RhoJ was expressed in zebrafish and to confirm its sequence and exon structure. 
To validate this prediction, zebrafish were mated and embryos at 23, 24 and 26 hours post 
5 | RhoJ in zebrafish development 
 
 155 
 
 
 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 Predicted amino acid sequences of RhoJ in human, mouse and 
zebrafish. The alignment of human, mouse and zebrafish RhoJ amino acid sequences 
were generated by using ClustalW program available at Network Protein Sequence 
Analysis (NPS@) web server: http://npsa-pbil.ibcp.fr/NPSA/npsa_clustalw.html. The 
boxes highlight the exon boundaries in each organism. Underneath the alignment, 
identical residues (red) are indicated by asterisks (*), strongly similar residues (green) 
are indicated by colons (:), weakly similar residues (blue) are represented by dots (.) 
and different residues (black) are left blank. Human and mouse RhoJ sequences are 
93% identical, human and zebrafish RhoJ sequences are 76% identical. 
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Figure 5.2 Full length RhoJ is expressed in zebrafish embryos. (A) Schematic 
showing the exon structure of zebrafish RhoJ and the fragments amplified by reverse 
transcription PCR (RT-PCR). To distinguish between expressed exons and spliced-out 
exons, primers were designed to cross exon boundaries (indicated by red arrows). (B) 
Non-denaturing polyacrylamide gel demonstrates the amplification of zebrafish RhoJ 
from cDNA obtained from a mixture of embryos at 23, 24 and 26 hours post 
fertilisation (hpf) using different primer pairs. EF1α was used as a positive control. A 
minus reverse transcriptase enzyme control (minus-RT) was used with EF1α primers. 
No template controls (NTC), containing water instead of cDNA, were added for each 
reaction. 
B 
A 
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fertilisation (hpf) were collected, removed from their chorions and lysed with trizol. From this 
lysate, RNA was extracted and cDNA was generated. This cDNA template was then used in 
reverse transcription PCR experiments to amplify the predicted coding region of zebrafish 
RhoJ. To confirm that none of the five exons were spliced out, PCRs were also performed 
using primers that were designed to cross various exon boundaries (figure 5.2A). No template 
controls were added for each primer pair where the reaction contained all the PCR reagents 
except the cDNA template. Elongation factor 1 alpha (EF1α) is a zebrafish housekeeping 
gene (281) and was used as a positive control. 
 
Full length RhoJ was found to be expressed in 23-26 hpf zebrafish cDNA with all five exons 
present (figure 5.2B). The full length coding sequence of zebrafish RhoJ was then cloned into 
pCR®-Blunt II-TOPO® (see section 2.4 DNA Constructs) and sequencing was found to 
match the predicted sequence.  
 
5.2.2 RhoJ mRNA expression during zebrafish stages of development 
At different developmental stages, the expressions of different proteins are regulated. 
Therefore it was interesting to investigate when RhoJ was expressed during zebrafish 
development. To investigate the expression of RhoJ during zebrafish embryogenesis, embryos 
from the stages of the main developmental periods were analysed for RhoJ expression; 8-cell 
(cleavage), 30% epiboly (blastula), 5-somite (segmentation), prim-5 and long-pec 
(pharyngula). The morphology of zebrafish embryos at these stages are illustrated in figure 
5.3A. The onset of embryonic transcription and the degradation of maternal transcripts is a 
gradual process from 1-cell to 16-cell stage of embryogenesis. Thus in 8-cell stage, the 
embryo is still carrying mRNA from the mother (282). At 30% epiboly, the embryo is 
preparing for gastrulation. Hemangioblasts, precursor cells to endothelial and pluripotent 
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hematopoietic cells, are known to exist in the blastodisc at this stage (283). At the 5-somite 
stage of the segmentation period, the first five somites develop. Neovascularisation is known 
to occur in the late stages of segmentation and then angiogenesis is prevalent from prim-5 to 
long-pec stages of the pharyngula period (280, 284).  
 
Embryos from various stages were collected and lysed. From these lysates, RNA was 
extracted and cDNA was generated. The same amount of RNA was used to generate each 
cDNA template. The cDNAs were then used in PCR experiments to amplify full length RhoJ 
and zebrafish housekeeping control, EF1α. No template and minus-RT controls were added 
as controls for genomic or cDNA template contamination and were set up as previously 
described.  
 
RhoJ was expressed in all five stages; 8-cell, 30% epiboly, 5-somite, prim-5 and long-pec 
(figure 5.3B). The expression level of RhoJ at 8-cell and 30% epiboly was relatively similar.  
However, at 5-somite, RhoJ expression was slightly downregulated. RhoJ expression was 
slightly increased at the prim-5 and long-pec stages of pharyngula. These data show that RhoJ 
transcripts are being made in all five embryonic stages of development however mRNA RhoJ 
expression was highest at the stage when angiogenesis is known to be occurring. 
 
5.2.3 RhoJ mRNA expression during zebrafish embryonic angiogenesis 
To further investigate the expression of zebrafish RhoJ, its tissue distribution was investigated 
by whole-mount in situ hybridization. Human RhoJ is highly expressed in ECs (206), and so 
it was important to determine whether zebrafish RhoJ also showed the same expression 
pattern. If so zebrafish would be a suitable model to study in vivo angiogenesis.  
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Figure 5.3 RhoJ is expressed in cleavage, blastula, segmentation and pharyngula 
stages of zebrafish development. (A) Lateral view drawings of the zebrafish 
embryonic developmental stages that were analysed for RhoJ mRNA expression. 
Development periods are labelled in black and stages are shown in blue. (B) Full length 
RhoJ was amplified by reverse transcription PCR from cDNA obtained from zebrafish 
embryos at 8-cell, 30% epiboly, 5-somite, prim-5 or long-pec stage. The same amount 
of RNA was used to generate each cDNA template. EF1α was used as a housekeeping 
control. Minus reverse transcriptase enzyme controls (minus-RT) and no template 
controls (NTC) were added for each reaction. 
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To analyse RhoJ mRNA expression in zebrafish embryos, antisense and sense riboprobes 
labeled with digoxigenin were generated from the pCR®-Blunt II-TOPO-zebrafish RhoJ 
cloned construct (see section 2.4 DNA Constructs). Whole-mount in situ hybridization 
experiments were performed on paraformaldehyde-fixed prim-5 (24 hpf) zebrafish embryos, 
since this is when embryonic angiogenesis is known to occur. A simplified diagram of the 
anatomy of a 24 hpf zebrafish embryo is shown in figure 5.4. At this stage, blood circulates in 
a closed circuit by leaving the heart and entering the dorsal aorta and caudal artery before 
returning through the caudal and posterior cardinal vein. The intersegmental arteries, which at 
this stage do not carry circulation, sprout from the dorsal aorta via angiogenesis.  
 
For the in situ hybridization experiments, embryos were digested with proteinase K to allow 
entry of the probes before being re-fixed with PFA. The probes were then hybridized to the 
complementary mRNA sequences in situ. The probes used were sense and antisense 
riboprobes for RhoJ and Friend leukemia virus integration 1 (Fli1) which is a transcription 
factor specifically found in artery and vein ECs in zebrafish embryos (285). Fli1 probes were 
generated by Dr. Rajeeb Swain (University of Birmingham, UK) and were used as a positive 
control for endothelial expression. An anti-digoxigenin antibody conjugated to alkaline 
phosphatase was then used before adding BM purple, a substrate for alkaline phosphatase, 
which develops a purple colour. The purple colour indicates the location of the gene of 
interest in the whole-embryo.  
 
Embryos probed with Fli1 antisense riboprobes revealed a clear vascular pattern with the 
main vessels stained purple such as the dorsal aorta, posterior cardinal vein and the 
intersegmental arteries (figure 5.5). However RhoJ appeared to be expressed in the somites of 
the embryo, which lie in between the intersegmental arteries. This expression was confirmed 
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Figure 5.4 Anatomy of zebrafish embryo. Lateral view drawing of a 24 hours post 
fertilisation (hpf) zebrafish embryo. At this stage, blood leaves the heart (H) and enters 
the dorsal aorta (DA). The circulation progresses into the caudal artery (CA) where 
blood empties into the caudal vein (CV) and the posterior cardinal vein (PCV) before 
returning to the heart. At this time, intersegmental arteries (ISA) are sprouting from the 
dorsal aorta, but do not yet carry circulation. At around 30 hpf, the ISA begin to 
connect with one another to form the dorsal longitudinal anastomotic vessel (DLAV). 
The somites (S) are muscle segments that lie between the intersegmental vessels. NC; 
notochord. 
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Figure 5.5 RhoJ mRNA is expressed in the somites of 24 hpf zebrafish embryos. 
Whole-mount in situ hybridization experiments were performed on 24 hours post 
fertilisation (hpf) embryos using full length zebrafish RhoJ sense and antisense 
riboprobes. Friend leukemia virus integration 1 (Fli-1) riboprobes were also used as a 
control for endothelial cell expression. The embryos are shown laterally and the red 
boxes represent the regions enlarged. The embryos used in the in situ hybridization 
experiments were formalin fixed, paraffin wax embedded cut into 1 µm transverse 
sections by Cancer Research UK. The transverse sections were made through the trunk 
with the dorsal side up. ISA: intersegmental arteries; DA: dorsal aorta; PCV: posterior 
cardinal vein; NT: neural tube; NC: notochord. Scale bars = 250 µm. Similar data were 
obtained in three independent experiments 
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by sectioning the trunk of the embryos into 1 µm transverse sections (figure 5.5). RhoJ 
expression was only found on either sides of the neural tube and notochord, where somites are 
distributed. Thus these data confirm that RhoJ does not have vascular expression during prim-
5 stage of angiogenesis and that RhoJ may have a function in muscle cells in zebrafish and 
not in the endothelium.  
 
The expression pattern of RhoJ at a later stage of the pharyngula period, long-pec (48 hpf), 
was also examined using whole-mount in situ hybridization experiments. Interestingly, RhoJ 
mRNA expression was not found in the somites of 48 hpf embryos but in the cephalic (head) 
region (figure 5.6). In order to gain further insight into what tissue type(s) RhoJ may be 
expressed in at this stage, the Zebrafish Information Network (ZFIN) gene expression 
database was used to find zebrafish genes (at 48 hpf) that had a similar expression pattern to 
RhoJ.  
 
Zebrafish genes, Rtn3 (reticulon 3) and Aldh7a1 (aldehyde dehydrogenase 7 family member 
A1), were found to have similar but not identical cephalic expression patterns to RhoJ (figure 
5.6). Thisse et al. (2004) identified the expression patterns of Rtn3 and Aldh7a1. They 
reported that Rtn3 is expressed in the somites, cranial ganglia, retinal ganglion, brain marginal 
zone, pectoral fin muscles and head muscles (286). In addition, Aldh7a1 was reported to be 
expressed in the retina, posterior and dorsal tectum, somites, pectoral fin muscles and head 
muscles. RhoJ-stained embryos showed expression that was similar to the pectoral fin muscle 
and cephalic muscle expression of Rtn3. Moreover, RhoJ expression was found to resemble 
the posterior and dorsal tectum, pectoral fin muscle and head muscle expression of Aldh7a1. 
Thus RhoJ may be expressed in cephalic musculature, pectoral fin muscles and posterior and 
dorsal tectums of 48 hpf zebrafish embryos. 
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Figure 5.6 RhoJ mRNA is expressed in the cephalic region of 48 hpf zebrafish 
embryos but not in somites. Whole-mount in situ hybridization experiments were 
performed on 48 hours post fertilisation (hpf) embryos using full length zebrafish RhoJ 
antisense riboprobes. Images of 48 hpf embryos stained with Rtn3 (reticulon 3) and 
Aldh7a1 (aldehyde dehydrogenase 7 family member A1) were obtained from the 
Zebrafish Information Network database (ZFIN: http://zfin.org) (286). The expression 
pattern of RhoJ was found to resemble the expression patterns of Aldh7a1 and Rtn3 to 
some extent and these similarities are annotated as follows: CM: cephalic musculature; 
PFM: pectoral fin muscle; PT: posterior tectum; DT: dorsal tectum. Scale bar = 250 
µm.  
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5.2.4 In vivo knockdown of RhoJ in zebrafish 
Although zebrafish RhoJ was not expressed in the endothelium, the effect of RhoJ in vivo 
knockdown on vessel formation was still investigated since RhoJ had upregulated expression 
during angiogenesis (figure 5.3). Synthetic antisense morpholino oligonucleotides have been 
successfully used in zebrafish to knockdown gene function by gene-specific inhibition of 
mRNA translation or by modifying pre-mRNA splicing (287, 288). Morpholinos have a 
similar base structure to RNA and DNA but have a morpholine ring instead of a ribose sugar. 
In addition, morpholinos have altered backbone linkages compared to RNA and DNA that are 
nonionic. Together, these modifications form a highly soluble analogue of RNA and DNA 
capable of hybridizing to specific single-stranded nucleic acid sequences by Watson-Crick 
base pairing (289). Advantages of using morpholinos over DNA or RNA oligomers are that 
the backbones are resistant to enzymatic degradation and are less likely to interact 
nonspecifically with cellular components since the backbones lack negative charge (290).  
 
Morpholinos that block translation of proteins work by binding to the 5'-untranslated region 
of mRNA through to the first 25 bases of the coding sequence. Hybridization of the 
morpholino at these regions prevents the ribosomal initiation complex (translation machinery) 
from binding. This prevents translation of the transcript resulting in knockdown of the 
protein. A translation blocker morpholino was designed to target the first 25 bases of the 
coding sequence of RhoJ mRNA.  
 
Splicing of pre-mRNA to make mature mRNA occurs through the activity of spliceosome 
complexes. Spliceosomes are directed where to make cuts by small nuclear ribonuclear 
proteins (snRNP) that bind to sequences in the pre-mRNA, flanking the positions of splice 
junctions. Morpholino oligos are able to enter the nucleus and interfere with pre-mRNA 
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splicing by targeting splice junctions to inhibit the binding of snRNPs that mark the splice 
sites for the splicesome. For knockdown of gene function, morpholinos are typically used to 
modify splicing to produce non-functional proteins. By targeting internal splice sites, an exon 
that encodes for one of the protein’s functional moieties can be spliced out from the mature 
mRNA (288). Thus to knockdown RhoJ function, a splice blocker morpholino was designed 
to bind specifically to the exon2-intron2 splice junction of RhoJ pre-mRNA, as illustrated in 
figure 5.8A. Blocking this splice site results in exon 2 not being in the final mRNA transcript 
for RhoJ and the lack of exon 2 results in the production of non-functional RhoJ protein.  
 
To control for non-specific effects, control morpholinos, which are not complementary to any 
known gene sequence were used. Using high concentrations of morpholinos can cause 
toxicity in embryos causing unspecific phenotypes and embryo lethality (291). Dose response 
assays determine the margin between the induction of a specific phenotype and the onset of 
toxicity. Thus it was necessary firstly to test the toxicity of the morpholinos at various 
concentrations and determine the lowest effective concentration. This was tested by treating 
embryos with translation blocker or splice blocker morpholinos at a range of doses and the 
dose that did not induce embryonic fatality was chosen. Embryo lethality was not found by 
using translation blocker morpholino at 1 mM and splice blocker morpholino at 0.5 nM (see 
appendix 5). In order to accurately compare between the conditions, control morpholinos 
were also injected at both these concentrations. 
 
In order to investigate the knockdown of RhoJ on angiogenesis in zebrafish, it was first 
important to determine whether the translation and splice blocker morpholinos were 
successfully knocking down and altering splicing of RhoJ respectively. RhoJ specific and 
control morpholinos were injected into zebrafish embryos at zygotic stages (1-8 cell stage) of 
embryogenesis. Embryos injected with translation blocker or control morpholino were grown 
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to 26 hpf and were then lysed in NP40 lysis buffer. To investigate whether translation blocker 
morpholino successfully knocked down RhoJ protein, embryo lysates were blotted with anti-
RhoJ antibodies and anti-β actin antibodies as a control for loading. Translation blocker 
morpholino was found to successfully knock down the expression of RhoJ in zebrafish 
embryos (figure 5.7).  
 
Fish injected with splice blocker or control morpholino were cultured until 26 hpf. These 
embryos were lysed in trizol, RNA was extracted and then cDNA was generated. To 
determine whether splicing at exon2-intron2 splice junction was successfully blocked by 
splice blocker morpholino, PCR was performed using primers designed to cross exon 1-3 
boundaries, indicated by red arrows in figure 5.8A. The amplified fragment of exon 1-3 using 
control cDNA would produce a band size of 175 base pairs (bp) in length. However, if the 
splice blocker morpholino was successful and exon 2 was not spliced into the mature mRNA, 
the band size would shift to 116 bp in length. The zebrafish housekeeping gene EF1α was 
used as a positive control. No template and minus-RT controls were set up as described 
previously to check for genomic DNA or cDNA template contamination. Splice blocker 
morpholino successfully modified splicing of the pre-mRNA transcript of RhoJ as there was a 
116 bp band detected in morpholino-treated fish cDNA (figure 5.8B). However there was also 
a 175 bp band found, which suggests that the morpholino was not completely efficient. This 
may be due to there being maternal transcripts of RhoJ being present at the zygotic stages of 
zebrafish embryogenesis, which cannot be modified as maternal transcripts are already 
spliced. Knowing the limitations of RhoJ splice blocker, this morpholino was still used in 
RhoJ knockdown studies. 
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Figure 5.7 Translation blocker morpholino successfully knocks down RhoJ 
protein. Embryos were injected with translation blocker or control morpholino at 1 
mM. Embryos were then lysed with NP40 lysis buffer and were blotted with anti-RhoJ 
antibodies and anti-β actin antibodies (as a control for loading) to determine successful 
knockdown of RhoJ protein expression. 
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Figure 5.8 Splice blocker morpholino modifies RhoJ splicing. (A) Schematic 
displaying the splicing modification of splice blocker morpholino (splice MO) on RhoJ 
pre-mRNA by binding complementary to exon2-intron2 splice junction in the pre-
mRNA transcript. To distinguish whether splicing at this junction was blocked, primers 
were designed to cross exon 1-3 boundaries (indicated by red arrows). When amplifying 
this region by PCR, the splice blocker morpholino injected fish amplify shorter 
fragments due to exon 2 being spliced out. (B) Embryos injected with 0.5 nM splice 
blocker morpholino or control morpholino were lysed with trizol, cDNA templates were 
generated using the same amount of RNA and reverse transcription PCR was performed 
using primers to cross exon boundaries 1-3. EF1α was used as a positive control. Minus 
reverse transcriptase enzyme controls (minus-RT) were used with EF1α primers and no 
template controls (NTC) were added for each primer pair. 
A 
B 
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 In 2002, a zebrafish transgenic line that expresses green fluorescent protein (GFP) 
specifically in all blood vessels throughout embryogenesis under the control of vascular-
specific Fli1 promoter was generated by Lawson and colleagues (292). This transgenic line 
allows detailed analysis of both wildtype and mutant embryonic vasculature, facilitating the 
identification of new mutants affecting in vivo angiogenesis. Fli1-GFP transgenic fish are 
commonly chosen to visualise the development of blood vessels over other methods such as 
confocal microangiography since this method only permits the visualisation of vessels that are 
connected to the active circulatory network. Thus the effect of RhoJ protein knockdown or 
splice modification on embryonic vessel formation was assessed using Fli1-GFP transgenic 
fish.  
 
Fish were injected with RhoJ specific or control morpholinos, cultured until 26 hpf and fixed. 
Uninjected transgenic fish were also fixed as a control for morpholino injection. The Fli1-
GFP transgenic fish were then fluorescently imaged for their EC specific GFP expression. 
Fish were fixed at 26 hpf since this is the stage when most of the intersegmental arteries have 
fully sprouted and reached the level of the dorsal neural tube being able to then merge with 
their neighbours from anterior and posterior segments to form the DLAV at 30 hpf (97).  
 
Following injection of translation or splice blocker morpholino, the development of the main 
vessels (dorsal aorta and posterior cardinal vein) were unaffected but the growth of the 
intersegmental arteries appeared to be either stunted or delayed in comparison to control 
morpholino injected fish (figure 5.9A). Affected embryos injected with RhoJ-specific 
morpholinos displayed under-developed intersegmental arteries, which did not reach the level 
of the dorsal neural tube. In order to quantify the effect of RhoJ knockdown on vessel 
formation, the embryos were analysed for impaired sprouting of the intersegmental arteries. 
Translation and splice blocker morpholino groups were found to have increased numbers of
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Figure 5.9 RhoJ knockdown impairs growth of intersegmental arteries in Fli1-
GFP zebrafish embryos. At embryonic stage, 1-8 cell, Fli1-GFP transgenic zebrafish 
embryos were injected with translation blocker (translation MO), splice blocker (splice 
MO) or control morpholino (control) or uninjected and cultured until 26 hours post 
fertilisation (hpf). Embryos were then fixed and viewed under a fluorescent 
microscope. The white boxes represent the regions enlarged. Arrows point to under-
developed intersegmental arteries (ISA). PCV: posterior cardinal vein, DA: dorsal 
aorta. Scale bar = 250 µm. (B) The effect of RhoJ knockdown on vessel formation was 
quantified by calculating the percentage of embryos with defective ISA sprouting. 
Values represent the means from three independent experiments (35 embryos from 
each experiment were scored). Error bars depict the standard error of the mean. One-
way ANOVA showed a significant effect of RhoJ knockdown on ISA formation 
(P<0.0001). Tukey’s multiple comparison test was used to compare translation MO 
with control 1 mM or splice MO with control 0.5 nM (*** = P<0.001). 
B 
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embryos with impaired intersegmental artery formation in comparison to control groups 
(figure 5.9B). The percentage of affected embryos injected with splice blocker morpholino 
was around 30% less than that of translation blocker morpholino. This can be explained by 
the fact that the RhoJ splice blocker does not modify all RhoJ transcripts, and is not as 
efficient as blocking RhoJ translation.  
 
Since RhoJ is expressed in the somites and not the vasculature (figure 5.5), it was essential to 
know whether the vascular defects found with RhoJ knockdown was a secondary effect of 
impaired somite formation. Thus to analyse somite morphology in morpholino injected fish, 
whole-mount in situ hybridization experiments were performed using myogenic 
differentiation 1 (MyoD) riboprobes, a zebrafish somite marker (293). Embryos that were 
injected with translation or splice blocker morpholinos displayed alterations in somite 
morphology where the somites were not uniformly arranged into V-shaped segments and did 
not have clear boundaries between the somites (figure 5.10A). RhoJ mutant embryos were 
found to have a range of phenotypic severity and were categorised into normal, moderate and 
severe phenotypes according to morphological characteristics. Moderately affected morphant 
embryos were found to have no more than 5 weak or undefined somite boundaries. More 
severely affected embryos displayed more than 5 weak or undefined somite boundaries and 
sometimes missing somites and bent tails. Normal embryos displayed normal 26 hpf somite 
morphology. The frequency of moderate and severe phenotypes was found to increase with 
injection of translation or splice blocker morpholinos (figure 5.10B).  
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Figure 5.10 RhoJ knockdown impairs somite formation in Fli1-GFP zebrafish 
embryos. (A) To analyse somite morphology, whole-mount in situ hybridization 
experiments were performed on morpholino-injected Fli1-GFP embryos using a somite 
muscle specific marker, myogenic differentiation 1 (MyoD). Red boxes represent the 
regions enlarged. Blue arrows point to missing somites (S). Embryos injected with 
translation blocker (translation MO) or splice blocker (splice MO) morpholinos 
displayed impaired somite patterning and weak or undefined somite boundaries (SB). 
Scale bar = 250 µm. (B) Somite morphology was scored according to the following 
criteria: normal (embryos have normal 26 hpf somite morphology); moderate 
disruption (embryos display ≤5 weak or undefined somite boundaries); severe 
disruption (embryos have >5 weak or undefined somite boundaries). Values represent 
the means from three independent experiments (35 embryos from each experiment 
were scored). Error bars depict the standard error of the mean. One-way ANOVA 
showed a significant effect of RhoJ knockdown on somite boundary formation 
(P<0.0001). Tukey’s multiple comparison test was used to compare translation MO 
with control 1 mM or splice MO with control 0.5 nM (*** = P<0.001). 
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5.2.5 Summary 
Zebrafish RhoJ was a hypothetical protein and its sequence had been predicted by homology 
with mammalian RhoJ and conserved exon sequences. Full length RhoJ was amplified from 
zebrafish cDNA and the sequence of this amplicon was found to match the predicted 
sequence. RhoJ mRNA was detected in all periods of embryonic development (cleavage, 
blastula, segmentation and pharyngula). The localisation of RhoJ mRNA expression during 
pharyngula was investigated. At 24 hpf, RhoJ expression was found in the somites. However, 
at 48 hpf, expression of RhoJ was not detected in the somites but was found in the head 
region instead. By comparing expression of RhoJ to other known zebrafish genes, this 
expression pattern resembles the posterior and dorsal tectums and cephalic and pectoral fin 
musculature. When RhoJ function was knocked down using antisense oligonucleotide 
morpholinos, angiogenic sprouting of the intersegmental arteries was impaired and somite 
patterning was disorganised, due to loss of proper somite boundaries. 
 
5.3 Discussion 
The mRNA expression of RhoJ at different embryonic stages of zebrafish development was 
assessed in 8-cell, 30% epiboly, 5-somite, prim-5 and long-pec embryos (figure 5.3). RhoJ 
was expressed in all stages with low expression in 5-somite, when somites are forming and 
high expression in prim-5 and long-pec, when angiogenesis is occurring (280). This suggested 
that RhoJ might be playing a role in vessel formation. However, in situ hybridization studies 
revealed that the mRNA expression of RhoJ in prim-5 embryos was not localised to the 
vasculature but was found in the somites (figure 5.5). With RhoJ being highly expressed in 
human ECs (206), it was surprising for zebrafish RhoJ not to be expressed in the endothelium.  
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Despite zebrafish RhoJ not being expressed in the vasculature, knocking down RhoJ function 
by interfering with the translation or splicing of RhoJ still impaired intersegmental artery 
development in Fli1-GFP transgenic fish (figure 5.9). Although the sprouting of the 
intersegmental arteries was impeded, the main vessels were unaffected, indicating that RhoJ 
knockdown affected only angiogenesis and not vasculogenesis. The high expression of RhoJ 
during embryonic angiogenesis in figure 5.3 and RhoJ knockdown resulting in impaired 
vessel formation might be explained by RhoJ downstream signalling being responsible for 
guiding the growth of angiogenic intersegmental vessels in between muscle segments. 
However subsequent experiments revealed that embryos injected with translation blocker or 
splice blocker morpholinos displayed defects in somite boundary morphology (figure 5.10). 
The somites were shown to have weak or absent somite boundaries with the gaps in between 
somites irregularly spaced, causing the somites to be very close to one another. This somite-
patterning defect may have in turn affected the migration of the intersegmental arteries. Thus 
the vascular defect found with RhoJ knockdown may have been due to loss of RhoJ function 
as a regulator of somite boundary formation. These data promote the notion that RhoJ does 
not play a role in EC biology in zebrafish as it does in mammals. 
 
Consistent with our data, Shaw et al. (2006) showed that a class of zebrafish somite 
morphogenesis mutants also displayed defects in trunk angiogenic vessel patterning due to 
lack of proper somite boundary formation. This group also showed that somite patterning 
defects are accompanied by mispatterned segmental expression of vascular guidance 
molecules such as semaphorin 3A1 (294). Semaphorin 3A1 is expressed in somites of 
zebrafish and is known to guide the patterning of the developing vasculature in between the 
somites by binding to PlexinD1, a receptor expressed on ECs (295). Therefore it is a 
possibility that breakdown of somite morphology in RhoJ morphants leads to the failure to 
properly express vascular guidance cues in somites/somite boundaries which causes the 
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impaired development of the intersegmental arteries. In summary, RhoJ knockdown studies 
showed that RhoJ plays a role in the development of somites boundaries, which are vital 
structures for the normal sprouting of angiogenic vessels.  
 
Embryogenic morphogenesis is a result of coordinated cell motility and cell-shape changes, 
which involves actin reorganisation and focal adhesion formation. Focal adhesion kinase 
(FAK), a nonreceptor tyrosine kinase, is a vital intracellular constituent of focal adhesions. 
Phosphorylation of FAK has been shown to promote both cell motility and cell adhesion. Ilić 
et al. (1995) demonstrated that FAK null embryos were able to initiate gastrulation normally 
but formed no somites during mouse embryogenesis. Cells isolated from these mice also had 
reduced motility and increased focal adhesions compared to control cells (296).  These results 
are similar to the in vitro loss of RhoJ function data shown in chapters 3 and 4, which implies 
that RhoJ is involved in focal adhesion turnover during cell migration. It was also reported by 
Henry et al. (2001) that FAK is highly concentrated at the somite boundaries of zebrafish 
embryos (297), suggesting a role for FAK in the formation and stabilisation of somite borders. 
Studies performed by Crawford et al. (2003) showed that paxillin, a focal adhesion-associated 
adaptor protein that binds to FAK, colocalises with phosphorylated FAK at the boundaries of 
somites in zebrafish (298). These data demonstrate that cell-matrix adhesions at somite 
boundaries are important in stabilising somite boundaries. Since we have shown that RhoJ 
plays a role in focal adhesion formation in mammalian cells (chapter 4), RhoJ may stabilise 
somite borders by directly or indirectly regulating focal adhesion formation at somite 
boundaries during zebrafish development. However, we have not investigated the subcellular 
localisation of RhoJ in zebrafish muscle cells and so we do not know if zebrafish RhoJ is 
expressed in focal adhesions. Zebrafish RhoJ is quite divergent to human RhoJ at the N- and 
C-terminal ends so may not have the same localisation in zebrafish (this could be investigated 
in future studies). 
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Two different RhoJ-specific morpholinos with non-overlapping sequences were used as 
controls for non-specific effects in the RhoJ loss-of-function studies. Both morpholinos 
produced the same phenotypes. This supports the hypothesis that the observed phenotypes 
were due to knockdown of RhoJ and not an interaction with an off-target mRNA, since 
morpholinos with different sequences do not generally elicit the same nonspecific effects. In 
addition, a control morpholino was also injected at the same concentration as the RhoJ-
specific morpholinos to show that the phenotypes found were specific to knockdown of RhoJ. 
However, it would also be informative to perform mRNA rescue experiments to further 
confirm the specificity of the RhoJ knockdown phenotype. This can be carried out by co-
injecting RhoJ mRNA that is not recognised by the translation blocker morpholino by 
creating silent mutations in the region of the coding sequence that the morpholino would bind 
to. In the case of the splice blocker morpholino, wild type RhoJ mRNA can be co-injected 
(299). 
 
Furthermore, the expression of RhoJ in long-pec embryos was not found in the somites but 
restricted to the head region (figure 5.6). Analysis of this expression pattern revealed that 
RhoJ may be expressed in the head muscles, pectoral fin muscles and posterior and dorsal 
tectums of 2 day old zebrafish embryos. There are different subtypes of cephalic muscles and 
RhoJ may not be expressed in all the head muscles. Co-ordinated contraction of these various 
cephalic muscles in zebrafish mediates the expansion and compression of the jaw and gills 
during feeding and respiration. The pectoral fins aid swimming and maneuvering in adult fish 
and begin to develop at around 40 hpf when somites 2-4 migrate to form the pectoral fin 
musculature (300). The tectums are regions of the midbrain that control vision. Thus RhoJ 
may have varying functions in zebrafish and to investigate these functions, further work 
would need to be carried out to see what happens when RhoJ is knocked down at long-pec 
stage. The downregulation of RhoJ expression in the somites and the upregulation of RhoJ 
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expression in cephalic structures at 48 hpf may be controlled at the transcriptional level. For 
example, epigenetic changes to DNA may be altering the expression of RhoJ by preventing 
transcription or tissue specific transcription factors may be switching RhoJ transcription ‘on’ 
or ‘off’ depending on the stage of development.  
 
The expression pattern of RhoJ has only been identified in prim-5 and long-pec zebrafish 
embryos and the localisation of RhoJ at other stages of development still remains to be 
investigated. Future work could include investigating the expression of RhoJ from fertilisation 
to adulthood using whole-mount in situ hybridization experiments, data from these 
experiments would provide further insights into the function of RhoJ in zebrafish at different 
stages of embryogenesis.  
 
The fact that RhoJ is not expressed in vasculature of zebrafish indicates that perhaps the role 
of RhoJ in actomyosin contractility is not required or that another gene is taking over RhoJ’s 
role in zebrafish. Due to the close homology of Cdc42, TC10 and RhoJ and the fact that they 
can all bind to the same effector proteins, it is reasonable to suggest that they may substitute 
for one another. In zebrafish there are three homologues for Cdc42, but in humans there is 
only one (301). A possible explanation for the lack of RhoJ in the endothelium is that one of 
the other Cdc42 homologues or TC10 could be taking over RhoJ’s role. This hypothesis was 
tested in our laboratory by Ms Diana Walsh (University of Birmingham) by investigating the 
mRNA expression patterns of the zebrafish Cdc42 homologues (zebrafish Cdc42, Cdc42 like 
1 and Cdc42 like 2) and TC10 by performing whole-mount in situ hybridization experiments. 
Although none of the GTPases were specifically expressed in the endothelium, they were all 
ubiquitously expressed and Cdc42 like 2 and TC10 showed increased staining intensity at the 
somite boundaries. Thus, since the other Cdc42 subfamily group members are expressed in 
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the vasculature at low levels, there is a chance that the other Cdc42 homologues may be 
taking the endothelial role of RhoJ in zebrafish. 
 
Divergent gene expression across species is extremely common. Variations in gene 
expression are controlled by cis-regulatory DNA sequences (promoters or enhancers) that 
contain binding sites for trans-acting regulatory proteins such as transcription factors (302). 
The specific combination of transcription factor binding sites within an enhancer determines 
its activity and specifies the timing, location and abundance for the gene it regulates. Many 
genes are controlled by multiple enhancers, and each of these control a subset of the gene’s 
expression pattern (303). Studies have shown that non-coding sequences upstream of genes 
and in intron regions have low conservation across species, indicating that these sequences 
drive gene expression variation in different species (304). The fact that zebrafish and human 
RhoJ amino acid sequences are 76% identical but are expressed in different tissues and may 
have completely different functions may be due to zebrafish and human RhoJ having 
variations in their cis-regulatory elements either in their promoter or enhancer regions. The 
cis-regulatory sequences controlling the expression of zebrafish RhoJ may have changed over 
evolutionary time through the process of mutation, causing RhoJ to have an altered expression 
profile. In order to understand more about what controls the expression of RhoJ in zebrafish 
and in mammals, the cis-regulatory DNA sequences that control RhoJ expression in each 
species could be examined.   
 
To summarise, although the amino acid sequences of human, mouse and zebrafish RhoJ were 
highly conserved, RhoJ mRNA expression was found in the somites of developing zebrafish 
embryos. Knockdown of zebrafish RhoJ impeded proper vasculature development, which was 
found to be due to impaired somite boundaries. Thus we hypothesise that RhoJ may be 
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involved in somitogenesis and/or maintenance of somite boundaries in 24 hpf zebrafish 
embryos but its function may also change according to its stage-specific expression.  
 
Since zebrafish RhoJ was surprisingly not expressed in ECs, it was then necessary to 
determine the expression profile of RhoJ in mammals. Preliminary studies were carried out to 
investigate the localisation of RhoJ expression in humans and mice and this work is described 
in chapter 6. 
 
 
  
 
  
 
 
 
 
 
 
 
 
C h a p t e r  s i x  
Expression profile of mammalian RhoJ 
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6.1 Introduction 
Bioinformatic analyses of endothelial cDNA libraries using publically available serial 
analysis of gene expression (SAGE) and expressed sequence tag (EST) libraries identified the 
small Rho GTPase, RhoJ, as being highly expressed by ECs. This prediction was further 
validated using reverse transcription and quantitative PCR in a range of primary cell isolates. 
RhoJ was highly expressed in human umbilical ECs (HUVEC) and human dermal 
microvascular ECs (HDMEC) but had little or no expression in fibroblasts, hepatocytes, 
lymphocytes or keratinocytes (206). Although Vignal et al. (2000) reported that mouse RhoJ 
expression is high in heart and moderate in lung and liver (197), the types of cells expressing 
RhoJ in these organs was unknown.  
 
The aim of this chapter is to map the expression of mammalian RhoJ as precisely as possible 
using the available tools. Since a RhoJ antibody suitable for immunohistochemistry or 
immunofluorescence had not been generated at the time of this research, whole-mount or 
fluorescent in situ hybridizations were performed using complementary digoxigenin-labelled 
RNA probes. 
 
Since RhoJ is highly expressed in ECs in vitro, it was necessary to determine whether RhoJ is 
also expressed in the endothelium in vivo and expressed during physiological angiogenesis. 
To visualise mouse RhoJ mRNA expression, whole-mount in situ hybridization experiments 
were performed on mouse embryos, at a stage when normal embryonic angiogenesis is known 
to occur. To determine whether RhoJ is expressed specifically in ECs, the tissue distribution 
profile of RhoJ in adult mice was assessed at the mRNA and protein level using quantitative 
PCR and Western blotting. To visualise the localisation of RhoJ in normal human tissues and 
to determine whether RhoJ is expressed in the endothelium of human cancerous tissues, the 
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mRNA expression of RhoJ in various human normal and cancerous tissues was examined 
using fluorescent in situ hybridization technology.   
 
In summary, this chapter aims to characterise the expression profile of mammalian RhoJ and 
to confirm the hypothesis that RhoJ is highly upregulated in ECs.  
 
6.2 Results 
6.2.1 RhoJ mRNA expression during mouse embryonic angiogenesis 
In order to localise the expression of RhoJ during normal embryonic angiogenesis, whole 
mount in situ hybridization was performed on developing mouse embryos at embryonic day 
(E) 9.5, the stage at which the vasculature is developing and angiogenesis is actively 
occurring (305). Digoxigenin labelled, complementary riboprobes were generated to mouse 
RhoJ and von Willebrand Factor (vWF), an endothelial specific expressed gene (306) from 
pGEM-3z mouse vWF and pGEM-3z mouse RhoJ cloned constructs (see section 2.4 DNA 
constructs). Sense riboprobes were also synthesised as negative controls. In brief, mouse 
embryos were digested with proteinase K to allow probe penetration. Riboprobes were then 
applied to allow hybridization to their specific mRNA sequences in situ. Anti-digoxigenin 
antibodies conjugated to alkaline phosphatase were used to locate the region of hybridization. 
A substrate for alkaline phosphatase, BM purple, was then added to develop a purple colour, 
revealing the location of the gene of interest’s mRNA expression. Figure 6.1 shows the 
mRNA expression pattern of RhoJ and vWF at E9.5. The expression pattern of RhoJ was 
similar to the vascular expression of the positive control, vWF. The enlarged regions reveal a 
clear vascular pattern with the main trunk vessel, dorsal aorta (red arrows), and the 
intersegmental vessels (yellow arrows) stained blue/purple. This data shows that RhoJ mRNA 
has endothelial expression during normal embryonic angiogenesis in mice at E9.5.
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Figure 6.1 RhoJ mRNA is expressed in the vasculature of E9.5 mouse embryos. 
Whole-mount in situ hybridization experiments were performed on E9.5 mouse 
embryos using full-length mouse RhoJ sense and antisense riboprobes. Von Willebrand 
Factor riboprobes were used as a positive control for endothelial cell expression. The 
white boxes represent the areas enlarged. The yellow arrows indicate the intersegmental 
vessels and the red arrows mark the dorsal aorta. Similar data were obtained in four 
independent experiments. Scale bar = 200 µm. 
 
 
6 | Expression profile of mammalian RhoJ 
 
 187 
6.2.2 Tissue distribution pattern of RhoJ at the protein and mRNA level in adult mice 
Since RhoJ mRNA expression was found in the endothelium of developing mouse embryos 
(figure 6.1), it was necessary to determine whether expression of RhoJ was specific to ECs. 
Immunohistochemistry or immunofluorescence is commonly used to visualise the expression 
of endogenous proteins in tissue sections. However in the absence of a suitable RhoJ 
antibody, the expression profile of RhoJ was examined in various adult mouse tissues using 
quantitative PCR and Western blotting. Expression patterns of RhoJ were compared with that 
of VE-Cadherin, a gene known to have an endothelial specific tissue distribution (307). Dr. 
Michael G. Tomlinson from The University of Birmingham, UK kindly provided various 
tissue lysates and cDNA samples that were obtained from 8-week old C57BL6 mice.  
 
Quantitative PCR was performed to detect mRNA expression levels of RhoJ and 
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (308, 309) in 
various adult mouse tissues (thymus, brain, heart, muscle, kidney, spleen, liver, lung). To 
accurately quantify gene expression, the expression level of RhoJ or VE-Cadherin was 
normalised to the expression level of GAPDH. RhoJ mRNA expression was found to be high 
in lung, moderate in spleen and low in liver, kidney, muscle, heart, brain and thymus. VE-
Cadherin was also highly expressed in lung but at low levels in liver, spleen, kidney, muscle, 
heart and thymus. VE-Cadherin mRNA expression was not found in brain (figure 6.2A).  
 
To detect RhoJ expression at the protein level, lysates were blotted with anti-RhoJ antibody, 
anti-VE-Cadherin antibody and as a control for equal protein loading, anti-tubulin antibody. 
Consistent with the analysis of RhoJ mRNA expression in figure 6.2A, the expression of 
RhoJ protein was high in lung, moderate in spleen and low in liver, kidney, muscle, heart and 
thymus. No RhoJ expression was detected in brain. VE-Cadherin also showed high expression 
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Figure 6.2 RhoJ tissue distribution pattern is similar to that of endothelial specific 
gene, VE-Cadherin. (A) The mRNA expression levels of RhoJ and VE-Cadherin in a 
variety of mouse tissues were analysed by using quantitative PCR. The expression 
levels of RhoJ and VE-Cadherin were normalised to the expression of housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Values represent the 
means from three independent experiments using tissues extracted from three different 
mice. Error bars depict the standard error of the mean. (B) Lysates of various mouse 
tissues were blotted with anti-RhoJ and anti-VE-Cadherin antibodies. Anti-tubulin 
antibodies were also used as a loading control. Similar data were obtained in three 
independent experiments using different donors. 
A 
B 
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in lung. Low VE-Cadherin expression was found in liver, spleen, kidney, muscle and heart 
but no expression was found in brain or thymus (figure 6.2B). The protein expression of RhoJ 
is similar to the expression of VE-Cadherin apart from the relative higher expression of RhoJ 
in spleen and thymus. The high level of lung expression of RhoJ at both the mRNA and 
protein level is consistent with an endothelial expression pattern. However, differences in the 
expression patterns of RhoJ and VE-Cadherin in the spleen and thymus suggest that RhoJ 
may be expressed in non-ECs in these tissues.  
 
6.2.3 RhoJ expression in mouse spleen and thymus 
The spleen is a peripheral lymphoid organ and is rich in B-lymphocytes (B-cells), platelets 
and megakaryocytes. The spleen serves to provide B-cells, a source of plasma cells, and 
hence antibodies for the body’s immune defences. Blood is filtrated in the spleen, where 
macrophages phagocytose old or damaged erythrocytes, white blood cells, platelets and 
bacteria. The spleen also holds a reserve of platelets, which are produced by megakaryocytes, 
to be supplied to the body in times of emergency clot formation (310).  
 
RhoJ was shown to have high expression in spleen, which was not consistent with endothelial 
specific expression of VE-Cadherin (figure 6.2). The expression of RhoJ in non-EC types of 
spleen was investigated by Western blotting. Whole cell lysates of primary mouse B-cells, 
platelets and megakaryocytes (kindly provided by Alexandra Mazharian and Ying Jie Wang 
from The University of Birmingham, UK) were blotted with anti-RhoJ antibody and as a 
control for equal protein loading, anti-tubulin antibody. Since RhoJ is most highly expressed 
in human ECs (206), the expression of RhoJ in B-cells, platelets and megakaryocytes was 
compared to the expression of RhoJ in human umbilical vein ECs (HUVEC).  
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RhoJ protein expression was detected in mouse B-cells and platelets but not in 
megakaryocytes (figure 6.3A). However, the expression of RhoJ in B-cells and platelets was 
relatively low compared to the expression of RhoJ in HUVEC. These data explain the high 
level of RhoJ expression found in mouse spleen seen in figure 6.2 and further confirms that 
RhoJ is not endothelial specific but is abundantly expressed by ECs.  
 
Thymic T-cell development occurs by pluripotent progenitor cells being released periodically 
from the bone marrow and migrating into the thymus (311), (312). Thymocytes undergo a 
number of stromal cell-dependant maturation stages, which are marked by changes in cell-
surface molecules. When progenitor cells first enter the thymus, they lack most of the cell 
surface molecules characteristic of mature T-cells such as co-receptors CD4 and CD8, these 
thymocytes are known as CD4-CD8- double negative (DN). Double negative thymocytes then 
mature into CD4+CD8+ double positive (DP), and finally mature into single positive (SP) 
CD4+ or CD8+ T lymphocytes (313).  
 
Tissue distribution analysis in figure 6.2 showed that RhoJ was expressed at the protein and 
mRNA level in mouse thymus. However endothelial specific gene, VE-Cadherin, was not 
detectable at the protein level and had relatively weak mRNA expression in thymus in 
comparison to RhoJ.  In order to determine which non-endothelial thymic cells express RhoJ, 
quantitative PCR using cDNAs generated from various fetal or adult mouse thymus was 
performed. cDNA samples of fetal (E15) thymus (whole organ culture), E15 CD45- 
deoxyguanosine (dGuo)-stroma (thymic stroma, depleted of thymocytes), E15 DN (CD4-
CD8-), adult DP (CD4+CD8+), adult SP (CD4+), adult SP (CD8+) and adult CD45+ 
unfractionated thymocytes (thymic stroma depleted) were kindly provided by Dr. Graham 
Anderson from The University of Birmingham, UK. In order to determine the level of RhoJ 
expression in non-endothelial thymic cell types, the expression of RhoJ in these cell types was 
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Figure 6.3 RhoJ is expressed in mouse B-cells, platelets and thymic epithelial cells. 
(A) Lysates of mouse B-cells, platelets and megakaryocytes (MK) were blotted with 
anti-RhoJ and anti-tubulin antibodies. Similar data were obtained in two independent 
experiments using cells from different donors. (B) The mRNA expression of RhoJ in 
mouse thymus-derived cDNA samples were analysed using quantitative PCR. 
Expression levels of RhoJ were normalised to the expression of housekeeping gene, 
hypoxanthine phosphoribosyl transferase (HPRT). Values represent the means from 
three independent experiments using cells derived from different mice. Error bars 
depict the standard error of the mean.  (C) Lysates of various human hematopoietic cell 
lines and human platelets were blotted with anti-RhoJ and anti-tubulin antibodies. In all 
cases, the expression of RhoJ at the protein and mRNA level was compared to the 
expression of RhoJ in human umbilical vein endothelial cells (HUVEC).  
B A 
C 
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compared to the expression of RhoJ in HUVEC. The mRNA expression level of 
housekeeping gene, hypoxanthine phosphoribosyl transferase (HPRT) (309), was also 
determined and was used to normalise the expression of RhoJ.  
 
RhoJ mRNA expression was detected in whole fetal thymus and CD45- dGuo-treated thymus 
(figure 6.3B). dGuo is selectively toxic to lymphocytes, which carry the leukocyte common 
antigen, CD45 (314), (315). Thus dGuo treatment produces a CD45- population of thymic 
stroma epithelial cells (316). Consistent with these data, RhoJ expression was not found in 
DN, DP, CD4+/CD8+ SP or unfractionated CD45+ thymocytes. Although RhoJ was 
expressed in whole thymus and thymocyte depleted-thymus, the expression of RhoJ was 75-
80% greater in HUVEC than in the thymic stroma. These data explain the low expression of 
RhoJ in thymus in figure 6.2 and suggest that RhoJ may be involved in T-cell development 
since thymocyte maturation is stromal cell dependant. 
 
In light of RhoJ being expressed in mouse B-cells, platelets and thymic epithelial cells (figure 
6.3) it was important to know whether RhoJ was expressed in transformed human 
hematopoietic cell lines or platelets. Since it was difficult to obtain human thymic epithelial 
cells and lymphocytes the closet option was to check RhoJ expression in human 
hematopoietic transformed cell lines. Western blot analysis was performed on various human 
B and T lymphoblast, megakaryoblast, erythroblast and platelet cells. Whole cell lysates of 
cell lines of DG75 and RAJI (B lymphoblast cells derived from Burkitt’s lymphoma); HPB-
ALL and JURKAT (T cell lines of acute lymphoblastic leukaemia); DAMI and MEG-01 
(megakaryoblastic cell lines derived from chronic myelogenous leukaemia); HEL (human 
erythroleukaemia cell line) and platelets were kindly provided by Dr. Michael G. Tomlinson 
from The University of Birmingham, UK. The lysates were blotted with anti-RhoJ antibody 
and as a control for loading, anti-tubulin antibody. HUVEC lysate was also blotted as a 
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positive control and for expression comparison. RhoJ protein was not detected in human B or 
T lymphoblasts, megakaryoblasts, erythroblasts or platelets (figure 6.3C).  
 
6.2.4 RhoJ mRNA expression in normal and cancerous human tissues 
As mentioned earlier, at the time of these studies a RhoJ-specific antibody was not available 
to use in immunohistochemistry or immunofluorescence to detect the localisation of 
endogenous RhoJ protein. Thus to determine the expression profile of RhoJ in a variety of 
human tissue sections, fluorescent in situ hybridization technology was developed to localise 
the mRNA expression of RhoJ instead. Sections from a variety of normal tissues were 
provided by the histology service of Cancer Research, UK and purchased from SuperBiochips 
Inc, Korea. Additionally, a small subset of cancerous tissue sections were also used in the 
fluorescent in situ hybridization experiments in order to determine whether RhoJ was 
expressed during pathological angiogenesis.  
 
RhoJ was localised using digoxigenin labelled RhoJ specific riboprobes generated from 
pGEM-3z human RhoJ cloned constructs (see section 2.4 DNA constructs). Once RhoJ 
specific riboprobes had hybridized to their complementary mRNA sequence in situ, sections 
were probed with an anti-digoxigenin antibody conjugated to rhodamine to reveal the location 
of RhoJ mRNA expression. Ulex europeaus agglutinin I (UEAI) is commonly used as a 
marker of ECs, since it recognises an endothelial specific glycosylation (317). Sections were 
stained with UEAI conjugated to fluorescein isothiocyanate (FITC) as a positive control for 
endothelial expression.  
 
RhoJ mRNA expression was found in ECs, with clear co-localisation with UEAI in a number 
of normal tissues such as adrenal gland, pancreas, heart, liver, lymph node, lung, muscle and 
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Figure 6.4 Endothelial RhoJ expression is found in normal and cancerous human 
tissues. Fluorescent in situ hybridization was performed on various normal (A-B) and 
cancerous (C) human tissue sections (CA; carcinoma). An antisense digoxigenin 
labelled riboprobe and a rhodamine labelled anti-digoxigenin antibody was used to 
detect RhoJ mRNA expression (red). Fluorescein labelled Ulex europaeus agglutinin I 
(UEAI) was used as an endothelial marker (green). DAPI was used to stain the nuclei 
(blue). Scale bar = 50 µm.  
B 
C 
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Human tissue Endothelial RhoJ  
expression 
Adrenal + 
Pancreas + 
Heart + 
Liver + 
Lung + 
Lymph node + 
Lung + 
Muscle + 
Placenta + 
Brain - 
Colon - 
Kidney - 
Testis - 
Bladder carcinoma + 
Bone tumour + 
Ovarian carcinoma + 
Rectal carcinoma - 
 
Table 6.1 Distribution of endothelial RhoJ expression in 
human normal and cancerous tissues.  
 
 
placenta (figure 6.4A). Although RhoJ expression was found in vessels, RhoJ staining was not 
restricted to the endothelium in most of these tissues. This is consistent with the data shown in 
figure 6.2 that although RhoJ expression is endothelial, its expression is not EC specific. 
Endothelial RhoJ expression was not found in brain, colon, kidney and testis (figure 6.4B). 
Instead, RhoJ expression was found in non-ECs of kidney and testis. RhoJ expression was 
found in the endothelium of bladder, bone and ovarian carcinomas but not in rectal carcinoma 
(figure 6.4C). Erythrocytes that were found in vessels of some tissue sections caused 
autofluorescence in both the red and green channels. The tissue distribution pattern of RhoJ 
endothelial expression is summarised in table 6.1. These data show that RhoJ is expressed in 
normal human vasculature of most organs and is also expressed in the endothelium of some 
tissues undergoing pathological angiogenesis. 
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6.2.5 RhoJ expression in human perivascular cells 
Once ECs form capillary-like structures in vivo, perivascular mural cells (smooth muscle cells 
and pericytes) are recruited to the abluminal endothelial surface. The ECs of arteries and 
veins are completely surrounded by single or multiple layers of vascular smooth muscle cells, 
whereas capillaries are only partially covered by a single layer of pericytes (10). Vascular 
smooth muscle cells and pericytes have many roles in regulating EC biology but their main 
functions are to maintain endothelial quiescence, vessel integrity and stability (11, 12).  
 
In section 6.2.4, fluorescent in situ hybridization and high-resolution laser scanning confocal 
microscopy showed that RhoJ highly co-localised with endothelial specific sugar-binding 
lectin, UEAI (figure 6.4), suggesting that RhoJ is expressed in human ECs in vivo. However 
RhoJ mRNA expression was also observed in vascular smooth muscle cells surrounding the 
vessel in skeletal muscle in figure 6.4A, suggesting that RhoJ may also be expressed in 
perivascular cells. In addition, it is also possible that, due to close proximity, expression of 
RhoJ in other blood vessel associated cell types would result in a localisation pattern similar 
to that of the endothelial specific glycosylation recognised by UEAI. To address these issues, 
the expression of RhoJ in perivascular cells at both the mRNA and protein level was 
determined and compared to endothelial RhoJ expression.  
 
To investigate the mRNA expression level of RhoJ in pericytes and vascular smooth muscle 
cells, quantitative PCR was performed on primary human placenta-derived pericyte (hPC-PL) 
and human aortic smooth muscle cell (HASMC) cDNA isolates. To determine whether RhoJ 
protein was expressed in these cell types, whole cell lysates of hPC-PL and HASMC were 
blotted with anti-RhoJ antibody and loading control, anti-tubulin antibody. Since RhoJ is 
highly expressed in ECs (206), the expression of RhoJ in hPC-PL and HASMC at the mRNA 
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Figure 6.5 RhoJ is expressed in human smooth muscle cells and pericytes. (A) The 
mRNA expression level of RhoJ was analysed in human umbilical vein endothelial 
cells (HUVEC), human aortic smooth muscle cells (HASMC) and human placenta-
derived pericytes (hPC-PL) using quantitative PCR and normalised to β-actin. (B) 
Whole cell lysates HUVEC, HASMC and hPC-PL at 10 µg were blotted with anti-RhoJ 
and anti-tubulin. This experiment was performed using single isolates only. The 
expression of RhoJ at the mRNA and protein level was compared to the expression of 
RhoJ in HUVEC.  
A 
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and protein level was compared to the expression of RhoJ in HUVEC. In both hPC-PL and 
HASMC a relatively low level of RhoJ mRNA and protein expression was found compared 
with HUVEC (figure 6.5). 
 
6.2.6 Summary 
To summarise, in vivo RhoJ expression was found in ECs undergoing physiological 
angiogenesis during mouse embryonic development.  The tissue distribution of mouse RhoJ 
was found to be similar to an endothelial expression profile but its expression was not 
restricted to ECs since RhoJ was also detected in mouse B-cells, platelets and the thymic 
stroma. In situ RhoJ expression was found in the endothelium of some but not all normal and 
pathological human tissue sections. RhoJ expression was also detected in non-ECs including 
perivascular pericytes and vascular smooth muscle cells.  Although the expression of RhoJ is 
not restricted to ECs, a cell type that expresses RhoJ at higher levels than ECs has not been 
found in this study.  
 
6.3 Discussion 
Since angiogenesis is a process specific to ECs, the expression of RhoJ during normal 
embryonic angiogenesis was investigated. Whole mount in situ hybridization experiments in 
mouse embryos at E9.5, a stage in development when angiogenesis is occurring were 
performed. The results revealed a vascular expression of RhoJ in mouse during embryonic 
angiogenesis (figure 6.1) consistent with the bioinformatic prediction by Herbert et al. (2008) 
that RhoJ is highly upregulated in ECs (206). These data suggest that RhoJ may have a 
potential role in embryonic angiogenesis. Data presented in chapters 3 and 4 suggest that 
RhoJ may be promoting EC migration and tube formation through the regulation of focal 
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adhesion turnover and actomyosin contractility. This data does not tell us whether RhoJ 
function is important for vasculogenesis or embryonic angiogenesis. However, the RhoJ 
knockout mouse that is currently being generated by our laboratory may help provide 
information on this. If no other Rho GTPase compensates for the absence of RhoJ, then these 
mice may die in utero. 
 
Tissue distribution analysis revealed that RhoJ and VE-Cadherin were both highly expressed 
in lung (figure 6.2), which is a highly vascularised tissue due to its function as a gas-exchange 
organ (318, 319). However the spleen was shown to have higher expression of RhoJ than VE-
Cadherin. Thus cell types of spleen were analysed for RhoJ expression. RhoJ was shown to be 
expressed in mouse B-cells and platelets but not in platelet precursor cells, megakaryocytes 
(figure 6.3A). These novel data show that although RhoJ may be primarily expressed in ECs, 
RhoJ’s expression is not specific to the endothelium. However, RhoJ was not found to be 
expressed in human platelets, B-cell or megakaryocytic hematopoietic transformed cell lines 
(figure 6.3C) therefore these data suggest that RhoJ may play a role in the functioning of B-
cells and platelets in mice. However, the expression of RhoJ in human primary B-cells is still 
yet to be explored. 
 
In addition, RhoJ expression was found in thymus, which again was not consistent with the 
expression profile of VE-Cadherin. Thus, various thymus-derived stromal cells and 
thymocytes were analysed for RhoJ expression (figure 6.3B). Our data showed that RhoJ was 
not expressed in mouse-derived immature or mature thymocytes or human hematopoietic T-
cell transformed cells (figure 6.3C) but was expressed in the stromal epithelial cells of mouse 
thymus. Griffith et al. (2009) have also shown that RhoJ is expressed in the mouse thymic 
medulla by using a microarray approach to identify stromal gene expression in tissues from 
microdissected thymic regions (320). These data support our findings and suggests that RhoJ 
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may be playing a role in T-cell central tolerance development in mouse. The 
microenvironment of the thymic medulla is where mature single positive T-cells undergo 
negative selection, rendering T-cells non-reactive to self (321). However, our work and the 
studies performed by Griffith et al. were looking at mouse thymus. The expression profile of 
RhoJ in human thymus still needs to be investigated. However, it would not be surprising if 
RhoJ were involved in human T-cell differentiation since different Rho GTPases have been 
shown to be important for T-cell development. In particular, recent evidence shows that 
Cdc42 is essential for human T-cell development (322). These data show that although RhoJ 
expression in ECs is upregulated, the expression of RhoJ is not EC specific and RhoJ may 
also be important for the functioning of the immune system. This work is also valuable in 
predicting and understanding the phenotypes that may arise in the RhoJ knockout mouse. 
 
Vignal et al. (2000) previously examined the pattern of RhoJ mRNA expression in various 
murine tissues using Northern blotting (197). Vignal et al. reported that RhoJ mRNA is 
expressed at high levels in heart and at moderate levels in lung and liver. This result differs 
from what we have found, which is high expression (protein and mRNA) in lung and spleen. 
The difference in findings could be explained by differences in the age of the mice from 
which the tissues were extracted. Additionally, there are variations in the signal of the 
housekeeping control between tissues in the Northern blot shown by Vignal et al., which 
could explain the slight contrast in our findings. Furthermore, Vignal et al. have studied the 
expression profile of RhoJ at the mRNA level only, whereas we have studied the expression 
pattern of RhoJ at both the protein and mRNA level with similar results. 
 
To visualise the localisation of RhoJ mRNA expression in human normal and pathological 
tissues, fluorescent in situ hybridization experiments were performed using digoxigenin 
labelled riboprobes complementary to human RhoJ. RhoJ was expressed predominantly in the 
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vessels of most normal and cancerous tissues (figure 6.4), suggesting that RhoJ may have a 
potential role in maintaining vessel integrity. It has been shown that regulation of endothelial 
barrier integrity, which is disrupted in many vascular diseases, involves RhoA, Rac1, Cdc42 
activity (1, 323). It has been documented that breakdown of endothelial integrity is due to 
increased endothelial tension created by increased actomyosin contractility and disassembly 
of cell-cell adhesions (323). In addition, evidence shows that individual Rho GTPases can 
positively and negatively regulate endothelial integrity, depending on their activation and 
cellular context (324). In sight of these observations, RhoJ may be playing a significant role 
in the maintenance of the endothelial barrier by working in conjunction with other Rho 
GTPases.  
 
Moreover, RhoJ mRNA was not detected in sections of the brain, gut (normal and cancerous), 
kidney and testis (figure 6.4). ECs can display great heterogeneity in their structure and 
protein expression between and within tissues due to vascular networks having specialised 
functions depending on their location (5). Therefore the lack of expression in the vessels of 
some tissues suggests that RhoJ may not be important for the maintenance of all blood vessels 
but only vessels of certain organs that have specialised requirements. Furthermore, in the 
blood vessels of organs where RhoJ is absent other Rho GTPases could be functionally 
substituting RhoJ.  
 
Tissue specific expression of RhoJ mRNA is most likely regulated at the transcriptional level 
and this may be regulated in several ways. DNA methylation is known to lock genes into ‘off’ 
preventing the formation of mRNA transcripts. Briefly, when regions of a gene are 
methylated, usually within the promoter, the gene is transcriptionally blocked but when these 
regions are under or non-methylated the gene is transcriptionally active or can be activated. 
Numerous studies have shown that tissue specific expression of genes is usually achieved 
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through altered DNA methylation (325, 326). Additionally histone modification such as 
histone H3 methylation on K9 and K27 and histone deacetylase recruitment to DNA 
methylation sites can induce chromatin to form into a more compacted state leading to 
repression of gene transcription. Therefore, DNA methylation and histone modification of 
RhoJ’s promoter region could be causing the lack of vascular RhoJ mRNA expression in 
some human tissues. Another possibility is that RhoJ transcripts are being processed in ECs of 
all tissues but may be degraded in some tissues through the natural RNAi mechanism. Or 
instead, RhoJ may be alternatively spliced in certain tissues providing an explanation for why 
our in situ probe did not detect RhoJ in vessels of some tissues. Alternatively, the promoter 
region could control RhoJ’s tissue expression profile, by controlling the binding of certain 
transcription factors. For example, in tissues where RhoJ is not expressed, the binding site for 
EC transcription factors may be missing.  
 
In recent years, several groups of transcription factors have been shown to influence the 
angiogenic process such as zinger finger, basic helix-loop helix, Hey factor proteins and many 
more (327). However, increasing evidence suggests that the ETS family of transcription 
factors play an essential role in angiogenesis since nearly all endothelial enhancers and 
promoters characterised so far contain multiple ETS binding sites (328-330). ETS-1, Erg, and 
Net (Elk3) are all members of the ETS family of transcription factors and have all been shown 
to be involved in angiogenesis in vitro and in vivo (331-333). Therefore it is likely that 
members of the ETS transcription factor family may regulate RhoJ transcription.  
 
In the present study, RhoJ expression also differed between human and mouse in some cases 
although both species displayed endothelial RhoJ expression. However data from chapter 5 
showed that zebrafish RhoJ was not detected in ECs at all and instead RhoJ was unexpectedly 
found in muscle tissue. The difference of RhoJ expression between mammals and zebrafish 
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could be explained by evolutionary mutations in the cis-regulatory sequences of zebrafish 
RhoJ that regulate its spatial and temporal expression leading to altered localisation and 
function of RhoJ in fish.   
 
Furthermore, RhoJ is expressed in the lining of blood vessels that are undergoing pathological 
angiogenesis in cancerous tissues (figure 6.4C). It may be possible for to RhoJ to play a 
different role in tumour vessels than in normal vessels. RhoJ may operate downstream of 
distinct stimuli in physiological and pathological angiogenesis, which influences the activity 
of different GEFs and GAPs. As we know, there is a tilt in the balance of pro- and anti-
angiogenic factors in pathological angiogenesis, therefore it is likely that the regulation of 
RhoJ activity is disrupted in these carcinomas, resulting in RhoJ being constitutively active 
and contributing to the pathological formation of new vessels. Moreover, it is also possible 
that RhoJ is not involved in pathological angiogenesis since it is not present in all tumours. 
However, identifying where RhoJ is does not give an indication to the levels of active RhoJ. 
Although RhoJ was found in most of the cancerous tissues screened, RhoJ was not found in 
rectal carcinoma sections, which is consistent with the lack of RhoJ expression in normal gut. 
This indicates that RhoJ may only be involved in the vascular diseases of tissues that it is 
expressed in at normal conditions.  
 
RhoJ was also expressed at low levels in human pericytes and aortic smooth muscle cells 
(figure 6.5). A recent study demonstrated that alterations in Rho GTPase dependent signal 
transduction specifically modulates pericyte shape and contractility, as well as regulating their 
ability to control endothelial growth (334). Therefore, RhoJ may also be involved in 
regulating the actin cytoskeleton of mural cells through its modulation of actomyosin 
contractility. However mural cells are known to express characteristics specific to their 
localisation (10). We have investigated the expression of RhoJ in pericytes derived from 
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human placenta and smooth muscle cells from human aorta only; therefore RhoJ may not be 
expressed in perivascular cells in all tissues. In addition, in vitro expression of RhoJ does not 
necessarily mean that these cells would express RhoJ in vivo. Thus the in vivo expression of 
RhoJ in perivascular cells would need to be investigated in future experiments.  
 
Expression of RhoJ in either human or mouse was not restricted to ECs, which confirmed that 
RhoJ is not endothelial specific. However, expression of RNA does not result in the presence 
of protein and this is the main limitation to using this approach. To be certain of human 
RhoJ’s expression profile, the expression of RhoJ protein would also have to be checked in 
human tissue sections using either immunohistochemistry or immunofluorescence. 
Additionally, as mentioned earlier the activity of RhoJ in these tissues cannot be determined 
from these experiments. This means that although RhoJ is expressed in normal non-
angiogenic, normal embryonic angiogenic and pathological angiogenic vessels, it is not 
known whether RhoJ is active or inactive. In future work, the active form of RhoJ could be 
detected in situ by localising a specific effector of RhoJ or using an antibody that binds only 
the GTP-bound form of this Rho GTPase. These approaches have been successful in detecting 
the GTP-bound form of Rac1 in situ (335, 336). These studies, on the expression profile of 
mammalian RhoJ, are not exhaustive since access to primary cells and human tissues were 
limited. Other normal tissues such as human spleen and thymus and other pathological 
angiogenic tissues are still yet to be explored for RhoJ expression. 
 
  
 
 
  
 
 
 
  
 
 
Conclusions and perspectives 
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The data presented in this thesis demonstrates a novel role for RhoJ in EC motility, tube 
formation and modulation of the actin cytoskeleton and focal adhesion formation. This work 
also shows an endothelial expression pattern of RhoJ in mammalian tissues, but a distinct 
localisation and function in zebrafish. This work advances the Rho GTPase and angiogenesis 
field since this is the first time that RhoJ has been localised to ECs and shown to be important 
for angiogenic processes. Most of the data in this thesis has been published in Kaur et al. 
(2011) (337), which is included in appendix 6.  
 
At present, the molecular mechanism by which RhoJ affects focal adhesion numbers and 
contractility is largely unknown. There is reciprocal communication between focal adhesions 
and actomyosin contractility (338). Components of focal adhesions have been shown to 
regulate contractility, and activation of myosin II can accentuate focal adhesion maturation 
and turnover (116, 338). Recently, our group discovered that endogenous RhoJ is 
intracellularly localised mainly to focal adhesions and partially to cytoplasmic vesicles (see 
appendix 6) (337). Considering this, it is likely that RhoJ primarily regulates focal adhesions, 
which in turn induces changes in contractility (figure 7.1). This hypothesis is consistent with 
our recent finding that RhoJ interacts with G protein-coupled receptor kinase-interacting 
protein (GIT1)/PAK interacting exchange factor (βPIX) complex (unpublished data; Mrs. 
Katarzyna Leszczynska), which also localises to focal adhesions and is known to be important 
for focal adhesion disassembly (339-341).  
 
Although inhibition of ROCK/myosin II ameliorated RhoJ knockdown phenotypes, it does 
not necessarily follow that RhoJ affects the RhoA-ROCK pathway. Instead, these inhibitions 
might have reduced contractility to such an extent that it compensated for the effect of RhoJ 
on focal adhesion turnover. On the other hand, we cannot reject the hypothesis that RhoJ 
directly regulates the RhoA-ROCK pathway until the exact mechanism of RhoJ function is 
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Figure 7.1 Potential mechanisms of RhoJ function in endothelial cells. GTP-bound 
RhoA activates ROCK, which in turn phosphorylates the regulatory light chain of 
myosin II and increases actomyosin contractility. RhoJ is localised to focal adhesions in 
endothelial cells. RhoJ negatively regulates actomyosin contractility and focal adhesion 
(FA) turnover, which reciprocally regulate each other. Due to the expression of RhoJ in 
FA, it is most likely that RhoJ regulates these processes by primarily modulating FA 
turnover. Inhibitory agents that reversed RhoJ knockdown-induced motility defects are 
shown in green. The use of these agents may have decreased contractility so much that 
it may have overruled RhoJ’s effect on FA turnover. However, it is also possible for 
RhoJ to interact with RhoA, RhoA GEFs/GAPs and/or ROCK to modulate actomyosin 
contractility directly. 
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elucidated. Therefore RhoJ may also negatively regulate contractility by interacting with 
RhoA, ROCK or RhoA’s GEF/GAP proteins (figure 7.1). The link between RhoJ and ROCK 
would need to be further defined in future work, which could include experiments such as 
GST pull-down, immunoprecipitation and yeast two-hybrid analyses to investigate whether 
RhoJ directly interacts with ROCK.  
 
Consistent with the finding that knockdown of RhoJ in ECs negatively regulates tube 
formation and motility, converse phenotypes have been found in in vitro angiogenesis assays 
with cells expressing dominant active RhoJ (appendix 6) (337). In addition, our collaborators, 
Dr. Sabu Abraham and Dr. Georgia Mavria, tested the effect of RhoJ 
knockdown/overexpression in a more physiologically relevant model of angiogenesis, named 
the organotypic assay, which involved co-culturing HUVEC with human dermal fibroblasts. 
The interaction of these cell types (in naturally produced ECM) results in the formation of 
tubules that are highly reminiscent of capillaries formed during in vivo angiogenesis (342, 
343). Knockdown of RhoJ in this assay reduced capillary branching whereas overexpression 
of active RhoJ resulted in excessive sprouting, which resembled the unstructured appearance 
of tumour vessels (appendix 6) (337). Thus these data further reinforce our conclusions about 
the roles RhoJ plays in ECs. However, it is important to determine if our in vitro observations 
are also present in in vivo models of angiogenesis. Future in vivo studies could include 
knockdown or overexpression of RhoJ in mouse Matrigel plug or sponge assays. Also, a way 
to see if RhoJ knockdown affects focal adhesion numbers and actomyosin contractility in vivo 
could involve setting up a Matrigel plug assay with ECs stably silencing RhoJ and staining 
the cells for actin and focal adhesion markers in sections of the plug. Furthermore, it would be 
interesting to see if the RhoJ knockout mouse displays any vascular defects or if ECs from 
these mice have impaired focal adhesion numbers and actomyosin contractility. 
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We have also shown that RhoJ is expressed in both physiological and pathological angiogenic 
vessels. During angiogenesis, endothelial tip cells must lose contact with surrounding cells in 
order to lead an angiogenic sprout (15, 344). In this situation, the breakdown of cell-cell 
junctions (triggered by angiogenic stimuli) may activate RhoJ signalling, which induces EC 
migration and morphogenesis. RhoJ signalling may therefore be important for the migration 
of endothelial tip cells. Moreover, RhoJ was also expressed in mature vessels. Like other Rho 
GTPases, RhoJ may be involved in maintaining vessel integrity. The disruption of 
intercellular junctions during permeability may trigger RhoJ activation, which might in turn 
induce cell spreading and motility to close intercellular gaps and restabilise vessel integrity. 
This hypothesis is consistent with the finding that RhoJ is latently activated (around 30 
minutes later) by thrombin stimulation (unpublished data; Mrs. Katarzyna Leszczynska). To 
test the role of RhoJ in regulating the endothelial barrier, firstly the effects of RhoJ on 
vascular permeability need to be examined. In addition, the activity levels of RhoJ during 
basal state, disruption and repair of the endothelial barrier need to be investigated. To gain 
insights into how RhoA, Rac1, Cdc42 and RhoJ may be working together in the maintenance 
of vessel integrity, it would be interesting to analyse the activity levels of RhoA, Rac1 and 
Cdc42 when RhoJ is active or inactive.  
 
The fact that RhoJ is not found in all vessels suggests that RhoJ is not important for all ECs 
and that it has specialised functions for certain tissues. Since RhoJ is not expressed in vessels 
of all solid tumours, it is also possible that angiogenesis is not dependant on RhoJ function. In 
the vessels where RhoJ is absent, an alternative member of the Rho family could be taking the 
role of RhoJ. To determine the mechanism behind the tissue specific expression of RhoJ in 
ECs; DNA methylation, histone modification, mRNA degradation, pre-mRNA splicing and 
promoter region analysis would need to be performed in ECs where RhoJ is expressed and 
compared to ECs where RhoJ is not expressed. The expression of RhoJ also differs across 
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species; RhoJ is not expressed in ECs in zebrafish and there are also differences in RhoJ 
expression between human and mouse. In order to understand the large differences in 
expression of RhoJ across species, it is necessary to examine the cis-regulatory sequences that 
control RhoJ expression in future experiments. Since RhoJ is not restricted to ECs, this 
highlights the notion that RhoJ may have a wide array of functions depending on species and 
cell type. 
 
Our findings are largely consistent with past studies that have shown a role for RhoJ in actin 
reorganisation (197, 198, 204). A previous report showed that RhoJ co-localised with 
early/sorting endosome markers in HeLa cells, where it played a role in early endocytosis 
(203). Indeed, this localisation was also observed in our laboratory in cells overexpressing 
RhoJ, however endogenous RhoJ localised mainly to focal adhesions (337). Evidence shows 
that during focal adhesion turnover, components such as paxillin are intracellularly trafficked 
and recycled to focal complexes from the back of the cell to the front through endocytosis 
(345-348). Therefore it may be possible for RhoJ to regulate the endocytosis of integrins and 
focal adhesion proteins during turnover. However, future studies would be required to test 
whether RhoJ is involved in the endocytic machinery that mediate focal adhesion turnover. 
Previous studies have also demonstrated that Rho GTPases are spatiotemporally activated 
during tube formation (349). Rac1 and Cdc42 activation is found during the early stages when 
cell-cell contacts form whereas RhoA activity is prominent during the later stages, which 
results in branching (349). In future experiments, it would also be interesting to analyse the 
temporal and spatial activation of RhoJ during specific stages of tube formation such as initial 
EC alignment, branching and lumen formation. In light of our data, our predictions are that 
RhoJ activation may occur during branching stages of in vitro tubulogenesis. 
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The present study shows a role for RhoJ in the migration of ECs however many aspects of EC 
biology still need to be explored. For example, ECs line the inner surface of blood vessels and 
are directly exposed to blood flow. Previous reports have shown that the mechanical forces 
generated by blood flow induce the redistribution of stress fibres and focal adhesions (350, 
351). For these reasons, it would be interesting to examine the effects of shear stress on RhoJ 
activity or knockdown phenotypes in future experiments. Also, in order to clarify the precise 
role of RhoJ in EC migration, it is vital to establish which upstream pathway drives RhoJ to 
focal adhesions. Recently, our laboratory demonstrated that RhoJ is activated by two major 
angiogenic factors VEGF-A (appendix 6) (337) and FGF-2 (unpublished data; Mrs. Katarzyna 
Leszczynska), which implies that RhoJ mediates its effects in EC motility and tube formation 
downstream of the VEGF-A and FGF-2 signalling pathways. However, it is necessary to 
investigate the exact signalling pathway upstream and downstream of this activation in future 
experiments.  
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Appendix 1: Titration of siRNA duplexes 
 
 
 
 
 
 
 
 
 
 
The lowest siRNA concentration to completely knockdown RhoJ protein in RhoJ-
specific siRNA transfected cells is 10 nM. Human umbilical vein endothelial cells 
were either mock transfected or transfected with negative control duplex (NCD), RhoJ 
duplex 1 (D1) or RhoJ duplex 2 (D2) at 10-fold titrated concentrations. Cells were 
harvested and lysed 2 days after transfection and Western blotting was performed using 
anti-RhoJ and anti-tubulin antibodies to determine the lowest concentration of siRNA to 
completely knockdown RhoJ protein. 
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Appendix 2: Matrigel tube formation assay set-up and quantitation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram of Matrigel tube formation assay and node-counting quantitation. (A) 
The well of a 12 well plate was wetted with PBS prior to adding 70 µL of Matrigel. The 
Matrigel was allowed to solidify and cells were then harvested and seeded on top. Cells 
were incubated in 1 mL of culture medium for a further 24 hours. (B) Image represents 
wild type HUVECs on Matrigel 10 hours post seeding. Nodes are circled according to 
the number of branches that are extending from the node-junction. Yellow: 2 branch 
points, Red: 3 branch points, blue; ≥4 branch points. 
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Appendix 3: Boyden chamber assay set-up and optimisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Boyden chamber assay set-up and chemoattractant optimisation. (A) Photograph of 
48-well Boyden chamber: Boyden chambers consist of upper and lower wells separated 
by a micro-porous membrane filter. The chemoattractant is placed in the lower wells 
and cells are added to the top wells. After a period of incubation, cells that migrated 
towards the chemoattractant are counted on the lower surface of the membrane. (B) The 
lower chamber wells contained the chemoattractant (10% FCS (fetal calf serum) and 
BBE (bovine brain extract)). In the upper wells, cells were seeded in control media (1% 
FCS) and incubated for 5 hours at 37 °C and 5% CO2. The cells that were attracted to 
the chemoattractant, migrated through the porous filter and adhered to the other side, 
where they could be stained with DAPI and counted. (C) To determine the highest 
migratory response to the chemoattractant, a 2-fold titration of FCS was performed and 
the percentage of FCS that produced the greatest migratory response was chosen. Cells 
were all seeded in 1% FCS media. 
A 
B 
C 
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Appendix 4: Schematic of Dunn chamber 
 
 
 
 
 
 
 
 
 
 
 
 
 
Schematic of Dunn chamber. The Dunn chamber consists of two concentric circles 
ground into one face of a glass slide, referred to as the inner and outer wells. A ring-
shaped ridge, referred to as the bridge, separates the two wells. The bridge is 20 µm 
lower than the rest of the glass slide. The outer well contains the chemoattractant and 
the inner well contains control media. A linear gradient of the chemoattractant forms by 
diffusion across the bridge between the two wells. Cells seeded onto a glass coverslip 
are inverted onto the slide. The cells that lie directly over the bridge of the chamber 
between the two wells can be observed using live imaging microscopy and their 
migratory paths towards the gradient can be mapped. Diagrams obtained from 
Hawksley’s Dunn chamber manual: www.hawksley.co.uk. 
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Appendix 5: Morpholino toxicity test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morpholino toxicity. To determine the toxicity of RhoJ-specific morpholinos, wild 
type zebrafish embryos (at cleavage stage) were injected with translation blocker or 
splice blocker morpholinos at various concentrations and the number of embryonic 
fatalities (at 24 hpf) were counted. A total of 25 embryos were injected for each 
condition. Embryo lethality was not found at 1 mM translation blocker and 0.5 nM 
splice blocker.  
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